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Abstract 
Alveolar macrophages are the main cell population in the naïve airway and are held in 
a state of tight regulation by several suppressive mechanisms. One would expect them 
to display a regulatory phenotype but here we show that at homeostasis they express 
markers of alternative activation such as YM1 and mannose receptor (MR) but not 
resistin-like molecule (RELM)-α. We show also that these markers are differentially 
regulated during influenza infection on macrophage populations in the lungs and 
airways.  
We hypothesised that removing the suppressive effects of IL-10 using an IL-10R 
blocking antibody would alter alveolar macrophage phenotype and the immune 
response to influenza infection. We now demonstrate that IL-10R blockade does not 
significantly alter the phenotype of alveolar macrophages at homeostasis but does 
increase in their numbers and infiltrate of monocyte/macrophages and T cells into the 
airways during a subsequent influenza infection.  
Blockade of the interaction between the co-stimulatory molecule GITR and its ligand 
GITRL is beneficial for disease outcome in mouse models of chronic lung inflammation; 
therefore we hypothesised that it may also abrogate influenza-associated immune 
pathology. We now show that GITR and GITRL are differentially expressed in the lungs 
and airways during influenza infection; however contrary to expectations, blockade of 
the interaction between the two accelerated influenza-induced weight loss and lung 
cellularity. This may indicate a novel regulatory role for GITRL in influenza-induced 
inflammation. 
This thesis shows that alveolar macrophages represent an atypical alternatively 
activated macrophage population, whose phenotype is not altered by IL-10R blockade. 
However, we show that prior IL-10R blockade can alter the immune response to 
subsequent influenza infection, and blockade of GITRL during influenza infection may 
be detrimental for the outcome of influenza infection.  
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1.0 Introduction 
With a surface area of 70m2, the human lungs provide a huge interface which is 
exposed to the outside environment. Approximately 500cm3 of air is taken in with each 
breath, which is loaded with antigen from pathogenic micro-organisms, allergens, 
pollutants, viruses and harmless plant and animal proteins, and the lungs must 
distinguish between what is harmful and what must be ignored. Immune responses to 
harmless inhaled antigen would mean that the average human being would die of 
chronic lung disease in childhood. However, the lungs must also recognise and kill 
invading pathogens, otherwise we would die of infections at a very early age. The lungs 
have developed several immune mechanisms to expel pathogens and tolerate 
harmless inhaled antigens which do not merit an immune response. 
1.1 Innate immune mechanisms of the lung 
The conducting airways provide a significant barrier against the entry of pathogens into 
the lungs. Inhaled particles are trapped in a mucous layer overlying the epithelium 
which itself is ciliated and functions to waft trapped particles up the airways to be 
expelled into the oropharynx. This prevents inhaled particulate antigen from entering 
further into the airways and also prevents it from coming into contact with the 
underlying epithelium. The mucin macromolecules that constitute the mucous layer are 
highly adapted to their function and due to the diversity in their carbohydrate side 
chains, can bind and trap a multitude of particles 1. 
The mucous layer additionally contains secretory Immunoglobulin (Ig) A, the 
predominant antibody class found along mucous membranes 2. IgA has high valency 
for antigens and cross links large antigens, preventing their attachment to the 
epithelium. Complexes of secretory IgA-bound antigen are then trapped in the mucous 
layer and are eliminated by ciliary beat of the airway epithelium.   
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As well as expelling particles and microbes trapped in mucous from the airways, 
epithelial tight junctions further provide a physical barrier to prevent microbes gaining 
access to the lung parenchyma. The epithelium is coated in a glycocalyx layer which is 
negatively charged and is therefore a further deterrent for pathogens 2.   
A periciliary liquid layer lies between the epithelium and mucous layer and contains 
anti-microbial compounds such as lactoferrin, lysozyme and anti-microbial defensins 
which halt microbial growth.  
1.2 Cells of the innate immune system   
Not all microbes are excluded by mucociliary export and therefore, cells of the immune 
system must recognise pathogenic microbes so that they can be cleared and if 
necessary an immune response can be mounted. Innate immune cells have evolved 
pattern recognition receptors (PRRs) to recognise pathogen-associated molecular 
patterns (PAMPs) such as bacterial cell wall components. PRRs expressed by cells of 
the innate immune system include Toll-like receptors (TLRs), retinoic acid inducible 
gene-I (RIG-I)-like receptors (RLRs) and the nucleotide-binding oligomerisation 
domain- (NOD)-like receptors (NLRs) 3. These PRRs recognise a range of microbial 
products, such as viral single stranded (ss) and double stranded (ds) RNA, bacterial 
cell wall components such as lipopolysaccharide (LPS) and lipotechoic acid (LTA), 
flagellin and viral proteins. Some of these pathogen receptors are summarised in Table 
1.1. PRRs can also be activated by host proteins released under conditions of stress 
by dying or activated cells, known as damage associated molecular pattern proteins 
(DAMPs). DAMPs include host DNA, heat shock proteins, uric acid, high mobility group 
box 1, adenosine and the S100 family of proteins, all of which are capable of activating 
PRR responses 4. 
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Table 1.1 Pathogen recognition receptors and their ligands. Some of the pathogen 
recognition receptors expressed by cells of the immune system.TLR – toll-like receptor. 
RLR – retinoid acid inducible gene (RIG)-I like receptor. NLR –  nucleotide 
oligomerisation domain (NOD)-like receptor. Ds RNA (double stranded RNA), ssRNA 
(single stranded RNA).  
Pathogen receptor Location Pamp Sensed
TLR-1 Cell membrane Bacterial lipoproteins
TLR-2 Cell membrane Lipotechoic acid
TLR-3 Endosome dsRNA
TLR-4 Cell membrane Certain viral proteins
LPS
TLR-5 Cell membrane Flagellin
TLR-6 Cell membrane Bacterial lipoproteins
TLR-7 Endosome ssRNA
TLR-8 Endosome ssRNA
TLR-9 Endosome CpG DNA
RLRs
RIG-I Cytoplasm Short dsRNA
ssRNA
MDA-5 Cytoplasm dsRNA
NLRs
NOD1 Cytoplasm Peptidoglycan from gram  
–ve bacteria
NOD2 Cytoplasm Muramyl dipeptide
NLRC4 Cytoplasm Flagellin
NLRP3 Cytoplasm Bacterial RNA, viral RNA 
and DNA, bacterial cell 
wall components
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This thesis will mainly focus on the phenotype of alveolar macrophages but other cell 
types important for defence of the lung will also be briefly discussed. 
1.2.1 Epithelial cells 
Epithelial cells represent the first line of defence against invading micro-organisms. As 
well as providing a physical barrier to the penetration of microbes into the lung 
parenchyma, mouse and human epithelial cells express TLRs 1-9 5-9 and NOD-1 and 
NOD-2 10 and can recognise and respond to a range of pathogens.  
In response to the presence of a TLR or NLR stimulus, an inflammatory cascade is 
induced with the activation of nuclear factor kappa B (NFkB) and mitogen activated 
protein (MAP) kinases. This leads to the production of pro-inflammatory cytokines such 
as tumour necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-8 (or the mouse 
ortholog macrophage inflammatory peptide (MIP)-2), granulocyte macrophage 
stimulating factor (GM-CSF) and a host of other cytokines and chemokines which 
activate resident alveolar macrophages and recruit other leukocytes to the airways 11, 
12. After stimulation, epithelial cells up-regulate the expression of cell adhesion 
molecules, enhancing the recruitment of cells to the airways and lungs 12. Furthermore, 
in response to invading microbes epithelial cells produce anti-microbial compounds 
such as β-defensins, 10, 13, 14 cathelicidins 14-16, lactoferrin 17, lysozyme 18-20 and lipocalin 
21, 22 which directly kill a range of bacterial species.  
1.2.2 Macrophages 
Alveolar macrophages compose 90% of the cells in broncho-alveolar lavage (BAL) and 
are the main cell type in the alveolar space. It is thought that at homeostasis their 
numbers are renewed by local proliferation, demonstrated by mouse studies in which 
blood monocytes are depleted without affecting alveolar macrophage numbers; 
incidentally, peritoneal macrophage numbers are also unaffected, indicating that local 
proliferation is a means of maintaining tissue-resident macrophage populations 23. 
Chapter 1: Introduction  
24 
 
Similarly, when the lungs are protected from whole body irradiation, alveolar 
macrophages are still of host origin 45 weeks later 24. They are, therefore a long-lived 
population. It is known that alveolar macrophages proliferate in response to 
macrophage colony stimulating factor (MCSF) and GMCSF which are produced by 
epithelium at homeostasis and during inflammation 25. When mice are subjected to 
whole body irradiation, however, the majority of macrophages in the airways are of 
donor origin 60 days after bone marrow transfer, indicating that alveolar macrophage 
numbers can also be replenished from the bone marrow 26. Human studies, where 
patients have received allogenic bone marrow transfers, show similar repopulation of 
alveolar macrophages 81 days after bone marrow transplant 27, 28. Other studies show 
that depletion of alveolar macrophages results in their re-population by donor blood 
monocytes 29. During inflammation, monocytes are recruited into the airways via the 
CC chemokine receptor 2 (CCR2)/CC chemokine (CCL2) axis 30.  
The main function of alveolar macrophages is to phagocytose invading pathogens and 
particulate matter, whilst preventing the activation of a systemic immune response. It is 
thought that a systemic immune response to microbes in the airways is only achieved 
once the phagocytic capabilities of alveolar macrophages are overcome 31. Alveolar 
macrophages express various scavenger receptors such as macrophage receptor with 
collagenous structure (MARCO), the mannose receptor (MR) and Fcγ receptors, which 
aid the phagocytosis of a range of bacterial species 32. Table 1.2 summarises the main 
macrophage phagocytic receptor families. Alveolar macrophages further express 
extracellular and intracellular TLRs, NLRs and RIG-I receptors to recognise PAMPs on 
microbial species 3. Activation through PRRs enhances the phagocytic capacities of 
alveolar macrophages, demonstrated after stimulation of TLR-4 with LPS 33. 
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Receptor family Example Function 
Integrin CD11c (CR4), CD11b 
(CR3) 
Binds C3b and mediates 
complement-mediated 
phagocytosis  
Adhesion to epithelium 
Ig Superfamily Fc receptors Antibody-mediated 
phagocytosis 
Scavenger receptors Scavenger receptor A Bacterial phagocytosis  
C-type lectin receptors Mannose receptor  Recognise microbial 
ligands and mediate 
phagocytosis of certain 
microbes and endogenous 
glycoproteins 
 
Table 1.2 Macrophage receptors involved in immune recognition and 
phagocytosis. Adapted from 32. CR: complement receptor. 
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Alveolar macrophages are relatively poor antigen presenters compared to other tissue-
resident macrophages 34, 35, and are not efficient at inducing a T cell response to whole 
antigen 36-38. However, alveolar macrophages can induce a robust immune response 
on activation of PRRs, with production of IL-12, TNF-α, interferon-gamma (IFN-γ) and 
monocyte chemotactic protein (MCP)-1 39, 40. Monocytes recruited into the airways are 
inflammatory and contribute to the phagocytosis of dead and dying cells as well as 
invading pathogens 41, 42.  
The lung parenchyma contains another macrophage population termed interstitial 
macrophages. These macrophages are morphologically similar to alveolar 
macrophages but are slightly smaller, resembling blood monocytes 29, 43. Interstitial 
macrophages are equally as phagocytic as alveolar macrophages, but have a better 
antigen presenting capacity, with higher expression of major histocompatibility complex 
(MHC) class II 44. Presumably, if microbes enter the lung parenchyma it is vital for 
interstitial macrophages to be able to instigate a robust immune response and contain 
the infection.   
Depending on the inflammatory stimulus or cytokine milieu they are subject to, 
macrophages can adopt different activation states with distinct functionality. The factors 
that affect macrophage phenotype can be derived from other immune cells, such as 
natural killer (NK) cells or T cells, or they can themselves produce factors that affect 
their own phenotype and function in an autocrine manner. The different macrophage 
subsets are discussed in the following sections. 
1.2.2.1 Classically activated macrophages 
Classically activated macrophages are the best studied macrophage phenotype, 
resulting from stimulation of macrophages with IFN-γ and/or TNF-α in addition to a TLR 
stimulus 45, 46. They are vital for the control of intracellular pathogens, and mice lacking 
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IFN-γ are highly susceptible to multiple bacterial, protozoal and viral infections, as are 
humans with disrupted IFN-γ signalling 47. 
The main source of IFN-γ during early innate immunity is NK cells that produce it in 
response to stress and infection 48, 49. As the immune response progresses, however, 
IFN-γ and TNF-α are likely to be produced by T cells, and therefore the adaptive 
immune response perpetuates the classical activation of macrophages. IFN-γ-activated 
macrophages produce large amounts of anti-microbial reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) and IL-12 which activates T cells and NK cells 49, 
50. 
Classically activated macrophages also produce IL-6, IL-23 and IL-1, which contribute 
to the generation of T helper (Th) 17 cells 51, whose production of IL-17 in turn recruits 
neutrophils to the site of infection 52. Whilst important for the clearance of invading 
pathogens, these macrophages mediate tissue pathology if un-restrained, exemplified 
by their role in tissue pathology in rheumatoid arthritis 53. 
1.2.2.2 Alternatively activated macrophages 
IL-4 and IL-13 are the main factors responsible for inducing alternatively activated 
macrophages, which are also known as wound healing macrophages 45. Alternatively 
activated macrophages are thought to be involved in tissue repair after inflammation. 
IL-4 appears to be one of the main cytokines produced on tissue damage 54. 
Alternatively activated macrophages are usually observed in Th2 inflammatory 
conditions such as asthma, allergy and parasite infections 55-58.  
They are characterised by high expression of the scavenger receptor MR, the 
chitinase-like molecule YM1 59-61, acidic mammalian chitinase (AMCase) and resistin-
like molecule alpha (RELM-α) 59, 60, 62. Alternatively activated macrophages also 
express arginase, which competes with the classically activated macrophage-
associated inducible nitric oxide synthase (iNOS) for arginine metabolism 61, 63, 64. 
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Arginase catalyses the conversion of arginine to ornithine, which is a precursor of 
polyamines and collagen, and contributes to the synthesis of the extra cellular matrix. 
RELM-α stimulates collagen 1 and alpha smooth muscle actin expression by lung 
fibroblasts that contribute to airway remodelling and fibrosis 65, 66. YM1 is proposed to 
have carbohydrate and matrix binding activity and to mask lectin binding sites, 
preventing entry of cells into inflamed tissues 67, 68. 
Alternatively activated macrophages clearly have roles in tissue repair, but are also 
known to contribute to the clearance of certain pathogens. For example, they are 
integral for the clearance of the gut nematdode Heligmonsomoides plygyrus 58 and 
Schistosoma mansoni 69. Additionally, they inhibit T cell proliferation by cell-cell contact 
mechanisms 70 including the expression of programmed death ligand 1 (PDL-1) 71 and 
the production of RELM-α, which negatively regulates Th2 cytokine production 72.  
Evidence that alveolar macrophages express YM1 73, 74 and MR 75, 76 indicates that they 
may be intrinsically alternatively activated at homeostasis, an idea that will be further 
explored in this thesis.  
1.2.2.3 Regulatory macrophages 
Regulatory macrophages are characterised by the production of IL-10 and differentiate 
in response to different conditions 45, 46. Ligation of macrophage Fc receptors reverses 
TLR-induced IL-12 production 77, 78 and stimulates IL-10 production 77, 79, 80. 
Furthermore, macrophage phagocytosis of IgG- or C3bi-opsonised erythrocytes or 
apoptotic neutrophils enhances IL-10 and reduces IL-12 production 81-83. Regulatory 
macrophages are necessary to limit TLR-induced inflammation, in order to avoid 
excess immune pathology. However, they can also be detrimental to the outcome of 
infection, as in the case of Leishmania major infection, where opsonised amastigotes 
stimulate Fc receptor-mediated production of IL-10, which delays clearance of the 
pathogen 84. Similarly, intra-tracheal administration of apoptotic cells prior to intra-nasal 
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infection with Streptococcus pneumoniae leads to reduced clearance of the bacteria 
accompanied by IL-10 production by macrophages, which is dependent on 
prostaglandin (PG) E2 
85.  Others show that phagocytosis of apoptotic cells enhances 
the production transforming growth factor (TGF)-β by macrophages and reduces LPS-
induced TNF-α production, which is also dependent on PGE2 
83. The role of opsonised 
antigen and apoptotic cells in deactivating macrophages has been widely studied, but 
other factors are capable of inducing macrophages with a regulatory phenotype. 
Adenosine stimulation reduces IL-12 and enhances IL-10 production by macrophages 
86-88. Despite generally described as being immune suppressive, regulatory 
macrophages retain the expression of the co-accessory molecules MHC class II and 
CD86, and are able to activate T cell responses in vitro 45.  
The different macrophage activation states and the signals that drive their 
differentiation are summarised in Figure 1.1. 
Macrophages differentiated under a particular condition are not terminally 
differentiated. Many studies show that alternatively activated macrophages can adopt a 
classically activated phenotype with the appropriate stimulus. For example, 
alternatively activated peritoneal macrophages become classically activated upon 
stimulation with IFN-γ and LPS 89.  
1.2.2.4 Macrophage subset nomenclature 
In human studies, classically activated macrophages are referred to as M1 
macrophages and alternatively activated (wound healing) macrophages as M2a 90. 
Some human studies distinguish between IL-10-producing macrophages based on the 
stimulus used: TLR/immune complex-stimulated macrophages are referred to as M2b 
and macrophages stimulated with glucocorticoids referred to as M2c 90.  
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Figure 1.1 Macrophage subsets. Macrophages can differentiate into different subsets 
with distinct cytokine profiles depending on the cytokine and TLR stimulus provided. 
Adapted from 91.  
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However this thesis will continue to refer to the three groups of macrophages as 
classically activated, alternatively activated and regulatory macrophages.  
1.2.3 Dendritic cells 
Dendritic cells (DCs) are the main antigen presenting cell (APC) population in the lungs 
and there are several different DC populations identified in the lungs, each with distinct 
functions. They loosely fall into two categories: conventional DCs and plasmacytoid 
DCs. Plasmacytoid DCs (pDCs) make up a small population in the lung interstitium and 
large conducting airways 92. Different subsets of conventional DCs are distinguished by 
the expression of the integrins CD11c and CD11b. Intra-epithelial DCs express CD11c 
and the integrin CD103 but not CD11b 93. These cells lie on the baso-lateral side of the 
airways just beneath the epithelium, and extend their dendritic processes into the 
airway lumen to sample antigen in the air space 93. The lung interstitium contains 
another DC subset, resident CD11b+ CD11c+ CD103- DCs 92.  
Conventional DCs migrate to the lymph nodes during infection and inflammation via the 
CCR5/CCL5 axis and are capable of inducing a T cell response 94, 95. During influenza 
infection, these cells also produce TNF-α and iNOS 94 and in the spleen are called 
TNF-α-producing iNOS-producing DCs (TIP Dcs) 96. pDCs express TLRs 3 and 7 and 
produce vast amounts of IFN-α during viral infections, playing a vital role in the 
clearance of respiratory viruses 97.  
Another population of DCs has recently been described in tumours which secrete IFN-γ 
and are called IFN-γ producing killer DCs 98; this population is also observed in the 
lungs following inflammatory stimuli 99. IFN-γ-producing killer DCs express markers of 
NK cells but have the ability to present antigen to T cells and activate a T cell 
response98.  
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1.2.4 NK cells 
NK cells are innate lymphocytes which make up 10% of all the lymphocytes in the un-
infected lung 100, but are also recruited to the lungs from the blood during infection 101. 
NK cells express activating receptors which recognise pathogen glycoproteins 102 and 
molecules expressed on the surface of infected cells 103, 104, and inhibitory receptors 
which recognise MHC class I molecules; the loss of inhibitory molecules leads to NK 
cell activation 105, 106. Inflammatory cytokines such as type 1 IFNs and IL-12 activate NK 
cells, whereupon they release cytolytic granules to kill infected cells and secrete IFN-γ 
which activates T cells 107. Secretion of IL-2 and/or IFN-γ by NK cells is necessary for 
robust CD8+ T cell responses 48. NK cells can also produce IL-10 to suppress 
inflammation 108. 
1.2.5 Granulocytes 
Neutrophils, eosinophils and basophils make up the granulocytes, and are 
characterised by cytoplasmic granules containing lytic enzymes and bactericidal 
substances. Neutrophils form an integral part of the host’s defence against invading 
micro-organisms. They are highly phagocytic and recognise a variety of micro-
organisms via the expression of TLRs. Neutrophils have highly microbicidal activity due 
to the production of reactive oxygen species following the uptake of pathogens, and the 
release of degradative enzymes such as serine proteases, metalloproteases and 
lysozyme. Neutrophils also release pro-inflammatory cytokines such as TNF-α and IL-
12, which prime the macrophage response 109. Eosinophils are important for the 
immune response against parasites and also mediate allergy. When activated, they 
degranulate to release their granule contents such as histamine, eosinophil peroxidase 
and plasminogen, which are toxic to parasites. Basophils are involved in the immune 
response against parasites and can degranulate to release histamine and proteolytic 
enzymes 110. They can also instruct the T cell response by the production of IL-4 111.  
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1.3 Cells of the adaptive immune system 
The adaptive immune system consists of the humoral arm and the cellular arm. The 
humoral arm is mediated by antibody produced by B cells. This thesis will focus on the 
cellular arm of the adaptive immune system. 
1.3.1 T cells 
T cells mature in the thymus and consist of two populations, the CD4 positive and the 
CD8 positive populations, which co-express CD3. CD4+ T cells are T helper cells (Th) 
whose main function is to secrete cytokines that educate other immune cells to 
respond to infection, and provide the signals to B cells to enhance antibody production. 
CD4+ T cells recognise antigen loaded onto MHC class II on APCs via specific 
interactions with their surface-expressed T cell receptor (TCR), which enables them to 
respond to infection.  
CD8+ T cells interact with antigen-MHC class 1 complexes on the surface of virally 
infected cells or tumour cells, whereupon they differentiate into cytotoxic effector cells. 
CD8+ effector T cells kill target cells via the release of cytolytic granules containing 
perforin monomers that polymerise to form cylindrical pores on the target cell 
membrane 112. Granzyme is then released into the target cell, which activates apoptotic 
pathways in the target cell. Another mechanism by which CD8+ T cells kill target cell is 
via the Fas/Fas ligand (FasL) pathway 113. FasL on the surface of CD8+ T cells binds to 
Fas expressed on target cells, leading to the association of Fas with Fas-associated 
protein with death domain (FADD), which activates a caspase cascade that ultimately 
leads to apoptosis of the target cells. MHC class II restricted CD4+ T cells are also 
reported to have cytolytic activity in vitro and in vivo during viral infections 114.  
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1.3.2 T cell activation 
T cell activation requires two distinct signals; firstly TCR recognition of antigen-MHC 
complexes, and a co-stimulatory signal, which is provided by interaction between 
molecules on the surface of the APC and the T cell. 
The TCR consists of αβ or γδ heterodimers. αβ T cells are much more common than γδ 
T cells, although the latter are usually found at mucosal surfaces 115. The TCR closely 
associates with the CD3 complex, which is necessary for the recognition of antigen by 
the TCR. CD4 and CD8 act as co-receptors, interacting with MHC molecules, and 
participating in signal transduction 116. The TCR complex, consisting of CD3 and 
CD4/CD8, recognises antigen in complex with MHC molecules on the surface of APCs. 
However, this interaction is insufficient to activate naïve T cells and TCR/MHC 
activation in the absence of co-stimulation results in T cell anergy.  
Co-stimulatory signals are provided by several molecules, the most studied of which 
are CD28 and cytotoxic T lymphocyte antigen 4 (CTLA4) on the surface of T cells that 
interact with the B7 molecules on the surface of the APC 117. Naïve T cells express 
CD28, and binding of B7 results in proliferation and activation of the effector functions 
of T cells when the MHC:peptide complex is also recognised 117. CTLA4 is up-regulated 
by activated T cells, and its interaction with B7 is inhibitory and down-regulates the 
activity of the T cell 117. CD28 co-stimulation is vital for T cell activation; however there 
exist several other co-stimulatory molecules which contribute to T cell activation. It is 
proposed that certain co-stimulatory molecules might be required for T cell activation 
and/or survival at different time points after TCR activation.  
Two main classes of co-stimulatory molecules have been studied; the immunoglobulin 
super family, for example, CD28 and the TNF receptor super family (TNFRSF) 118. 
Members of the TNFRSF include 4-1BB, CD27 and OX40, all of which have roles in 
the survival of T cells 118. CD27 is constitutively expressed by T cells, with increased 
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expression upon activation 119 and blockade of this molecule inhibits proliferation and 
cytokine secretion by activated T cells 120. Additionally, CD27 deficient mice have 
impaired primary and secondary T cell responses to influenza infection 121. OX40 is 
expressed by T cells 1 to 2 days after antigen encounter 122, and signalling through 
OX40 enhances survival of T cells and boosts cytokine production 123. This indicates 
that OX40 plays a major role in the survival of T cells. Similarly, 4-1BB ligand deficient 
mice have fewer antigen-specific T cells and fewer memory T cells upon infection in 
vivo 124.  
1.3.3 T cell subsets 
Depending on the antigenic stimulus and resulting cytokine milieu CD4 T cells can 
differentiate into a number of T cell subsets with distinct cytokine profiles and effector 
functions. 
1.3.3.1 Th1 cells 
Th1 cells are induced in response to viral and bacterial infections and autoimmune 
disease and are characterised by the production of large amounts of IFN-γ 125. 
Differentiation of T cells into Th1 cells is dependent upon DC and NK cell production of 
IL-12 in response to the invading micro-organism 126. Th1 cell differentiation is 
controlled by the transcription factor Tbet, which induces the production of IFN-γ via 
activation of signal transducer and activator of transcription 4 (STAT4) 127, 128. IFN-γ 
produced by Th1 cells activates innate immune cells such as macrophages and 
enhances CD8+ T cell cytoxicity 129-131. IFN-γ polarises the classical activation of 
macrophages, inducing their production of inflammatory cytokines such as TNF-α, 
enhances iNOS activity 130 and directly inhibits the differentiation of other T helper 
subsets 132.  
Th1 responses are vital for the clearance of several respiratory pathogens, such as 
influenza. Treatment of influenza-infected mice with IFN-γ rescues mice from lethal 
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influenza infection by enhancing the NK cell response 133. Respiratory synctial virus 
(RSV) infection in humans skews the immune response away from a protective Th1 
response to a Th2 response that impedes viral clearance 134.  
1.3.3.2 Th2 cells 
Th2 cells are induced in vivo during allergy or parasitic infections. They are 
characterised by the production of IL-4, IL-5, IL-13 and IL-25. IL-4 induces B cells class 
switching to IgE production 135. IL-5 recruits eosinophils 136 and IL-13, along with IL-4, 
induce the production of mucous by goblet cells and broncho-constriction of airway 
smooth muscle cells 137. Furthermore IL-4 and IL-13 induce the alternative activation of 
macrophages 45. Th2 cells are induced by IL-4 activation of STAT6 and subsequently 
the transcription factor GATA-binding protein 3 (GATA3), which controls the 
transcription of Th2-associated cytokines 138-140. As with Th1 cells, Th2 cells can 
negatively regulate the development of other T cell subsets. Negative regulation of 
Th17 responses by Th2 cells is thought to be via the up-regulation of growth factor 
independent 1 (GFI1), a transcriptional repressor of Th17 generation 141. 
IL-4, required for the induction of Th2 responses, is thought to originate from basophils, 
which produce IL-4 upon FcεR crosslinking 142, NK T cells, which can produce it upon 
TCR engagement 143, or activated Th2 cells themselves 144. Interestingly, DCs are 
capable of inducing Th2 responses, despite the fact that they are not known to produce 
significant amounts of IL-4 145. Aside from IL-4, a few other cytokines are known to 
promote Th2 responses. Thymic stromal lymphopoietin (TSLP) produced by epithelial 
cells, mast cells and basophils induces Th2 cytokines production, suppresses IL-12 
production and enhances the ability of DCs to prime a Th2 response 146, 147. IL-25 
induces IL-4, IL-5 and IL-13 production by naive T cells 148 and IL-33 induces IL-5 and 
IL-13 production by T cells and the polarisation of alternatively activated 
macrophages149.  
Chapter 1: Introduction  
37 
 
Th2 cells dominate in asthma, secreting cytokines to recruit eosinophils, basophils and 
mast cells into the airway and amplifying the amount of pro-inflammatory mediators in 
the airways 137. Furthermore, the Th2 cytokine IL-13 is thought to be responsible for 
airway remodelling during allergic airways disease 137.  
1.3.3.3 Th17 cells 
Th17 cells produce IL-17, and are controlled by the orphan retinoid receptor RORγt 
transcription factor, the expression of which is under the control of STAT3 150. The 
transcription factors Runx and interferon regulatory factor 4 (IRF4) are important for the 
expression of RORγt in CD4+ T cells 151, 152. The up-regulation of RORγt and thus the 
differentiation of murine Th17 cells is induced by IL-6 and TGF-β 153, although it is now 
known that IL-21 can substitute for IL-6 in inducing Th17 differentiation 154. Additionally 
IL-23, while unnecessary for the initial differentiation of Th17 cells, is necessary for 
their sustained differentiation and proliferation 153. However, some studies show that 
human Th17 cells require IL-23 and IL-1β but not TGF-β for their differentiation 155, 156. 
Furthermore, TGF-β receptor knockout mice have Rorγt positive lamina propria CD4+ T 
cells, and naïve T cells differentiate into Th17 cells under the influence of IL-1β, IL-6 
and IL-23 in the absence of TGF-β 157. Others propose a role for IL-18 in the induction 
of Th17 cells along with IL-23 and IL-1β 158. It is suggested that Th17 cells generated in 
the absence of TGF-β are more pathogenic in vivo compared to those generated in the 
presence of TGF-β 157. 
As well as IL-17, Th17 cells secrete IL-21, which furthers their own differentiation 159 
and IL-22, which is involved in the innate immune response of non-haematopoietic 
cells 160, 161. Th17 cells can also secrete TNF-α, express the chemokine receptor CCR6 
and migrate to its ligand, CCL20 in mouse models of rheumatoid arthritis 162.  
IL-17 recruits neutrophils and macrophages to the site of inflammation and is critical for 
the clearance of certain intra-cellular pathogens, such as pulmonary infections with 
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Klebsiella pneumoniae 163 and Pseudomonas aeruginosa in mice 164. IL-17 reportedly 
plays a pathogenic role in various auto-immune diseases; for example, it is directly 
involved in bone and cartilage erosion in arthritis 165 and is thought to play a role in the 
pathogenesis of experimentally-induced encephalitis (EAE) 166. CD8+ T cells can also 
produce IL-17 and represent a T cytotoxic (Tc) 17 population 167. 
DCs stimulated in vitro with a combination of apoptotic cells and TLR agonists produce 
IL-6, IL-23 and TGF-β, thereby inducing a Th17 response 168. This is one of the 
mechanisms thought to induce Th17 cells during infections with certain pathogens such 
as Bacteroides fragilis and Citrobacter rodentium, which induce apoptosis in infected 
cells 169. Additionally, Mycobacterium tuberculosis can induce Th17 responses in vitro 
and in vivo 170. 
A subset of human skin-homing T cells which secretes IL-22 but not Th17 has recently 
been described, and denoted Th22 cells 171, 172. IL-22 production by these cells is 
independent of RORγt 171, 172. It is not yet known if this subset of T cells is distinct from 
Th17 cells 173.  
1.3.3.4 Regulatory T cells (Tregs) 
Tregs are a distinct T cell subset whose main function is to negatively regulate 
inflammation by the production of immune modulatory cytokines. Two main subsets of 
Tregs exist, depending on the way in which they are differentiated. Natural Tregs 
(nTregs) differentiate in the thymus, and inducible Tregs (iTregs) are found in 
secondary lymphoid organs and non-lymphoid tissue 174. Both iTregs and nTregs are 
characterised by the expression of the transcription factor forkhead box protein 3 
(Foxp3). nTregs are generated in the thymus via mechanisms that are dependent upon 
interactions with MHC class II on the cortical epithelium of the thymus 175. The 
generation of iTregs is dependent on IL-2, TGF-β and TCR stimulation 176, 177. iTregs 
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and nTregs suppress effector T cells by the production of IL-10 and TGF-β as well as 
cell contact mediated suppression by CTLA-4 expression 178. 
 IL-10 and TCR stimulation drives the generation of Foxp3 negative regulatory T cells 
which produce IL-10 (Tr1 cells) 179 or TGF-β (Th3 cells) 180 that function to regulate 
infection-induced inflammation 181.  
Tregs are vital for regulating inflammation in respiratory syncytial virus (RSV) 
infections, and their depletion increases morbidity in murine infections 182; transfer of 
Tregs into mice suffering from allergic airway inflammation reverses inflammation and 
remodelling 183. 
The generation of the different T cell subsets is depicted in Figure 1.2. Th1, Th2 and 
Th17 cells can also produce IL-10 and this represents a mechanism by which effector 
T cells can switch off their own activation.  
1.3.3.5 Plasticity of T helper cell subsets 
It has become clear that T helper cells that have differentiated into a certain T helper 
cell subset retain some plasticity with regards to cytokine production and the 
expression of subset-specific transcription factors. For example, Th17 cells generated 
in the absence of TGF-β express T-bet 158, and highly purified Th17 cells transferred 
into non-obese diabetic/severe combined immune deficiency (NOD/SCID) mice 
became IFN-γ-producing Th1 cells in vivo, causing diabetes 184. Another recent study 
describes Th17 cells in vivo that convert to Th1 cells during the progression of 
experimental autoimmune encephalitis (EAE) 185 and Foxp3+ CD4+ T cells that produce 
IL-17 have been described in the lamina propria of Crohn’s disease patients 186.  
Furthermore, Th1 cells stimulated with ovalbumin and IL-18 have been shown to 
produce the Th2-associated cytokine IL-13 alongside IFN-γ 187. These studies show 
that T cells already differentiated to become a particular T helper subset are able to 
switch phenotype depending on the cytokine milieu. 
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Figure 1.2 T cell subsets. T cells differentiate into distinct subsets with different 
cytokine profiles depending on the cytokine milieu. The different T cell subsets are 
reviewed in 173.  
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1.4 Homeostatic regulation of inflammation in the lungs and airways 
Epithelial cells represent the first line of defence against pathogens which infiltrate the 
airways. Additionally they are crucial for maintaining airway cells in a quiescent state so 
as to avoid unnecessary inflammation. Epithelial cells are therefore a key regulator of 
immune homeostasis in the airways and lungs. 
Alveolar and bronchial epithelial cells produce surfactant proteins (SP) A, B, C and D 
188, 189 which comprise 10% of pulmonary surfactant that is vital for maintaining 
appropriate surface tension in the airways 190, an absence of which leads to the 
collapse of the lung. Surfactant proteins also have immune modulatory properties. SP-
A and SP-D bind to signal inhibitory regulatory protein (SIRP)-α on the surface of 
alveolar macrophages, reducing Fcγ receptor-mediated phagocytosis 191, and inhibiting 
TNF-α production 192. However, SP-A and SP-D can also enhance phagocytosis by 
opsonising apoptotic cells 193. In this way surfactant proteins prevent inflammation 
during phagocytosis of apoptotic cells by alveolar macrophages. Interestingly, mice 
lacking SP-A develop low-grade lung inflammation and age-dependent emphysema 194, 
195. 
Epithelial cells produce IL-10 which regulates the activity of alveolar macrophages and 
DCs by diminishing MHC class II expression, therefore lowering their activation status 
and ability to present antigen 196, 197. They express the integrin αvβ6 which catalyses the 
conversion of locally produced latent TGF-β into its active form 198. Alveolar 
macrophages are in close proximity to the epithelium and are therefore subject to the 
anti-inflammatory effects of TGF-β. Furthermore, mice lacking the β6 integrin have 
enhanced expression of matrix metal protease- (MMP) 12 in alveolar macrophages and 
develop age-dependent emphysema 199. 
The epithelium exerts a further suppressive mechanism in the airways via the myeloid 
inhibitory molecule CD200, which is expressed on the luminal surface of the 
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epithelium200. The ligand for CD200, CD200 receptor (CD200R) is highly expressed by 
alveolar macrophages and when bound to CD200, imparts a negative signal to alveolar 
macrophages, resulting in the down-regulation of inflammatory cytokines 201. Alveolar 
macrophages from CD200R knockout mice have a lower threshold of activation than 
wild type mice and produce inflammatory cytokines to relatively low levels of 
inflammatory stimulus 200.   
Alveolar macrophages, as well as being highly regulated at homeostasis, can also 
regulate adaptive immunity in the lungs. For example, depletion of alveolar 
macrophages is associated with enhanced inflammation in the lungs and airways 202 
and enhanced T cell responses to inhaled antigens 203, 204. Additionally, alveolar 
macrophages sequester particulate inhaled antigen by phagocytosis 31. This prevents 
DCs gaining access to antigen and therefore prevents the induction of a T cell 
response 31. DCs induce a T cell response only when the phagocytic capabilities of 
alveolar macrophages have been compromised 31. Like the epithelium, alveolar and 
lung interstitial macrophages secrete IL-10 at homeostasis, which inhibits the 
maturation and migration of antigen-loaded DCs.43.  
Treg-derived IL-10 is also important for regulation of airway homeostasis. Mice with IL-
10 deficient Treg cells display increased cellular infiltrate in the lungs and airways at 
homeostasis compared to wild type littermate controls 205. Additionally, these mice have 
more severe inflammation in models ovalbumin-induced allergy 205. 
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1.5 Influenza virus 
1.5.1 Epidemiology 
Influenza is a major cause of morbidity and mortality worldwide, with approximately 
20% of children and 5% of adults affected each year. Despite developments in 
vaccines and anti-viral drugs, seasonal influenza epidemics still occur each year, 
resulting in approximately 12000 fatalities in England and Wales, and affecting 5 – 10% 
of the population 206. In the last century there were three influenza pandemics, from 
influenza viruses of different haemagglutinin (H) and neuraminidase (N) subtypes. 
Pandemics arose in 1968 (H3N2), 1957 (H2N2) and the 1918 (H1N1) pandemic (or 
Spanish flu) which was the most devastating, and killed approximately 50 million 
people worldwide. This century has so far seen the 2009 “swine flu” pandemic (H1N1), 
which was first documented in Mexico in April 2009 and was thought to have infected 
over 50 million people worldwide by December 2009 207. Swine flu cases were still 
being reported for autumn/winter 2010 although the full epidemiological data for this 
season is not yet available.  
The elderly and immune compromised are usually the most susceptible to seasonal 
influenza epidemics and pandemics; however, the 2009 and 1918 pandemics 
disproportionately affected children and young adults compared to the older age 
groups 208, 209. The resistance of the older population to the 2009 pandemic swine flu is 
hypothesised to be due to partial immunity in older people. Indeed, studies show that 
33% of adults over the age of 60 have cross-reactive antibodies to H1N1 208, 210, 211.  
Influenza infection can lead to symptoms ranging from mild to severe with myalgia, 
malaise, headaches, cough, sore throat and fever to viral pneumonia and acute 
respiratory distress. Certain pandemic influenza strains such as the pandemic 2009 
swine flu can induce gastro-intestinal symptoms such as diarrhoea and vomiting 210.  
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1.5.2 Classification and structure 
Influenza is an enveloped negative sense single stranded RNA virus of the 
Orthomyxoviridae family, with a segmented genome consisting of 8 genes encoding 10 
proteins. There are 3 types, influenza A, B and C, though only influenza A and B have 
been implicated in seasonal epidemics. Influenza virus has two major surface 
glycoproteins, neuraminidase (NA) and haemagglutinin (HA), which form the basis for 
the classification of different virus strains and are the most immunogenic of the viral 
proteins. Influenza A viruses are sub-divided into 16HA subtypes (H1-16) and 9 NA 
subtypes (N1-9). All 16 HA and 9 NA subtypes are found in birds but so far only H1, 2, 
3 and 5, and N1 and 2 are known to infect humans 212. 
The segmented nature of the influenza genome allows for reassortment between 
different virus strains which infect the same cell. For example, the pandemic swine flu 
is thought to have arisen after reassortment of swine, human and avian viruses 210. The 
process of reassortment of different virus strains to create a new strain is called 
antigenic shift and accounts for the annual nature of influenza epidemics. Antigenic drift 
can also occur, which is due to the error prone viral RNA polymerase that induces point 
mutations in viral proteins. Antigenic shift and drift in the HA and NA proteins leads to 
viruses which are not recognised by neutralising antibody from a previous infection, 
and can select for viruses which are resistant to anti-viral drugs.  
1.5.3 Influenza replication cycle 
HA and NA are important virulence factors. HA is necessary for attachment of the virus 
to sialic acid receptors on epithelial cells, and NA catalyses the cleavage of sialic acid 
residues, allowing virion progeny to be released from infected cells.  Another important 
virulence factor is the M2 protein, which is an ion channel and acts to regulate the pH 
of endosomes in infected cells early on in infection. The NS1 proteins of certain 
influenza viruses such as H5N1 antagonise anti-viral interferons, contributing to their 
pathogenicity 213. Three polymerase subunits PB1, PB2 and PA carry out replication 
Chapter 1: Introduction  
45 
 
and transcription of influenza virus RNA, which is encapsulated by viral nucleoprotein 
(NP).  
The infective process begins with influenza virus binding to epithelial cells. HA 
preferentially binds to sialic acid linked to galactose. Human influenza viruses bind to 
sialic acid linked to galactose via an α2,6 linkage while avian influenza viruses bind to 
sialic acid linked to galactose via an α2,3 linkage 214. These specificities match the 
sialic acid residues on the respiratory epithelium of humans and birds; however, recent 
data suggests that α2,3 linked sialic acid receptors can be found deeper in the lung 
tissue of humans 215.  
HA exists as a precursor form which must be cleaved by host proteases into HA1 and 
HA2 216. Once the virus has been taken up by the host cell via endocytosis, the vesicle 
fuses with endosomes and becomes progressively acidified by the action of M2 protein. 
HA1 and HA2 mediate the fusion of the virus with the endosome and consequently the 
release of viral nucleoprotein out of the endosome into the nucleus. Seasonal influenza 
virus HA molecules are cleaved at a conserved arginine, which restricts the proteases 
that can cleave it, and thus the tissues and cells the virus can infect 217. Highly 
pathogenic influenza viruses have a multi-basic cleavage site which is cleaved by a 
wide range of host proteases and this renders these viruses able to infect multiple cells 
and tissues outside of the respiratory tract 217. 
Once in the nucleus, viral polymerases replicate viral RNA and synthesise mRNA. The 
mRNA is exported into the cytoplasm, where it is translated by host ribosomes. Early 
phase proteins such as the polymerase proteins, are transported back to the nucleus, 
where they function to amplify the replication of viral RNA. The rest of the viral proteins 
move to the golgi apparatus where they are glycosylated before assembly near the 
host cell membrane 218. The viral nucleoproteins assemble in the nucleus and 
aggregate with the structural proteins at the cell membrane, where they bud off the cell 
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membrane. NA catalyses the cleavage of terminal sialic acid residues on the cell 
membrane and facilitates virus release.  The replication of influenza virus is 
summarised in Figure 1.3.                                                                                                                               
1.5.4  Host response 
Influenza virus is recognised by PRRs expressed by the innate immune system 
including TLRs 3, 7, 8 and 9, RLRs and NLRs, which sense viral RNA and proteins 219, 
220. Influenza-infected epithelial cells produce a range of chemokines, including 
regulated on activation, normal T cell expressed and secreted (RANTES), MCP-1, IL-8 
and type 1 interferons such as IFN-α and IFN-β. IFN-α and β enhance antigen 
presentation by APCs, and cause up-regulation of MCP-1 and MCP-3, leading to 
recruitment of monocyte/macrophages 49, 221. Macrophages produce RANTES, MCP-1, 
MCP-3,  MIP-1α, and MIP-1β. Pro-inflammatory cytokines such as IFN-γ and TNF-α 
are produced by NK cells, macrophages and activated T cells 222. 
The extent of these early responses determines the extent of bystander tissue damage. 
Excess innate stimulation leads to an excess infiltrate into the lungs of T cells and other 
immune cells causing occlusion of the airways, in addition to the cell death caused by 
the virus itself. As vaccine strategies and antiviral drugs may have limited efficacy, 
attention has turned to the immune response itself, in an effort to reduce the lung 
pathology associated with influenza infections. Previous work in the laboratory has 
focused on regulating the inflammatory response to influenza infection, whilst 
maintaining viral clearance. For example, the blockade of TNF-α reduces pulmonary 
injury during influenza infection and ameliorates weight loss 223. 
Manipulation of OX40, an inducible late co-stimulatory molecule has shown promising 
results. It is up-regulated 1-2 days after antigen encounter and provides a positive 
signal to activated T cells, preventing activation-induced cell death (AICD) 123.  
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Figure 1.3. The influenza virus replication cycle. 1. The virus attaches to host cells 
via HA binding to sialic acid residues on respiratory epithelium. 2. The virus is 
endocytosed and endocytic vesicles fuse with endosomes and M2 mediates the 
acidification of the endosome, which leads to the release of viral nucleoprotein. 3. HA 
fuses with the endosome and viral nucleoprotein is released into the cytoplasm and 
transported to the nucleus. 4. Viral polymerases transcribe mRNA and replicate viral 
RNA. 5. mRNA is translated in the cytoplasm by host ribosomes. 6. Early phase 
proteins are transported back to the nucleus and further amplify viral RNA. 7. Late 
phase proteins are glycosylated in the endoplasmic reticulum and golgic apparatus. 8 
and 9. Late phase proteins aggregate with nucleoproteins at the cell membrane. 10. 
Assembled viral particles bud off the cell membrane. 
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Blockade of OX40 eliminates influenza-induced weight loss and cachexia and reduces 
cellular infiltrate into the lungs but importantly, does not impair viral clearance 224. 
Clearly, it is possible to manipulate respiratory immunity to alleviate symptoms without 
compromising pathogen clearance. However, to date the laboratory has only tested 
OX40 and inducible co-stimulator (ICOS) manipulations, both co-stimulatory molecules 
of the TNF receptor super family. One was beneficial, the other was not. It is postulated 
that ICOS was less beneficial because it reduced the T cell response too far and 
impaired viral clearance 225. Similarly, others show that 4-1BB is vital for protection 
against influenza, as its absence leads to an inefficient T cell response and virus out 
growth 124. These data highlight the variable outcomes of manipulating co-stimulatory 
molecules in influenza infection, and to understand this better, interruption of other 
receptor/ligand pairs are required and will be discussed in this thesis.  
1.5.5 Treatment and prevention 
Two main classes of anti-viral drugs exist against influenza – the NA inhibitors and the 
ion channel inhibitors. NA inhibitors, such as zanamavir and oseltamivir, block the 
enzymatic activity of NA, preventing the release of progeny virion particles from 
infected cells. However, in recent years high rates of oseltamivir-resistant viruses are 
reported 226, 227. Rimantidine and amantadine block the activity of the M2 ion channel 
and thus the release of viral nucleoprotein into the cytoplasm, which is a vital part of 
the virus replication 226. However, influenza virus strains with resistance to these drugs 
are emerging 226. Other anti-viral drugs under development include a nucleoside 
analogue which inhibits the polymerase activity of influenza viruses 228 and monoclonal 
antibodies against HA 229. 
Existing vaccines are grown in fertilised hens’ eggs and inactivated by formaldehyde or 
β-propiolactone. Vaccines consist of whole inactivated forms of type A and B influenza 
virus, detergent treated split products or purified HA and NA antigen formulations of the 
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three virus strains recommended by the WHO 230. Protection is provided by the 
production of haemagglutinin specific antibodies, and efficacy rates vary but are usually 
between 50 and 90% 230. However, due to antigenic variation of influenza virus, it is 
difficult to anticipate what strains will emerge in future epidemics.  New vaccines in 
development include live attenuated viruses, virosomes, which consist of the virus 
surface proteins on liposomes, and DNA vaccines 228. It is hoped that these new 
vaccines will be more immunogenic, with quicker production times.  
1.6 IL-10 and IL-10 receptor 
1.6.1 IL-10 
IL-10 is a 178aa cytokine, which was first discovered as a cytokine produced by Th2 
cells that was capable of inhibiting cytokine production by Th1 cells, hence it was 
originally called cytokine synthesis inhibitory factor (CSIF) 231.  
Although IL-10 was discovered as a Th2-associated cytokine, it is now clear that 
multiple T cell subsets can produce it. IL-10 is produced by Foxp3 positive Treg cells in 
vivo, and mediates the immune suppressive effects of Tregs 232. IL-10 is also produced 
by Th1 cells which co-express IFN-γ 233. This is obderved in vivo in mouse models of 
Toxoplasma gondii, RSV and influenza infections, where most of the IL-10 that is vital 
for limiting immune pathology is produced by Th1 cells which do not express Foxp3 233-
235. Human studies also show IFN-γ and IL-10-producing CD4+ T cells in the BAL fluid 
of patients suffering from active pulmonary tuberculosis 236. Equally, a population of IL-
12-dependent IL-10 and IFN-γ co-producing CD4+ T cells is reported in the blood of 
patients suffering from Lyme disease 237.  
Macrophages and DCs produce IL-10 upon microbial stimulation or after ligation of 
CD40 238, 239. Lung and alveolar macrophages produce IL-10 at homeostasis that alters 
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the ability of DC to induce allergic responses in mice 43. B cells 240, mast cells 241 and 
eosinophils 242 are also known to produce IL-10. 
1.6.2 Regulation of IL-10 expression  
IL-10 production by macrophages and myeloid DCs in response to TLR stimulation is 
dependent on the Toll/IL-1 receptor (TIR)-domain-containing adaptor molecule myeloid 
differentiation primary response protein 88 (MYD88) and TIR-domain-containing 
adaptor protein inducing IFN-β (TRIF) 238, 243. Deletion of TRIF and MYD88 abrogates 
TLR stimulation-induced production of IL-10 by murine macrophages in vitro 238. 
Similarly, deletion or blockade of MAPK attenuates IL-10 production upon stimulation of 
macrophages with TLR-4 and TLR-2 agonists 244. Similar results are reported for the 
production of IL-10 by macrophages upon stimulation with TLR-9 agonists 245.  
Strong TCR stimulus and high IL-12 induce the production of IL-10 by Th1 cells in vitro. 
IL-10 production is dependent on STAT4 and extra-cellular signal-related kinases 
(ERK) 1 and 2 activation 246, while production of IL-10 by Th2 cells is thought to be 
under the control of the Th2-associated transcription factor GATA-3 247. However, the 
production of IL-10 by Th2 cells also requires ERK activation 246. IL-10 production by 
naïve T cells after TCR stimulation can also be induced by IL-21 248 and IL-27 via 
STAT1 and STAT3 activation 249-251. 
1.6.3 Functions of IL-10 
IL-10 has broadly immune suppressive effects on a range of cell types. For example, 
IL-10 suppresses IFN-γ, IL-2, TNF-α and GM-CSF production by Th1 cells 231 and 
maintains expression of Foxp3 on Tregs 252. IL-10 inhibits LPS-induction of NFkB 
activation 253, the degradation of IkBα, the inhibitory subunit of NFkB, and DNA binding 
by NFkB 254. Others show that IL-10 negatively regulates the production of IL-17 by T 
cells and macrophages and suppresses expression of the Th17 transcription factor 
RORγt 255.  
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IL-10 decreases IL-6 and TNF-α production by activated macrophages 256, inhibits the 
ability of monocytes to induce a T cell response 257 by down-regulating their expression 
of MHC class II expression 258, 259 and modulates the expression of the co-stimulatory 
molecule B7 on macrophages 260-262. It decreases TLR-4-induced production of MIP-1α 
by human peripheral blood monocytes and alveolar macrophages 263 and MIP-3α, MIP-
3β 264 and RANTES 265 production by human monocytes. LPS-induced production of 
MIP-2, MCP-1 and MCP-5 by murine macrophages is reduced in the presence of IL-10 
266, as is antigen presentation and subsequent T cell priming by bone marrow-derived 
macrophages 267. 
Addition of IL-10 to murine DC/T cell co-cultures partially inhibits the production of IFN-
γ by Th1 cells 268. It inhibits the expression of the co-stimulatory molecules CD80 and 
CD86 by human dermal dendritic cells and also reduces their ability to stimulate naïve 
T cells 269. Additionally, IL-10 promotes the apoptosis of human epidermal DCs in 
culture 270 and inhibits the maturation of human DCs 271. It decreases IFN-γ-induced 
TNF-α and IL-12 production by DCs and attenuates the increase in CD80 and CD86 
expression induced by IFN-γ 272. Therefore, overall IL-10 reduces the ability of DCs to 
activate and prime a T cell response. 
The inhibitory effects of IL-10 extend to mast cells, where Fc epsilon receptor (FcεR) 
expression is reduced 273, 274 and apoptosis in developing mast cells increased 275. 
However, others show that IL-10 also stimulates the proliferation of differentiated mast 
cells, which implies that the effects of IL-10 may be dependent on the stage of their 
differentiation 276. LPS-induced production of IL-8, TNF-α and IL-1β by human 
neutrophils is reduced by IL-10 277, 278 as is production of the chemokines MIP-1α and 
MIP-1β 279. IL-10 also down-regulates the production of IFN-γ inducible protein 10 (IP-
10) on stimulation of neutrophils with IFN-γ and LPS 280. 
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In contrast to its effects on other immune cells, IL-10 promotes B cell activity by 
increasing MHC class II expression, viability 281 and antibody production 282-284. 
Therefore, for B cells IL-10 can act in a stimulatory manner to increase B cell 
activation. 
The effect of IL-10 on different immune cell subsets is displayed in Figure 1.4.  
 
 
 
Figure 1.4. Effects of IL-10 on immune cell subsets. IL-10 has broadly immune 
suppressive effects on immune cells, however, it enhances B cell responses and 
antibody production. Reviewed in 285, 286.  
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1.6.4 IL-10 receptor  
IL-10 receptor (IL-10R) is composed of two subunits and is a member of the class II 
cytokine receptor super family 287-289. It exists as a tetramer comprising 2 molecules 
each of IL-10R1 and IL-10R2 290. IL-10R1 constitutively interacts with Jak1 and IL-10R2 
is associated with the JAK kinase Tyk2 291. Binding of IL-10 to its receptor activates 
Jak1 and Tyk2 287, which phosphorylate tyrosine residues in the extracellular domain of 
IL-10R1 288. These tyrosinse residues serve as docking sites for STAT molecules 288 
(Figure 1.5). 
IL-10R signalling leads to activation of STAT1 and STAT3 in T cells and monocytes 287. 
In B cells IL-10 signalling activates DNA binding activity of STAT5 as well as STAT1 
and STAT3 292, 293.  
STAT3 is necessary for the anti-proliferative effects of IL-10 on murine macrophages 
as well as the inhibition of the production of inflammatory cytokines 294, 295. The 
importance of STAT3 in mediating the suppressive effects of IL-10 is observed in mice 
which have macrophages and neutrophils deficient of STAT3; in these mice, 
macrophages have enhanced MHC class II expression and the mice develop colitis in 
response to commensal gut flora, as do IL-10 knockout mice which are also highly 
susceptible to endotoxic shock 296, 297. 
Murine IL-10R can bind both murine and human IL-10, however, human IL-10R is 
specific for human IL-10 286. IL-10R is expressed by mouse and human mast cells, B 
cells, macrophages and epithelial and epidermal cells 289, 298-302. 
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Figure 1.5 The IL-10/IL-10R signalling complex. Binding of IL-10 to IL-10R activates 
the Jak kinases Jak1 and Tyk2, initiating a chain of events which leads to STAT 
molecules docking onto IL-10R1. These STAT molecules then become phosphorylated 
and translocate to the nucleus where they regulate gene expression. Adapted from 290. 
 
IL-10R expression is down-regulated by IFN-γ-activated human macrophages upon 
Fcγ receptor ligation 303, whereas signalling in murine alveolar macrophages is inhibited 
by TLR stimulation 197. Stimulation of macrophages and DCs with agonists to TLRs 2, 4 
and 9 inhibits IL-10-induced STAT-3 activation, inhibiting the ability of IL-10 to suppress 
macrophage activation 197, 304. 
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1.6.5 IL-10 and IL-10R in disease  
The IL-10/IL-10R axis has been extensively studied in different disease scenarios. The 
importance of IL-10 is evident by the phenotype of IL-10 and IL-10R knockout mice, 
which develop spontaneous colitis in response to commensal gut flora 297. Generally, a 
lack of IL-10 renders mice more resistant to certain pathogens, with the drawback that 
these mice usually develop severe immune pathology. However, the addition of IL-10 
can reduce immune pathology, at the risk of mediating a chronic infection. 
IL-10 produced by lung interstitial macrophages inhibits DC maturation and migration, 
preventing induction of allergic airways disease by adoptive transfer of bone marrow-
derived DCs stimulated with ovalbumin antigen (OVA) 43, 305. 
IL-10 in influenza infections is produced by effector CD4+ and CD8+ T cells which co-
produce IFN-γ 233, 306. Blockade of IL-10 during influenza infection has however yielded 
conflicting results. A study by Sun et al shows that blockade of IL-10R during influenza 
infection increases mortality and infiltrating monocyte/macrophages into the lungs, with 
increased IL-12, and IFN-γ positive virus-specific T cells in BAL fluid 233. These authors 
therefore suggest that that T cell-derived IL-10 is vital for ameliorating influenza-
induced inflammation. Conversely McKinstry et al show that IL-10 knockout mice and 
mice treated with an IL-10R blocking antibody have enhanced survival during lethal 
influenza infection due to the presence of a protective Th17 population in the lungs 306. 
McKinstry et al suggest that IL-10 inhibits the formation of a protective Th17 response 
during influenza infection. A further study from the Metzger group also shows that IL-10 
deficient mice have enhanced survival to a high dose influenza infection and display 
accelerated viral clearance with increased IFN-γ levels in BAL fluid 307. The authors 
attribute the enhanced clearance of influenza virus by IL-10 deficient mice in this study 
to increased anti-viral antibody production 307. 
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These discrepancies in the effect of IL-10 on influenza infections might be due in part 
to different doses of virus used for infections, different strains of mice and different 
amounts of IL-10R blocking antibody used. For example, the McKinstry and Metzger 
studies used a high dose of influenza virus, while the Sun study used a lower dose of 
the virus 233, 306, 307.  
Recent reports show that IL-10 can drive the alternative activation of macrophages. IL-
10 deficient mice infected with Schistosoma mansoni have lower expression of RELM-
α and YM1 in lung tissue compared to wild type mice 308 and blockade of IL-10R during 
Schistosoma mansoni infection reduces MR and YM1 expression by peritoneal 
macrophages 308.  
IL-10 is beneficial for disease outcome in mouse models of experimental autoimmune 
encephalitis (EAE) and Toxoplasma gondii 309, 310, Trypanosoma cruzi 311, Plasmodium 
yoelii 285 and Schistosoma mansoni infections 312, where it controls immune pathology 
and enhances the resolution of inflammation. On the other hand, persistence of certain 
infections is associated with IL-10 production, such as Leishmania major 313, 
Leishmania donovani 314, 315, Listeria monoctyogenes 316-318, and lymphocytic 
choriomeningitis virus (LCMV) infections in mice 319. In human disease, human immune 
deficiency virus (HIV)-infected individuals with progressive disease have a higher 
frequency of IL-10-producing CD4+ T cells compared to individuals with non-
progressive disease 320 and disease severity in systemic lupus erythematosus (SLE) 
patients correlates with serum levels of IL-10 321. Blockade of IL-10 in SLE patients 
decreases disease severity 322, 323.  
IL-10 therefore plays a major role in the balance between efficient clearance of 
pathogens and immune pathology and affects macrophage phenotype. IL-10 also has 
a major role in the regulation of immune homeostasis in the gut, as is evident in IL-10 
and IL-10R deficient mice that develop colitis 297.  Like the gut, the lungs are exposed 
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to myriad antigenic stimuli, including microbial stimuli, and it would be detrimental to 
mount a systemic immune response to all antigenic stimuli. This thesis will therefore 
investigate the effect of IL-10R blockade on innate immune homeostasis in the lungs 
and how this is altered during a subsequent influenza infection, once IL-10R blockade 
has ceased. I will explore the concept that a prior blockade of a negative regulator such 
as IL-10 can alter the lung micro-environment and the immune response to a 
subsequent influenza infection. 
1.7 GITR and GITRL 
Glucocorticoid-induced TNF receptor-related protein (GITR; also known as TNFRSF18) 
and its ligand GITR ligand (GITRL; also known as TNFSF18) belong to the TNF 
receptor super family and TNF super family respectively.  
1.7.1 Structure and expression profile 
GITR was discovered in 1997 as the result of a screen of molecules which were up-
regulated when a murine T cell line was stimulated with dexamethasone 324. GITR is 
induced by T cell activation treatments such as anti-CD3, Concanvalin A or phorbol 12-
myristate 13-acetate (PMA) and ionomycin stimulation 324. However, others have since 
shown that GITR is expressed on resting murine effector T cells, with high expression 
on Tregs 325-327. Shimizu et al also show that GITR is expressed on murine NK cells 
and splenic macrophages and B cells 325.  
To date, 4 isoforms of mouse GITR have been described, including a splice variant 
which lacks the trans-membrane and intra-cellular domains of GITR and therefore is a 
secreted protein which could act as a decoy receptor 328, 329.  
Mouse GITRL is expressed by splenic macrophages and B cells 326, 330, DCs 331, 
endothelial cells 332 and peritoneal macrophages 330. Expression of mouse GITRL on 
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splenic macrophages increases transiently upon activation, peaking four hours after 
stimulation with LPS 326.  
Human GITR and GITRL were reported soon after mouse GITR, and originally called 
activation induced TNF receptor family member (AITR) and AITRL 332, 333. Human GITR 
bears 55% identity with mouse GITR and is highly expressed on CD4+CD25+ Tregs, as 
is the case in mice, but is weakly expressed on CD4+CD25- T cells 332, 334, 335. As well as 
constitutive expression by T cells, GITR is also expressed by human NK cells 336. 
Human GITRL is expressed by activated endothelial cells 332, 333, NK cells, activated 
pDCs 337 and human retinal epithelium, on which it is up-regulated by inflammatory 
cytokines 338. A summary of the expression of mouse and human GITRL on various 
immune cell subsets is shown in Table 1.3.  
Mouse GITR is a 228 aa type 1 trans-membrane protein with 3 cysteine pseudorepeats 
in the extracellular domain 324, 329 and bears significant homology to other TNF receptor 
super family members OX40, 4-1BB and CD27 324. The structure of mouse GITR is 
shown in Fig. 1.6. Human GITR is a 234 aa type 1 trans-membrane protein 332 and like 
mouse GITR, human GITR displays 3 cysteine rich pseudorepeats in its extracellular 
domain, and bears significant homology with 4-1BB and CD27 332, 333. 
Mouse and human GITRL exist as a dimer in solution, although human GITRL is also 
stable as a trimer 339-341. Both human and mouse GITRL are type II transmembrane 
proteins 339.  
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CELL TYPE  GITR  GITRL  
T CELLS: 
• CD4+ CD25+  Tregs  
• CD4+  CD25-  (naïve)  
•  CD4+  CD25-  (activated)  
 
++ 
+ 
++  
 
- 
- 
+ ? *  
MACROPHAGES: 
• Unstimulated  
• Activated  
 
-  
+  
 
+ 
+  
NEUTROPHILS  ?  ? 
B CELLS  +  +  
ENDOTHELIAL CELLS  -  +  
DENDRITIC CELLS  -  +  
PLASMACYTOID  DENDRITIC 
CELLS  
-  +  
NK CELLS  +  -  
 
Table 1.3 Summary of the expression of GITR and GITRL. * Some studies show 
GITRL expression by T cells after TCR stimulation 326 but not others 330; GITRL is not 
reported on activated human T cells.  
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Figure 1.6 The structure of mouse GITRL. Mouse GITRL is composed of 2 
protomers, and exists as a dimer in solution. Protomers A and B are yellow and pink, 
respectively 339.  
 
1.7.2 Outcome of GITR signalling 
GITR is co-stimulatory for T cells and signalling through GITR leads to their survival 
and proliferation 330, enhances production of IL-2 and IFN-γ 342 and renders them less 
susceptible to the suppressive effects of regulatory T cells 325, 327, 343. Although GITR 
triggering leads to the proliferation of CD4+CD25- cells, other studies show that GITR 
stimulation can lead to the expansion of both CD4+CD25+ Tregs and CD4+CD25- T cells 
344, 345. The abrogation of responsiveness of effector T cells to suppression by Tregs is 
not observed with human T cells, although GITR is co-stimulatory for human effector T 
cells 346, 347. 
Ligating GITR on T cells leads to the activation of NFkB 333, 348 and the MAPK family 
members JNK, ERK and p38 348. GITR, like other TNFR family members interacts with 
TNF receptor-associated factor (TRAF) proteins to mediate signalling; GITR interacts 
with TRAFs 1, 2, 3, 4 and 5 348-351. Ligating GITR ultimately leads to survival and 
proliferation of T cells but others show that GITR also interacts with the pro-apoptotic 
Figure 1.?  Structure of mouse GITRL. Mouse GITRL is composed of 2 protomers, and 
exists a  a dimer in olution. Proto rs A and B are yellow and pink, respectively. Picture 
from Zhou Z PNAS 2008.
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protein Siva, indicating that ligation of GITR could also lead to apoptosis 352. Fig 1.7 
summarises GITR signalling in mouse T cells. 
Blockade of GITR on T cells in vitro reduces their proliferative activity in response to 
TCR stimulus 326. It was originally thought that splenocytes and lymph node cells from 
GITR knockout mice have higher proliferative capacity than wild type T cells, and are 
more sensitive to AICD 353. However other studies since show that CD8+ T cells from 
GITR knockout mice have impaired responses to TCR stimulus while CD4+ T cell 
responses are normal 354. GITR is up-regulated by T cells upon TCR stimulation, but if 
TCR stimulation is sub-optimal, CD28 stimulation is sufficient to up-regulate GITR 
expression 326.  
The effects of signalling through GITR on non-T cells appear to be cell-specific. Human 
and mouse macrophages up-regulate cell adhesion molecules such as ICAM-1 and 
pro-inflammatory factors such as MCP-1, IL-8, TNF-α and IL-6 and MMP-9 355, 356, that 
are dependent on NFkB 356.  
NK cells constitutively express low levels of GITR, which is enhanced on activation 336, 
337. The effect of GITR triggering on NK cells is controversial; certain studes report that 
it activates NK cell cytotoxicity with increased IFN-γ production 337, 357, while others 
show that tumour-expressed human GITRL imparts a negative signal to NK cells via 
GITR and down-regulates cytotoxicity, including IFN-γ production 336. The discrepancy 
between studies is interesting and may indicate that GITR signalling on NK cells has 
different effects in mice and humans. However, it is possible that in the in vivo mouse 
models the clearance of tumours after treatment with anti-GITRL antibody is due to 
GITR-mediated T cell activation and not directly due to effects on NK cells. 
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Figure 1.7 Signalling pathways induced by GITR ligation. GITR interacts with 
TFAFs 2, 4 and 5, which activates p38 mitogen activated protein kinase (MAPK) and c-
jun terminal protein kinases (JNK) via MAPK phosphorylating proteins MAPK kinase 
(MKK) and MKK kinase (MKKK). GITR triggering also activates NFkB signalling by a 
sequence of events beginning with the activation of NFkB-inducing kinase (NIK), which 
activates the downstream kinase IkB kinase (IKK) that phosphorylates the inhibitory IkB 
complex, leading to its degradation and release of the NFkB subunits from 
suppression. The result of NFkB, JNK and p38 MAPK activation is survival and 
proliferation via activation of the pro-survival proteins Bcl-XL and Bfl-1. GITR signalling 
can also activate the pro-apoptotic protein SIVA, which directly inhibits Bcl-XL and 
leads to apoptosis via the caspase pathway. Signalling via TRAFs 1 and 3 negatively 
regulates NFkB activation. Adapted from 118, 358. 
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Although GITR is expressed by splenic B cells, the effect of ligating GITR on these 
cells has not yet been elucidated.   
1.7.3 Outcome of GITRL signalling  
Like GITR, GITRL signalling is cell-specific. Signalling through GITRL on human 
macrophages induces the up-regulation of pro-inflammatory factors such as IL-6, IL-1β 
TNF-α and IL-8 that is dependent on the phosphorylation of ERK1/2, and inhibited by 
p38 and JNK1/2 355, 359. Treatment of murine macrophages with recombinant soluble 
GITR induces the production of inflammatory mediators such as COX-2 , MMP-9 and 
iNOS 360-362.  
GITRL is expressed by murine pDCs and expression is up-regulated by 
dexamethasone 363. Grohmann et al further show that reverse signalling through GITRL 
induces the non-canonical pathway of NFkB activation and leads to the production of 
IDO by pDCs 363. Therefore, for pDCs, the effect of signalling through GITRL appears 
to be anti-inflammatory.  
Over-expression of GITRL on human myeloid DCs enhances the ability of DCs to 
stimulate CD8+ T cells, leading to enhanced cytotoxic activity and cytokine 
production346.  
1.7.4 GITR and GITRL in human disease and mouse models of human disease 
The involvement of GITR and GITRL has been investigated in a range of mouse 
models of human disease. For example, treatment of mice with an agonistic anti-GITR 
antibody exacerbates the auto-immune diseases EAE 364 and collagen-induced arthritis 
365, 366, and GITR and GITRL are expressed in synovial fluid from human rheumatoid 
arthritis patients 334, 355. However, anti-GITR agonists enhance the immune response to 
persistent pathogens such as ocular HSV 367, Leishmania donovani 368 and Trichinella 
spiralis 369. Similarly, GITR-mediated co-stimulation of T cells results in clearance of 
murine tumours and melanoma 370-375, and enhances vaccine efficacy 376-378.  
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Blockade of the interaction between GITR and GITRL has proven beneficial for several 
mouse models of pulmonary inflammatory disease. During bleomycin-induced lung 
inflammation, which is an acute model of lung inflammation, GITR knockout mice have 
improved disease outcome compared to wild type mice, with reduced lung 
pathology379. Similarly, GITR knockout mice have better disease outcome during 
carrageenan-induced lung inflammation, which is a model of chronic lung inflammation 
380. Wild type mice treated with a GITR fusion protein also have improved disease 
outcome, similar to GITR knockout mice, and the authors attribute this to a blockade of 
the pro-inflammatory effects of GITR signalling. Potentiating signalling through GITR 
during ovalbumin-induced airway allergy in mice leads to enhanced production of Th2 
cytokines and airways allergic disease; this implies GITR blockade could represent a 
therapeutic target 365. 
This thesis will focus on the role of GITR in the context of acute infection-induced 
inflammation caused by influenza.  
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1.9 Thesis objectives 
The activity of resident innate immune cells in the lung and airway clearly rests on a 
delicate balance. We hypothesise that slight alterations of this balance will adjust 
innate immunity and other subsequent responses to lung viral infection. Lung viral 
infection causes prolonged alterations. We further hypothesise that these alterations 
are also dictated by the initial starting innate phenotype in the lung.   
In this thesis I seek to address the following aims: 
1. Determine the precise phenotype of alveolar and lung macrophages at rest and 
following influenza infection. 
2. Determine the effect of transient IL-10R blockade on alveolar macrophage 
phenotype and the immune response to subsequent influenza infection. 
3. Determine the importance of GITR and its ligand in lung homeostasis and 
during influenza infection.    
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2.0 Materials and Methods 
2.1 Laboratory animals 
2.1.1 Mice 
Six to eight week old female Balb/c and C57BL/6 mice (Harlan Olac Ltd, Bicester UK) 
were maintained in specific pathogen-free conditions at BioSafety Level 2. All mice 
were kept in accordance with institutional and UK Home Office guidelines. 
2.2 Mouse infections  
On day 0, C57BL/6 or Balb/c mice were anaesthetised with isofluorane and infected 
with 1.4x105 pfu recombinant influenza virus strain A/HK/X31 (H3N2), a kind gift from 
Professor Wendy Barclay, Imperial College London. The virus was titrated by specific 
influenza virus plaque assay (see section 2.8). In some cases, mice were infected 
again six weeks later with 100 plaque forming units (pfu) recombinant influenza virus 
strain A/PR/8/1934/H1N1, which had been titrated by influenza-specific plaque assay. 
Influenza stocks were diluted in 50μl sterile endotoxin-free phosphate-buffered saline 
(PBS) and administered intra-nasally (i.n.) to mice held in an upright position. Mice 
were weighed daily and weight recorded as a percentage of original weight. Mice were 
then culled at various time points after infection by intra-peritoneal (i.p.) injection of 
pentobarbital and exsanguination via the femoral artery.  
2.3 Reagents for in vivo studies 
2.3.1 GITRL reagents 
Anti-GITRL antibody (Ab) was a kind gift from Professor Steve Cobbold (Oxford 
University, UK) and supplied as an ammonium sulphate cut. The antibody was then 
further purified by dialysis with PBS (dialysis cassettes were purchased from Thermo 
Scientific Inc.) on a protein G column (GE Healthcare), after which it was concentrated 
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by centrifugation using protein concentration tubes (GE Healthcare). The antibody 
concentration was then determined using a Bradford assay kit (Thermo Scientific Inc) 
and tested for endotoxin contamination by limulus amebocyte lyaste (LAL) (Kate 
Tomlinson, UCB).  
Balb/c mice were administered 200μg anti-GITRL Ab or rat IgG (BioXcell) i.p. on day 0 
(at the same time as infection), and on day 2, day 4 and day 6 post infection. 
Antibodies were diluted in 300μl sterile endotoxin-free PBS.   
Recombinant GITR:Fc fusion protein, composed of the cysteine-rich region of mouse 
GITR fused to human IgG1 was purchased from Axxorra (Enzo Life Sciences, UK). 
Mice were given 1μg i.p every from the day of infection. GITR:Fc was diluted in 300μl 
sterile endotoxin-free PBS. 
2.3.2 IL-10R reagents 
Anti-IL-10R antibody (IB1.3A) was purchased from Bioxcell (West Lebanon, NH, USA). 
C57BL/6 mice were injected i.p. with 200μg anti-IL-10R Ab or rat IgG on days -8, -6, -4 
and -2. The antibody was diluted in 200μl sterile endotoxin-free PBS. .  
2.4 Cell recovery and isolation 
2.4.1 Airway cells, tissue and serum recovery 
Blood from the femoral artery was centrifuged at 8000rpm for 8 minutes and the serum 
removed and stored at -70°C for analysis of cytokines. Bronchoalveolar lavage (BAL) 
was performed by inflating the lungs six times with 1.5ml 1mM EDTA in Hanks 
Balanced Salt Solution (HBSS) [both from GIBCO]. BAL fluid was then centrifuged for 5 
minutes at 1200pm, the supernatants frozen at -20ºC and the pellet resuspended in 
R10F (RPMI medium [PAA Laboratories] containing 10% (vol/vol) foetal calf serum 
(FCS) [Sigma Aldrich, MO, USA], 50U/ml penicillin and 50µg/ml streptomycin [both 
Sigma Aldrich, MO, USA]). Lungs, spleen and mediastinal lymph node were collected 
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and stored in R10F. Lymph nodes were disrupted into single cell suspension by 
passage through a 100µm sieve (BD Labware, NJ, USA). Lung and spleen tissue was 
disrupted by digestion with Liberase (Roche, Switzerland) and DNase grade II (Sigma 
Aldrich MO, USA). Briefly, lung and spleen tissue was finely chopped and incubated for 
30 minutes with 2.5mg/ml units of Liberase (Roche, Switzerland) and 50μg/ml DNase 
grade II (Sigma Aldrich MO, USA) in R10F, after which EDTA was added to a final 
concentration of 5mM. Tissue was then passed through 100µm sieve (BD Labware, 
NJ, USA) and washed in R10F. Cell suspensions were spun for 5 minutes at 240 x g, 
MLN cells were resusupended in R10F and red blood cell lysis was performed for lung 
and spleen tissue by resuspension of the pellet in 3ml ACK buffer (0.15 M ammonium 
chloride, 1 M potassium hydrogen carbonate and 0.01 mM EDTA, pH 7.2) before they 
were spun (5 min at 240 x g) and washed with R10F. Cell viability was assessed by 
Trypan blue exclusion and all cells were resuspended in R10F and 2 x 105 used per 
stain. 
2.4.2 Isolation of alveolar macrophages for in vitro studies 
BAL was performed on C57BL/6 or Balb/c mice as described before and cells in BAL 
fluid enumerated and plated out at 7 x 104 per well. Alveolar macrophages were 
isolated by adherence to plastic for 1 hour at 37ºC in 5% CO2 in DMEM, after which 
non-adherent cells were washed off. In some cases, LPS (10ng/ml) (Sigma Aldrich, 
MO, USA), IFN-γ (100ng/ml) (Sigma Aldrich, MO, USA), PolyI:C (20ng/ml) (Sigma 
Aldrich, MO, USA) or R10F were added in triplicate, otherwise Imiquimod (Invivogen) 
was added to the cells at concentrations ranging from 1 to 5μg/ml. Cells were then 
incubated at 37ºC in 5% CO2 for various time points. Cell supernatants were removed 
at various time points and stored at -70°C for cytokine analysis. In some cases 
macrophages were harvested by incubation with Versene EDTA (GIBCO) for 10 
minutes, after which they were scraped off and after being washed with R10F, were 
stained with specific antibodies.  
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2.4.3 Isolation of bone marrow-derived macrophages 
Femurs were removed from Balb/c or C57BL/6 mice and bone marrow was extracted 
by flushing through with RPMI medium. Red blood cell lysis was performed as 
described above. Bone marrow cells (3x105 per ml) were incubated with 20ng/ml 
MCSF in 10ml RPMI plus 20% (vol/vol) FCS and penicillin (50U/ml), streptomycin 
50µg/ml and 10% HEPES (wt/vol) pH 7 for 72 hours at 37ºC and 5% CO2 (all from 
Sigma Aldrich, MO, USA).  Another 5ml of medium containing MCSF were then added 
to the 10ml already in culture, followed by incubation for another 72hrs at 37ºC and 5% 
CO2. The cells were then harvested by incubation with EDTA followed by scraping; 
cells were then enumerated by trypan blue exclusion. Bone marrow-derived 
macrophages (7x104 per well) were then stimulated with LPS (10ng/ml) (Sigma Aldrich, 
MO, USA), IFN-γ (100ng/ml) (Sigma Aldrich, MO, USA), and incubated at 37ºC and 5% 
CO2. At various time points, cell supernatants were removed for cytokine analysis. 
Cells were harvested by incubation with Versene EDTA for 10 minutes followed by 
scraping. After being washed with R10F the cells were stained with specific antibodies 
and analysed by flow cytometry.  
2.5 Flow cytometry 
2.5.1 Cell surface antigens 
All antibodies were purchased from eBiosciences, unless otherwise stated. A minimum 
of 2 x 105 or maximum of 1 x 106 cells were stained using combinations of FITC, PE, 
PerCp or PeCy5.5, PE, PECy7, APC, purified or biotin-conjugated antibodies, followed 
by labelled secondary antibodies. Cells were stained for 30 minutes on ice, with 
antibodies dissolved in PBA [PBS containing 1% bovine serum albumin (BSA) and 
0.1% sodium azide (Sigma Aldrich, MO USA)].  
The cells were then washed twice with PBA, in some cases stained with a secondary 
antibody and then fixed with 2% formaldehyde for 20 minutes at room temperature, 
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after which the cells were washed twice with PBA and resuspended in PBA and stored 
at 4°C. The flow cytometry antibodies used are listed in Table 2.1. 
2.5.2 Intracellular cytokine staining 
For the detection of T cell-derived intracellular cytokines 1 x 106 cells were incubated 
for 3 hours at 37ºC and 5% CO2 with R10F containing phorbol 12-myristate 13-acetate 
(50 ng/ml), ionomycin (500 ng/ml; Calbiochem) and brefeldin A (10 mg/ml). Cells were 
then stained with anti-CD4 and anti-CD8 antibodies and fixed as above. After 
permeabilisation for 10 minutes with PBA containing 1% (wt/vol) saponin, cells were 
stained with anti-TNFα, anti-IFN-γ or anti-IL-17 antibodies diluted in saponin buffer. 30 
minutes later cells were washed twice with saponin buffer and once more with PBA. 
Samples were run on the cytometer within 4 hours of intracellular staining. 
2.5.3 RELM-α, YM1 and MR intra-cellular staining 
For the detection of intra-cellular RELM-α, YM1 and MR, 1 x 106 cells were incubated 
for 4 hours with R10F containing brefeldin A (10 mg/ml). Cells were then stained with 
anti-CD11c, anti-CD11b and anti-F480 antibodies and fixed as previously described. 
After permeabilisation for 10 minutes with PBA containing 1% saponin, cells were 
stained with anti-RELM-α, anti-YM1 or anti MR antibodies diluted in saponin buffer for 
20 minutes. In the case of RELM-α and YM1 after 2 washes in PBA containing 1% 
saponin buffer, cells were further stained with a fluorophore-conjugated anti-rabbit or 
anti-rat antibody respectively. Then 30 minutes later stained cells were washed once 
with saponin buffer and twice more with PBA. Samples were run on the cytometer 
within 4 hours of intracellular staining. All samples were run on a FACS Canto flow 
cytometer and results were analysed using FlowJo software. 
  
Chapter 2: Materials And Methods 
71 
 
Antibody Conjugation Dilution 
used  
Clone Company 
Purified rabbit anti-
murine RELM-α 
Purified 2μg/ml Polyclonal 
antibody 
Peprotech 
Purified anti-rabbit 
IgG 
Purified 2μg/ml Polyclonal 
antibody 
Invitrogen 
Anti-rabbit IgG2a PE 200 54447 Invitrogen 
Rat anti-mouse YM1 
(ECF-L) 
Purified 2μg/ml 281926 R&D 
Anti-rat IgG FITC 100 Polyclonal 
antibody 
Abcam 
Rat anti-mouse 
CD206 (MR) 
Alexa FLUOR 488 25 MR5D3 AbD 
serotec 
Rat IgG2a negative 
control 
Alexa FLOUR 488 25 YTH71.3 AbD 
serotec 
Rabbit anti-mouse 
CCR2 
Purified 2μg/ml E68 Abcam 
Anti-mouse GITR 
Ligand 
PE 50 YGL386 eBioscience 
 
Anti-mouse GITR 
Ligand 
Biotin 50 YGL386 eBioscience 
Anti-mouse GITR PE 200 DTA-1 eBioscience 
Anti-mouse GITR Biotin 200 DTA-1 eBioscience 
Anti-rat IgG2a PE 200 M2a-15F8 eBioscience 
Anti-rat IgG1 PE 50 M1-14D12 eBioscience 
Anti-mouse F4/80 PE-Cy7 200 BM8 eBioscience 
Anti-mouse CD11c APC 200 N418 eBioscience 
Anti-mouse CD11b PerCp 400 M/170 eBioscience 
Anti-mouse CD200R APC 200 OX110 eBioscience 
Anti-mouse CD4 APC 200 GK1.5 eBioscience 
Anti-mouse CD4 FITC 100 GK1.5 eBioscience 
Anti-mouse CD4 PerCp 200 GK1.5 eBioscience 
Anti-mouse CD19 FITC 100 Ebio1D3 eBioscience 
Anti-mouse B220 PerCp 200 RA3-6B2 eBioscience 
Anti-mouse CD8 APC 200 53-6.7 eBioscience 
Anti-mouse CD8 PerCp 200 53-6.7 eBioscience 
Anti-mouse CD103 PE 200 2E7 eBioscience 
Anti-mouse FoxP3 PE 200 FJK-16s eBioscience 
Anti-mouse IL-10R APC 25 547324 R&D 
Anti-mouse CD80 APC 200 16-10A1 eBioscience 
Anti-mouse MHCII PE 400 NMR-4 eBioscience 
Anti-mouse IFN-γ PE-Cy7 200 XMG1.2 eBioscience 
Anti-mouse TNF-α PE 200 MP6-XT22 eBioscience 
Anti-mouse IL-17 APC 200 Ebio17B7 eBioscience 
  
Table 2.1 Antibody list    
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2.5.4 Foxp3 staining 
Foxp3 staining was performed according to manufacturer’s instructions (eBiosciences). 
Briefly, cells were stained with anti-CD4 and and anti-CD25 antibodies as before, and 
fixed for 30 minutes in Fixation/Permeabilisation buffer supplied by the manufacturers. 
After washing with Permeabilisation buffer cells were next stained with anti-Foxp3 PE 
in Permeabilisation buffer for 30 minutes. Cells were then washed again with 
Permeabilisation buffer and resuspended in PBA. All cells stained with Foxp3 were run 
on the flow cytometer within 4 hours of staining. 
2.6 Tissue imaging 
2.6.1 Haematoxlyin and Eosin staining of lung tissue 
The superior right lobe was inflated with 100μl PBS and fixed with 2% formalin in PBS 
at room temperature overnight. The tissue was then transferred to 70% ethanol and 
later embedded in paraffin wax. 4μM sections were stained with haematoxylin and 
eosin (Lorraine Lawrence, Imperial College, UK). 
2.7 Influenza-specific viral plaque assay 
Lung lobes were homogenised in DMEM media and the homogenates were freeze-
thawed three times and spun at 2100rpm for 5 minutes. Supernatants were then plated 
out in duplicate doubling dilutions onto a monolayer of 5 x104  Madine Darby canine 
kidney (MDCK) cells per well. After a 3 hour incubation at room temperature, a 1% 
methyl cellulose overlay was placed on the samples, and the samples were incubated 
for 72 hours at 37°C and 5% CO2. Cell monolayers were then washed with PBS and 
permeabilised with 0.5% Triton-X-100 (Sigma) after which they were washed and 
incubated with anti-influenza antibody (Serotec) for 90 minutes, followed by anti-mouse 
horseradish peroxidase (HRP) (Dako) for 90 minutes. Infected cells were then 
visualised using 3-amino-9-ethylcarbazole substrate and plaque forming units were 
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enumerated by light microscopy; total plaque forming units were calculated by number 
of plaques x dilution factor x volume of lung homogenate. 
2.8 Detection of soluble factors in lung homogenate and BAL fluid 
2.8.1 Detection of soluble factors in lung homogenate and BAL fluid by ELISA 
ELISA kits were used to measure soluble levels of IL-6, (Ebioscience) TNF-α 
(BDBiosciences), and YM1 (R&D) and individual manufacturer’s instructions were 
followed. Soluble RELM-α was measured using optimised antibody pairs purchased 
from Peprotech and the manufacturer’s instructions were followed. Briefly, lungs were 
homogenised in DMEM and centrifuged for 5 minutes at 2100rpm. Supernatants were 
then used for the ELISA and diluted as appropriate. BAL fluid was used neat or diluted 
as appropriate. Microtitre plates were coated with 100μl of capture antibody dissolved 
in PBS or coating buffer specified by the manufacturers; capture antibody was 
incubated at room temperature or 4°C according to manufacturer’s instructions. After 5 
washes with PBS containing 0.05% Tween 20 (Sigma Aldrich, MO USA) plates were 
blocked with 10% FCS in PBS or 1% BSA in PBS, depending on the manufacturer’s 
instructions, for 1 hour at room temperature. After a further 5 washes as before, 100μl 
of each sample was applied to the plate in duplicate and incubated at room 
temperature for 2 hours. Various dilutions of standards were also plated out according 
to the manufacturer’s instructions. Plates were washed again and samples were 
incubated with a biotinylated detection antibody for 1 hour at room temperature, 
washed as before and incubated with avidin-HRP for 30 minutes at room temperature 
in the dark. Samples were then washed and incubated with tetramethlybenzidine 
(TMB) substrate solution. The reaction was stopped with H2SO4 and optical densities 
read at 450nm using 570nm as a reference. The concentration of cytokine in each 
sample was determined using a standard curve.   
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2.8.2 Detection of soluble factors in lung homogenate and BAL fluid by Luminex 
multi-plex assays 
Luminex multi-plex assays were performed according to the manufacturer’s 
(Biolegend) instructions and using reagents provided by the manufacturer. Briefly, filter 
plates were washed with wash buffer (BioLegend, CA) and samples and standards 
were added diluted 1:1 with assay buffer (BioLegend, CA) and incubated at room 
temperature with shaking for 2 hours with pre-mixed beads coated with antibodies 
against the analytes of interest. Wells were then washed 3 times with assay buffer. The 
detection antibody cocktail mix (BioLegend, CA) was then added to the wells 
containing the pre-mixed beads and incubated with shaking for 1 hour at room 
temperature. Steptavidin-PE (BioLegend, CA) was then added to the pre-mixed 
bead/detection antibody mix and incubated for 30 minutes with shaking at room 
temperature. Sample and standard wells were then washed twice and beads 
resuspended in PBA and read on Luminex machines. Data was analysed using 
StarStation software. 
2.9 Statistics 
All mouse experiments were performed with groups of 4/5 mice per group, unless 
otherwise stated. In vitro stimulations of cells were performed with 3/4 wells per 
condition unless otherwise stated. GraphPad Prism was used for all statistical 
calculations. Different statistical tests were used depending on the type of data sets to 
be analysed. They include: non-parametric Mann Whitney t test, not assuming 
Gaussian distribution and Kruskal Wallis one-way analysis of variance (ANOVA) with 
Dunns post test. Data are presented as mean +/- standard error of the mean (SEM). p 
values were considered significant as follows * = p<0.05 ** =, p<0.01, *** = p<0.001.
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3.0 The phenotype of alveolar macrophages 
3.1 Introduction 
3.1.1 Alveolar macrophages at homeostasis 
Alveolar macrophages constitute 90% of the cells in a naïve airway and due to the 
constant antigenic onslaught experienced by the airways they must perform a 
balancing act between ignorance of innocuous inhaled antigen and mounting a robust 
immune response to pathogens. To a large extent the lung micro-environment provides 
the specific cues that allow alveolar macrophages to respond or not. 
Alveolar macrophages are highly phagocytic and one of their main functions is to 
sequester antigen from dendritic cells in the airway and interstitium in order to avoid an 
immune response being mounted against harmless antigen. Intra-tracheal 
administration of antigen activates a T cell response via dendritic cell migration to the 
lymph node only when the phagocytic abilities of alveolar macrophages have been 
overwhelmed 381. This mechanism ensures that particulate antigen can be cleared 
without inducing inflammation unless it exceeds a certain threshold. 
Alveolar macrophages express high levels of scavenger receptors, which facilitate the 
phagocytosis of un-opsonised antigen. The mannose receptor (MR) is a C-type lectin 
involved in phagocytosis, which is constitutively expressed by alveolar macrophages 
382, but is inducible on other macrophages after stimulation with IL-4 and IL-13, and 
therefore is considered a marker for alternatively activated macrophages 62.  MR 
mediates the endocytosis and phagocytosis of microbes expressing mannose-rich 
glycoproteins for MHC class II presentation by macrophages 383. Ligands recognised by 
MR are found on bacterial species such as Klebsiella pneumoniae 384, Streptococcus 
pneumoniae 385, Leishmania donovani 386 and Trypanosoma cruzi 387. 
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MR expression is reduced 10-fold by IFN-γ, which also decreases MR-mediated 
endocytosis 388, 389. However, others show that the combined actions of IL-4 and IFN-γ 
can actually enhance MR-mediated phagocytosis 390. Interestingly, MR expression on 
human alveolar macrophages is enhanced by SP-A, which is abundant in the airways, 
and could explain its constitutive expression on alveolar macrophages 391. Additionally, 
alveolar macrophages from SP-A deficient mice display lower expression of MR, which 
supports the findings in human macrophages 391. 
A key mechanism that restricts the activation of alveolar macrophages is the high 
expression of CD200R that transmits a negative signal to alveolar macrophages upon 
ligation by CD200 392. CD200 itself is highly expressed on endothelium and the luminal 
aspect of epithelium in the un-inflamed lung 200. CD200R is up-regulated by human 
macrophages upon treatment with IL-4 and IL-13, and is thought to be a marker of 
alternative activation on human macrophages 393. However it is also up-regulated by 
macrophages on a per cell basis during mouse models of influenza infection where 
IFN-γ and TNF-α dominate and may represent a strategy to terminate inflammation 200. 
Due to their presence at an environmentally exposed site one might expect alveolar 
macrophages to display an alternatively activated or regulatory phenotype. 
Alternatively activated macrophages are usually associated with allergy, worm 
infections or other Th2 inflammatory diseases 63, 394, where they play a role in wound 
healing 69, 395-397 and regulation of nutrient homeostasis and glucose tolerance 398. They 
are highly phagocytic, but have lower killing ability than classically activated 
macrophages 89. Alveolar macrophages constitutively express two markers of 
alternative activation, YM1 and MR – others however are yet to be determined. A 
number of markers of alternative activation are investigated in this chapter and these 
include the following: 
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3.1.2 YM1 
YM1 is a secreted protein originally discovered as crystals in the lungs of mice with 
immune defects, such as mice deficient in NADPH oxidase, CD40L deficient mice and 
the moth-eaten mouse, which has a severe autoimmune and immune deficiency 
syndrome 399. Subsequent studies show that YM1 is a novel mammalian lectin which 
recognises N-acetyl-D-glucosamine (GlcNac) oligosaccharides and heparan, and has 
significant homology to known mammalian chitinases, including chitotriosidase a 
human chitinase 400. YM1 and its close homologue YM2 (91% identical) are thought to 
have been formed from a gene duplication event with another mouse chitinase, acidic 
mammalian chitinase 68, 401, 402. The two isomers are only distinguishable by gene 
sequence analysis and therefore protein analysis does not allow a distinction between 
the two 403.  However, it is generally agreed that YM1 does not have chitinase activity 68 
and is now generally regarded as a marker for alternatively activated macrophages 59, 
60. 
YM1 mRNA is abundant in the lungs and spleen of mice, and YM2 is abundant in the 
kidneys, stomach and thymus 404. YM1 is expressed by alveolar macrophages in the 
un-inflamed airway 73, 74 and is also produced by epithelial cells, alternatively activated 
macrophages and neutrophils 404. It is reportedly the most highly inducible molecule by 
macrophages upon IL-4 and IL-13 stimulation, which occurs in a STAT-6 dependent 
manner 67, 405 and is down-regulated by IFN-γ 60, 406. 
YM1 crystals are found in Th2-associated chronic lung inflammatory disease models 
such as cryptococcosis 407, 408 and YM1 is highly produced in the lungs in mouse 
models of allergy and asthma 409. Studies of YM1 in infectious disease models have 
mainly focused on nematode infections of the gut, where alternatively activated 
macrophages are induced and YM1 is highly expressed 70, 410. 
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The function of YM1 is currently unknown. It is postulated to be an eosinophil 
chemoattractant; indeed it is often known as eosinophil chemoattractant factor L (ECF-
L) 411 but this action of YM1 is contested by others who claim it is not actually 
chemotactic for eosinophils 68. YM1 is also proposed to be involved in the resolution of 
inflammation, by masking lectin binding sites and preventing entry of inflammatory cells 
to the inflamed tissues 67. Others propose that YM1 promotes Th2 cytokine production 
during allergic inflammation in the lung by inhibiting the production of 12(S)-
hydroxyeicosatetraenoic acid (12(S)-HETE) by the enzyme 12/15-lipoxygenase (12/15-
LOX); 12(S)-HETE negatively regulates the ability of DCs to stimulate Th2 cytokine 
production by CD4+ T cells 403. It is suggested that 12(S)-HETE is a ligand for the 
myeloid regulator peroxisome proliferator-activated receptor gamma (PPAR-γ) 412, 
which when ligated decreases lung inflammation and remodelling during allergic 
inflammatory lung disease 413. Therefore, YM1 promotes Th2 inflammation in an 
indirect manner.  
To date, YM1 has not been investigated in the context of Th1 cytokine-dominated 
inflammation in the lung. 
3.1.3 Resistin-like molecule alpha 
Resistin-like molecule alpha (RELM-α), also associated with the alternatively activated 
macrophage phenotype, is a secreted protein which belongs to a family of resistin-like 
molecules including RELM-β and RELM-γ 414. RELM-α mRNA is present at highest 
concentrations in adipose tissue but is also found in mammary tissue, the lungs, 
tongue and heart 414. In contrast, RELM-β is mainly produced by colonic epithelium 415. 
RELM-α is found at high levels in the lungs during allergy and asthma, where it is 
associated with chronic Th2 pulmonary inflammation 65, 72, 416, and in the gut during 
nematode worm infections 410. RELM-α is produced by epithelial cells, alternatively 
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activated macrophages and eosinophils and is highly induced by stimulation of 
macrophages in vitro with IL-4 and IL-13 45, 417. 
Many roles are proposed for RELM-α, some of them conflicting. RELM-α stimulates the 
production of collagen and smooth muscle actin by fibroblasts, therefore promoting 
fibrosis during bleomycin-induced lung inflammation 66 and these results have been 
replicated by others upon over-expression of RELM-α in fibroblasts 65. It is thought that 
these effects of RELM-α signalling on fibroblasts imply a role in wound healing and 
tissue repair, especially during nematode infections 410. On the other hand Munitz et al 
show that RELM-α promotes inflammation in a mouse model of colitis, inducing the 
recruitment of neutrophils, lymphocytes and eosinophils and enhancing the production 
of TNF-α and IL-6 by macrophages upon stimulation with LPS 415. Furthermore, Nair et 
al demonstrate that RELM-α down-regulates the production of Th2 cytokines in the 
lung, and RELM-α deficient mice have significantly worse disease severity during Th2-
dependent Schistosoma mansoni egg-induced lung inflammation 72. Others propose a 
role for RELM-α in glucose tolerance during intestinal inflammation and the regulation 
of eosinophil chemoattractants 418. 
RELM-α expression has not been fully mapped on macrophage populations in the un-
inflamed lung, nor has it been investigated in the context of a Th1-biased acute 
inflammatory infection. 
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3.1.4 Hypothesis 
The goal of this chapter is to determine the phenotype of alveolar macrophages at 
homeostasis. I will test the hypothesis that alveolar macrophages are intrinsically 
alternatively activated due to the environment they reside in. I will attempt to answer 
the following questions: 
 Do alveolar macrophages express markers of alternative activation at 
homeostasis and how does this compare to other macrophage 
populations in the lung? 
 How does the expression of the above markers change during 
influenza-induced inflammation? 
 What factors control the expression of markers of alternatively activation 
on alveolar macrophages? 
 Do macrophages co-express co-stimulatory molecules with markers of 
alternative activation? 
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3.2 Results 
3.2.1 Lung and airway myeloid populations at homeostasis 
Broncho-alveolar lavage (BAL) was performed to isolate alveolar macrophages and the 
cells recovered from naïve C57BL/6 mice were stained with anti-CD11c, anti-CD11b 
and anti-F4/80 antibodies. CD11c is the αX subunit of the integrin αXβ2, also known as 
complement receptor 4 (CR4) and was originally identified as a marker of dendritic 
cells 419. However, it is now also widely used as a marker for alveolar macrophages 420. 
CD11b is the αM subunit of the αMβ2 integrin, also known as CR3, which is a receptor 
for C3b 421. CD11b (also known as mac-1 or CD18) is expressed by dendritic cells, 
monocytes, macrophages, neutrophils, eosinophils and sometimes by T cells 421. Both 
CR3 and CR4 enhance cell adhesion and phagocytosis activity of macrophages 422, 423. 
Myeloid cells were first selected on the basis of size and granularity by flow cytometry 
(Fig. 3.1A) and then analysed for the expression of CD11c and CD11b. Naïve alveolar 
macrophages expressed high levels of CD11c and low to intermediate levels of CD11b 
(Fig. 3.1B). They were also positive for F4/80 (Fig. 3.1C), which is a monocyte and 
macrophage-specific marker 424, and this was consistent with current protocols for 
identifying alveolar macrophages 43, 425. Airway lavage produces a virtually pure 
population of cells, as 90 to 95% of the cells recovered from the airways of a naïve 
mouse are alveolar macrophages 426. 
Lung homogenates were also stained with the same markers to provide a tissue-
resident comparison. After selection of myeloid cells on the basis of size and 
granularity, these cells were analysed for expression of CD11b and CD11c, which 
revealed 4 main populations; (Fig. 3.2A). The CD11c+ CD11blow cells were separated 
into 2 populations; expression of the integrin CD103 was used to identify CD11c+ 
CD103+ intra-epithelial dendritic cells 92 (Fig. 3.2B; R2)   
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Figure 3.1 Alveolar macrophages are the main population in the naïve airway. 
Broncho-alveolar lavage (BAL) cells derived from C57BL/6 mice were stained with anti-
CD11c APC, anti-CD11b PerCp and anti-F4/80 PE-Cy7. Viable cells (A) were gated 
based on forward and side scatter and alveolar macrophages were selected based on 
co-expression of CD11b and CD11c (B) and these cells were also positive for F4/80 
(C). Data represent 5 mice and 3 independent experiments. 
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Figure 3.1 Alveolar macrophages are the main population in the naïve airway. Broncho-
alveolar lavage (BAL) derived from C57BL/6 mice was stained with anti-CD11c APC, anti-CD11b
PerCp and anti-F4/80 PE-Cy7. Viable cells (A) were gated based on forward and side scatter
and alveolar macrophages were selected based on co-expression of CD11b and CD11c (B) and
these cells were also positive for F4/80 (C).
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Figure 3.2 Myeloid populations in the naïve lung. The lungs were extracted from 
uninfected C57BL/6 mice, digested and single cell suspensions stained with anti-
CD11c APC, anti-CD11b PerCp, anti-F4/80 PE-Cy7 and anti-CD103 PE. (A) Viable 
cells were selected and gated based on CD11b and CD11c expression. (B) CD11c+ 
CD11blow cells were analysed for CD103 expression. R2: CD11blow CD103+ DCs. (C) 
Lung DCs (R3) were defined as CD11b+ CD11c+ cells (R1; A), which were F4/80-. (D) 
Lung CD11c+ macrophages, R4 were defined as CD11chigh F4/80+ CD11blow (E) Lung 
CD11b+ monocyte macrophages were defined as CD11bhigh CD11clow F4/80+, R5. Data 
are representative of 5 mice per experiment and 3 independent experiments. 
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Figure 3.2 Myeloid populations in the naïve lung. The lungs were extracted from
uninf cted C57BL/6 mic , digested and single cell suspensions stained with a ti-CD11c
APC, anti-CD11b PerCp, anti-F4/80 PE-Cy7 and anti-CD103 PE. (A) Viable cells were
selected and gated based on CD11b and CD11c expression; R2: CD11b+ CD11c+ myeloid
DCs. (B) CD11c+ CD11blow cells were analysed for CD103 expression. R2: CD11blow
CD103+ DCs. (C) Alveolar macrophages, R3 were defined as CD11chigh F4/80+ CD11blow
(D) Lung monocyte macrophages were defined as CD11bhigh CD11cmedium F4/80+, R4.
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Lung myeloid dendritic cells were CD11b+ CD11c+ cells (R1; 3.2A), which were F4/80 
negative (Fig 3.2C; R3). CD11c+ lung macrophages were identified by the expression 
of F4/80 (Fig. 3.2D; R4). These CD11c+ macrophages were consistently seen in the 
lungs and were similar to alveolar macrophages in their size and granularity, and 
expression of CD11c, CD11b and F4/80. Others have indeed defined them as alveolar 
macrophages 43. It is likely that airway lavage does not flush all the cells out of the 
airways and so CD11c+ macrophages in the lung probably represent this population of 
residual alveolar macrophages. It is also possible that the CD11c+ macrophage 
population observed in the lungs represents lung macrophages in an intermediate 
stage of differentiation on the way to becoming alveolar macrophages 29. R5 (Fig. 3.2E) 
shows a second population of lung monocyte/macrophages, which were CD11clow 
CD11bhigh F4/80+, and these have been shown by others to be found in the lung 
interstitium 43.  
3.2.2 Comparing the expression of different markers of alternative activation 
We hypothesised that due to the regulated environment of the lungs and airways 
perhaps alveolar macrophages were alternatively activated or regulatory. Others report 
that mouse and human alveolar macrophages constitutively express MR 382 and YM1 
73, 74, and therefore we commenced to confirm MR and YM1 protein expression on 
macrophage populations in the un-inflamed lung and airways. We also examined the 
expression of another marker of alternative activation, RELM-α. 
C57BL/6 mice were culled, BAL performed and the lungs removed. BAL cells and lung 
homogenates were stained for intra-cellular expression of YM1, RELM-α and MR, 
which is only weakly expressed on the cell surface 427, 428. 
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Alveolar macrophages were almost all YM1 positive (97 +/- 1.2%), as were lung 
CD11c+ macrophages (97% +/- 0.7%), which we hypothesise to be residual alveolar 
macrophages not washed out by BAL (Fig. 3.3A). The similar YM1 expression 
displayed by these two populations lends further support to the theory that they may be 
the same population. There was a lower percentage of YM1 positive lung 
monocyte/macrophages with 86.7 +/- 3.9% positive for YM1 (Fig. 3.3A). 
Next, RELM-α expression was examined on lung and airway macrophages. Unlike 
YM1, there was a very low percentage of RELM-α positive alveolar and lung CD11c+ 
macrophages; however, there was a significant proportion of RELM-α positive lung 
monocyte/macrophages (62 +/- 6.6% positive) (Fig. 3.3B). Interestingly, alveolar and 
lung CD11c+ macrophages showed similar expression of RELM-α, which was dissimilar 
to expression by lung monocyte/macrophages. 
Most alveolar macrophages were positive for MR (98 +/- 0.5% positive), as previously 
published 382 and there was a similarly high percentage of MR positive lung CD11c+ 
macrophages (67 +/- 12%) (Fig. 3.3C). In contrast, there was a very low percentage of 
MR positive lung monocyte/macrophages (Fig. 3.3C). Surfactant protein A is known to 
up-regulate expression of MR on human macrophages 391. It is possible to imagine a 
similar scenario in the mouse as alveolar macrophages, which associate with alveolar 
epithelium and the surfactant monolayer, have high expression of MR compared to 
lung CD11b+ monocyte/macrophages which reside in the interstitial lung tissue. Airway 
macrophages are therefore YM1high, RELM-αlow, MRhigh and CD200Rhigh 200. 
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Figure 3.3 Expression of YM1, RELM-α and MR by macrophage populations in 
the lungs and airways. C57BL/6 mice were culled, BAL performed and the lungs 
extracted. BAL cells and lung homogenates were stained with anti-F4/80 PE-Cy7, anti-
CD11c APC and anti-CD11b PerCp to isolate lung and airway macrophage 
populations: alveolar macrophages (CD11chigh CD11blow F4/80+ - left hand column), 
lung CD11c+ macrophages (CD11chigh CD11blow F4/80+ - middle column), lung CD11b+ 
macrophages (CD11clow CD11bhigh F4/80+ - right hand column). After fixing, cell were 
permeabilised and then stained with rat anti-mouse YM1 followed by goat anti-rat IgG 
FITC (A), or rabbit anti-mouse RELM-α followed by goat anti-rabbit IgG FITC (B) or 
anti- mouse MR FITC (C). Histograms are representative of n=5; data from 3 
experiments. Shaded histograms represent isotype control and clear histograms 
represent specific antibody staining.  
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Figure 3.3 Expression of YM1 on macrophage populations in different tissues. C57BL/6 mice 
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3.2.3 Soluble YM1 and RELM-α in the lungs and airways 
Intra-cellular staining of lung and airway macrophages revealed different expression 
profiles of YM1 and RELM-α, but it was important to assess whether the amount of 
protein secreted into either compartment differed. Therefore, the levels of soluble 
RELM-α and YM1 were compared in lavage alone and in lung homogenate that would 
also contain some residual airway sample. 
C57BL/6 mice were culled, BAL performed and the lungs extracted and snap-frozen. 
Supernatants of lung homogenate, together with BAL fluid, were analysed by ELISA for 
soluble YM1 and RELM-α. Levels of YM1 in the BAL fluid were on average 2.6 times 
higher than levels in the lung homogenate (Fig. 3.4A), and correlates with intra-cellular 
staining of YM1 on airway and lung macrophages, which showed that there was a 
higher percentage of YM1 positive macrophages in the airways compared to the lungs. 
This suggests some element of site specific production, and as mentioned before we 
cannot rule out that levels present in lung homogenates do not actually represent 
residual airway protein. However, regardless of contamination of lung specimens with 
airway proteins, the lavage specimen still shows higher levels and we therefore believe 
that it represents a valid comparison. 
Based on flow cytometry data which indicated that there was a low percentage of 
RELM-α positive alveolar macrophages and lung residual CD11c+ macrophages, it was 
expected that there would be little soluble RELM-α in the airways. Conversely we 
expected moderate amounts in the lungs as lung monocyte/macrophages stained 
positive by flow cytometry (Fig. 3.3B). 
On the contrary, there was some RELM-α in the BAL fluid – at 5.1 +/- 3.9 ng/ml this 
was approximately 193 times less than the amount of YM1 (Fig. 3.4B). Levels of 
RELM-α in the lung were similarly low, at an average of 3.9 +/- 1.7ng/ml in the lung 
homogenates and approximately 94 times less than YM1 levels (Fig. 3.4B).  
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Figure 3.4 Levels of soluble YM1 and RELM-α in the naïve lung and airways. 
Naïve C57BL/6 mice were culled and BAL performed and the lungs extracted. BAL 
fluid and lung homogenate were then tested for soluble YM1 (A) and RELM-α (B) levels 
by ELISA as described in the Methods section. n=5+/- SEM, data are representative of 
2 experiments; * = p<0.05.   
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Figure 3.4 Levels of soluble YM1 and RELM-alpha in the naïve lung and airways. Naïve C57BL/6 
mice were culled and BAL performed and the lungs extracted. BAL fluid and lung homogenate were then 
tested for soluble YM1 (A) nd RELM-alpha (B) levels by ELISA as described in the Methods section. 
n=5+/- SEM; * = p<0.05. 
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RELM-α is produced by epithelial cells and perhaps this is the source of the soluble 
RELM-α observed in the BAL fluid 65. 
Overall, there was significantly more YM1 in the lungs and airways compared to RELM- 
α. This correlated with flow cytometry data which indicated that there was a higher 
percentage of YM1 positive cells in the lungs and airways than there were RELM-α 
positive cells. 
3.2.4 Macrophages during inflammation 
RSV is a common respiratory infection which induces a mixed Th1 and Th2 response 
429, 430.  RSV infection induces the production of IL-4 and IL-13 by alveolar 
macrophages, which polarises their transformation into alternatively activated 
macrophages with elevated expression of arginase 1, YM1 and RELM-α 431. Shirey et 
al further show that IL-4R null mice, which fail to produce alternatively activated 
macrophages during RSV infection, suffer worse pulmonary inflammation and lung 
pathology compared to wild type mice 431. The authors suggest that this induction of 
alternatively activated macrophages provides a mechanism by which the lung can 
repair inflammation-induced pathology. 
Like RSV, influenza infection causes severe lung pathology, and we hypothesised that 
during influenza infection alveolar macrophages might change their phenotype to 
become more alternatively activated in order to resolve the excessive lung pathology. 
To analyse alveolar macrophage phenotype during influenza infection, a time course 
experiment was performed. C57BL/6 mice were infected intra-nasally (i.n.) with 1.4x105 
plaque-forming units (pfu) of influenza strain X31 on day 0 and sacrificed 1, 3, 6 or 14 
days after infection, at which time the airways were sampled by BAL and the lungs 
were removed. Day 1 represents the induction phase of the immune response, day 3 
the peak of innate immunity, day 6 the peak of adaptive immunity and day 14 
represents the resolution phase of infection 49. 
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As expected, influenza infection led to weight loss, which peaked at day 6 of the 
infection (Fig. 3.5A). The increase in weight loss corresponded with an increase in 
inflammatory infiltrate into the lungs and airways, which was reflected in the total viable 
cell counts in BAL fluid and lung homogenate (Fig. 3.5B) and could be seen in 
haematoxylin and eosin (H and E) stained lung sections (Fig. 3.5C). Peak viral load 
occurred between days 1 and 3 of infection and influenza virus was undetectable in the 
lungs by day 14 of infection (Fig. 3.5D). 
During influenza infection there is a substantial inflammatory infiltrate into the airways. 
We show this in our influenza model in the airways, represented by the forward and 
side scatter plot of cells from BAL fluid at day 3 of infection (Fig. 3.6A). Alveolar 
macrophages up-regulated the expression of CD11b, but retained high CD11c 
expression (Fig 3.6B; R1) and remained F4/80 positive (Fig. 3.6C; R3). This up-
regulation of CD11b by alveolar macrophages during pulmonary inflammation is 
reported by others 432, 433. Although alveolar macrophages can renew by self-
proliferation, during inflammation monocytes are also recruited into the lungs and 
airways 434, 435. These cells were distinguishable by high CD11b expression, medium 
expression of CD11c and expression of F4/80 (Fig. 3.6B; R2 and Fig. 3.6D; R4). These 
monocyte/macrophages are described as inflammatory, induce apoptosis of epithelial 
cells during influenza infection, and contribute to influenza-induced pathology 42, 94. The 
number of alveolar macrophages and airway monocyte/macrophages was calculated 
by multiplying the percent of cells positive for the various markers by the percentage of 
cells in the myeloid gate and then by the total viable cell count (Fig. 3.6E). 
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Figure 3.5 Influenza infection induces weight loss and infiltration of cells into the 
airways. C57BL/6 mice were infected intra-nasally (i.n.) on day 0 with 1.4x105 plaque-
forming units (pfu) of influenza X31 on day 0 and weight loss monitored daily and 
expressed as a percentage of original weight (A). Mice were sacrificed on days 1, 3, 6 
and 14 after infection, BAL performed and the lungs extracted. Total viable cell counts 
of airway cells in BAL fluid (blue line) and lung homogenates (red line) were 
determined by Trypan blue exclusion (B). (C) Haematoxylin and eosin staining of 
histology sections of naïve and influenza-infected mouse lungs (day 6 of infection) was 
carried out as described in the Methods section. (D) Snap-frozen lung lobes were 
assessed for influenza virus by plaque assay as described in the Methods section. 
Data shown are representative of 3 experiments; n=5 +/- SEM.  ND = not detected. 
Data for Figure 3.5C was provided by Dr. John Goulding.  
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Figure 3.5 Influenza infection induces weight loss and infiltration of cells into the airways.
C57BL/6 mice were infected intra-nasally on day 0 with 1.4x105 plaque-forming units (pfu)
influenza X31 on day 0 and weight loss monitored daily and expressed as a percentage of original
weight (A). Mice were sacrificed on days 1, 3, 7 and 10 after infection, BAL performed and the
lungs extracted. Total viable cell counts of airway cells in BAL fluid (blue lin ) and lung
homogenates (red line) were determined by trypan blue exclusion (B). (C) Haematoxylin and eosin
staining of histology sections of naïve and influenza-infected mouse lungs (day 6 of infection) was
carried out as described in the Methods section. Data shown are representative of 3 experiments;
n=5 +/- SEM.
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Figure 3.6 Macrophages in the airway at day 3 of influenza infection. C57BL/6 
mice were infected i.n. with 1.4x105 pfu influenza X31; at day 3 of infection, BAL was 
performed and lungs extracted. Single cell suspensions of lung homogenate and BAL 
cells were stained with anti-CD11c APC, anti-CD11b PerCp and anti-F4/80 PECy7. 
Myeloid cells were selected on the basis of size and granularity (A) and then by CD11c 
and CD11b expression (B). Alveolar macrophages were identified as being CD11c+ 
cells (R1; B) which were F4/80+ (R3;C) and airway monocyte macrophages were 
classed as CD11b+ cells (R2; B) which were F4/80+ (R4;D).  (E) The number of alveolar 
macrophages (blue line) and airway CD11b+ monocyte/macrophages (red line) was 
calculated by multiplying the percentage positive cells x percent of myeloid cells x 
viable cell count. (F) The numbers of lung CD11c+ macrophages (blue line) and lung 
CD11b+ monocyte/macrophages (red line) were determined as for the airways. Data 
are representative of 3 experiments; n=5 mice per group +/- SEM.  
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Figure 3.6 Macrophages in the airway at day 3 of influenza infection. C57BL/6 mice were infected
intra-nasally (i.n.) with 1.4x105 (pfu) influenza X31; at day 3 of infection, BAL was performed and lungs
extracted. Single cell suspensions of lung homogenate and BAL fluid were stained with anti-CD11c
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R4
Days after influenza infection
Days after influenza infection
Naïve Day 3 
Chapter 3: The Phenotype Of Alveolar Macrophages 
93 
 
Like the airways (Fig. 3.6E), the lungs contained a significant macrophage infiltrate 
during influenza-induced inflammation that consisted of the two lung-resident 
macrophage populations, the CD11c+ macrophages and the CD11b+ macrophages 
(Fig. 3.6F), the numbers of which were calculated as described above for airway cells.  
3.2.5 YM1 and RELM-α expression on airway macrophages during influenza 
infection 
The expression of YM1 was then determined on airway macrophage populations at 
days 1, 3, 6 and 14 of influenza infection. 
Most naïve alveolar macrophages were positive for YM1 (97 +/- 1.2%) and at day 1 this 
had not changed significantly (Fig. 3.7A and C). However, at day 3 and 6 of the 
infection, there was a reduction in YM1 positive cells to approximately 32 +/- 2% (Fig. 
3.7A and C). At day 14 of the infection, the percentage of YM1 positive cells was once 
again high and most alveolar macrophages were YM1 positive (91 +/- 2.12%) (Fig. 
3.7A and C), as observed for naïve alveolar macrophages. The reduction in the 
percentage of YM1 positive alveolar macrophages during influenza correlates with 
reports that suggest that YM1 mRNA expression is down-regulated by IFN-γ, which is 
highly produced during influenza infection 60, 406. Alternatively, the reduction in the 
percentage of YM1-expressing alveolar macrophages could indicate an increase in the 
secretion of this soluble protein. Importantly, the percentage of YM1 positive alveolar 
macrophages was restored to levels seen in naïve mice after resolution of influenza 
infection.  
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Figure 3.7 YM1 expression on airway macrophages during influenza infection. 
C57BL/6 mice were infected intra-nasally on day 0 with 1.4x105 pfu influenza X31 and 
culled 1, 3, 6 and 14 days after infection. BAL was performed and BAL cells stained 
with anti-CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy7, fixed, permeabilised and 
stained with rat anti-mouse YM1 followed by goat anti-rat FITC. Representative 
histograms show YM1 expression by alveolar macrophages (CD11chigh CD11bmedium  
F4/80+) (A) and airway monocyte/macrophages (CD11cmedium  CD11bhigh F4/80+) (B). 
The percentage of YM1 positive alveolar macrophages (C) and 
monocyte/macrophages (D) was determined by flow cytometry. Data are 
representative of 2 independent experiments; n=5 +/- SEM. * = p<0.05, ** p<0.01 
compared to day 0 for alveolar macrophages and day 1 for monocyte/macrophages. 
ND = not detected. Shaded histograms represent isotype control and clear histograms 
represent specific antibody staining. 
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Figure 3.7 YM1 expression on airway macrophages during influenza infection. C57BL/6 mice were
infected intra-nasally on day 0 with 1.4x105 pfu influenza X31 and culled 1, 3, 6 and 14 days af er
infection. BAL was performed and BAL cells stained with anti-CD11c APC, anti-CD11b PerCp, anti-
F4/80 PECy7, fixed, permeabilised and stained with rat anti-mouse YM1 followed by goat anti-rat FITC.
Representative histograms show YM1 expression by alveolar macrophages (CD11chigh CD11bmedium
F4/80+) (A) and airway monocyte/macrophages (CD11cmedium CD11bhigh F4/80+) (B). The percentage of
YM1 positive alveolar macrophages (C) and monocyte/macrophages (D) was determined by flow
cytometry. Data are representative of 2 independent experiments; n=5 +/- SEM. * = p<0.05, ** p<0.01,
*** p<0.001 compared to day 0 for alveolar macrophages and day 1 for monocyte/macrophages.
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At homeostasis, alveolar macrophages constitute 90% of the cells in the airways, 
however during inflammation, monocyte/macrophages are recruited into the airways; 
this population is only observed in the airways during inflammation and so it was not 
possible to analyse them for expression of YM1 during influenza infection. Like alveolar 
macrophages, most airway monocyte/macrophages expressed YM1 (97 +/- 8.27%) at 
day 1 of infection and there was a slight decrease of around 10% in the percentage 
positive at day 3 and 6 post infection (Fig. 3.7B and D). However, at day 14, unlike the 
alveolar macrophages, there was a further reduction in the percent of YM1 positive 
monocyte/macrophages in the airways, with 24 +/- 3.06% YM1 positive (Fig. 3.7B and 
D).  
Compared to the decrease in the percentage of YM1 positive alveolar macrophages, 
the percentage of YM1 positive airway monocyte/macrophages did not significantly 
decrease until day 14 of infection. At day 14 of influenza infection, the number of 
airway monocyte/macrophages is relatively low, as infection is resolving and therefore 
the percentage of YM1 positive cells is a fraction of a relatively small number of cells 
and may not be physiologically relevant.  
In contrast to YM1 expression, naïve alveolar macrophages did not express RELM-α – 
less than 1% positive – but the percentage positive increased from day 1 of infection, 
with 9 +/- 3.09% positive at day 1 and 68 +/- 2.85% RELM-α positive at day 3 (Fig. 
3.8A and C). At day 6 of infection, the percentage of RELM-α positive alveolar 
macrophages decreased to 48.72 +/- 4.92% and at day 14 of the infection, the 
resolution phase of infection, the percentage of RELM-α positive alveolar macrophages 
was once again reduced with only 14 +/- 7% positive (Fig. 3.8A and C). It was 
interesting that the percentage of RELM-α positive alveolar macrophages increased 
during a classic Th1 infection such as influenza, as the accepted dogma dictates that it 
is induced by IL-4 and IL-13 46. This indicates that factors produced in the airways 
during influenza infection are capable of inducing RELM-α expression.  
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Figure 3.8 RELM-α expression on airway macrophages during influenza 
infection. C57BL/6 mice were infected i.n. with 1.4x105 pfu influenza X31 and culled 1, 
3, 6 and 14 days after infection. BAL was performed and BAL cells stained with anti-
CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy7, fixed, permeabilised and stained 
with rabbit anti-mouse RELM-α followed by goat anti-rabbit IgG  FITC. Representative 
histograms show RELM-α expression by alveolar macrophages (CD11chigh CD11bmedium  
F4/80+) (A) and airway monocyte/macrophages (CD11cmedium  CD11bhigh F4/80+) (B). 
The percentage of RELM-α positive alveolar macrophages (C) and 
monocyte/macrophages (D) was determined by flow cytometry. Data represent 2 
independent experiments; n=5 +/- SEM. * = p<0.05, ** p<0.01 compared to day 0 for 
alveolar macrophages and day 1 for monocyte/macrophages. ND = not detected. 
Shaded histograms represent isotype control and clear histograms represent specific 
antibody staining. 
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Figure 3.8 RELM-alpha expression on airway macrophages during influenza infection. C57BL/6
mice were infected with 1.4x105 pfu influenza X31 and culled 1, 3, 6 and 14 days after infection. BAL
was performed and BAL fluid stained with anti-CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy7, fixed,
permeabilised and stained with rabbit anti-mouse RELM-α followed by goat anti-rabbit IgG FITC.
Representative histograms show RELM-α expression by alveolar macrophages (CD11chigh CD11bmedium
F4/80+) (A) and airway monocyte/macroph ges (CD11cmedium CD11bhigh F4/80+) (B). (C) Th percentage
of RELM-α positive alveolar macrophages (C) and monocyte/macrophages (D) was determined by flow
cytometry. Data represent 2 independent experiments; n=5 +/- SEM. * = p<0.05, ** p<0.01 compared to
day 0 for alveolar macrophages and day 1 f r monocyte/mac oph ges.
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It would be of interest to test the effect of TNF-α, IFN-γ and type 1 interferons on 
RELM-α expression by alveolar macrophages in vitro, as these cytokines are highly 
produced during influenza infection 221. Again, importantly, we observed that although 
the percentage of RELM-α positive alveolar macrophages increased during influenza 
infection, it was low again at resolution, as observed for naïve mice. 
Monocyte/macrophages could not be analysed in the airways at day 0 because they 
are not present in the airways of naïve mice, so analysis of this population began at 
day 1 of influenza infection. At day 1, the percentage of RELM-α positive 
monocyte/macrophages was higher than alveolar macrophages at the same time point, 
with 75% +/- 4.6% positive (Fig. 3.8B and D). The percentage of RELM-α positive 
monocyte/macrophages increased at day 3, with 88 +/- 2.3% positive and this fell to 63 
+/- 6.88% at day 6 and by day 14 only 22 +/- 5.49% were RELM-α positive (Fig. 3.8B 
and D). 
The increase in the percentage of RELM-α positive airway monocyte/macrophages 
was not as dramatic as observed for alveolar macrophages. However, at day 1, the 
majority of airway monocyte/macrophages already expressed RELM-α. This would 
indicate that either these monocytes come into the airways already expressing RELM-
α, or they up-regulate it upon entry into the airways. Again, we see unexpected 
expression of RELM-α during influenza infection. This might indicate that cytokines 
produced early during influenza infection might induce and maintain RELM-α 
expression at a high level. Like YM1, there was a low percentage of RELM-α positive 
airway monocyte/macrophages at day 14 of influenza infection. This could indicate that 
these cells change their phenotype after the inflammatory insult is gone or that they are 
being cleared after the infection. 
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3.2.6 YM1 and RELM-α expression on lung macrophage populations during 
influenza infection 
Like alveolar macrophages, most naïve lung CD11c+ macrophages were YM1 positive 
(97 +/- 0.73%) and this did not significantly change at day 1 of the influenza infection 
(Fig. 3.9A and C). However at day 3, there was a 13% reduction in the percentage of 
YM1 positive lung CD11c+ macrophages (85 +/- 1.63%) and this was further reduced at 
day 6 to 61.8 +/- 1.87% (Fig. 3.9A and C). At day 14, the percentage of YM1 positive 
lung CD11c+ cells had increased to 89 +/- 2.9% (Fig. 3.9A and C). The trend in YM1 
expression by these lung-associated CD11c+ macrophages is similar to CD11c+ 
macrophages found in the airways and lends further support to the idea that that these 
might represent residual alveolar macrophages not washed out by lavage.  
The decrease in the percentage of YM1 positive lung CD11c+ macrophages during 
inflammation might indicate that secretion of YM1 was enhanced or factors in the 
influenza-infected lung micro-environment might down-regulate YM1 expression. As we 
observed for alveolar macrophages, the percentage of YM1 positive alveolar 
macrophages returned to levels seen for naïve mice after resolution of influenza. 
The percentage of YM1 positive CD11b+ monocyte/macrophages in the lungs generally 
decreased during the influenza time course. At day 0 87 +/- 3.94% of 
monocyte/macrophages were positive for YM1 and this was reduced to 71 +/- 7.96% at 
day 1 and by day 3 only 25 +/- 6.22% were YM1 positive; this did not significantly 
change for the rest of the time points (Fig. 3.9B and D). The decrease in YM1 
expression by lung CD11b+ monocyte/macrophages was interesting as the percentage 
of YM1 positive cells never returned to levels seen for naïve mice. It would be 
interesting to analyse a later time point to determine if the majority of cells again 
expressed YM1. 
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Figure 3.9 YM1 expression on lung macrophages during influenza infection. 
C57BL/6 mice were infected with 1.4x105 pfu influenza X31 i.n. and culled 1, 3, 6 and 
14 days after infection. Lungs were removed, digested and single cell suspensions 
stained with anti-CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy7, fixed 
permeabilised and stained with rat anti- mouse YM1 followed by goat anti-rat igG FITC. 
Representative histograms show YM1 expression by lung CD11c+ macrophages 
(CD11chigh CD11bmedium  F4/80+) (A) and CD11b+ monocyte/macrophages (CD11cmedium  
CD11bhigh F4/80+) (B). The percentage of YM1 positive lung CD11c+ macrophages (C) 
and CD11b+ monocyte/macrophages (D) was determined by flow cytometry. Data 
represent 2 experiments. n=5 +/- SEM. * = p<0.05, ** p<0.0, *** p<0.001 compared to 
day 0. Shaded histograms represent isotype control and clear histograms represent 
specific antibody staining. 
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Figure 3.9 YM1 expression on lung macrophages during influenza infection. C57BL/6 mice were
infected with 1.4x105 pfu influenza X31 and culled 1, 3, 6 and 14 days after infection. Lungs were
removed, dig sted and single cell suspensions stained with a ti-CD11c APC, ti-CD11b PerCp, anti-
F4/80 PECy7, fixed permeabilised and stained with rat anti- mouse YM1 followed by goat anti-rat igG
FITC. Representative histograms show YM1 expression by lung CD11c+ macrophages (CD11chigh
CD11bmedium F4/80+) (A) and CD11b+ monocyte/macrophages (CD11cmedium CD11bhigh F4/80+) (B). The
percentage of YM1 positiv lung CD11c+ macrophag s (C) and CD11b+ mon cyte/macrophages (D)
was determined by flow cytometry. Data represent 2 experiments. n=5 +/- SEM. * = p<0.05, ** p<0.01
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The expression of RELM-α by lung CD11c+ macrophages during influenza infection 
was similar in trend to the expression observed on alveolar macrophages, with the 
percentage positive starting off low and peaking at day 3 of infection, and back to pre-
infection levels by day 14 (Fig. 3.10A and C). There was a general reduction in the 
percentage of RELM-α positive lung CD11b+ monocyte/macrophages throughout 
influenza infection (Fig. 3.10B and D).  At day 0, 62 +/- 6.63% of CD11b+ macrophages 
were RELM-α positive and this decreased throughout the influenza infection up to  day 
14 (Fig. 3.10B and D).  
The reduction of RELM-α positive lung CD11b+ monocyte/macrophages was similar to 
the reduction of RELM-α positive airway monocyte/macrophages and in contrast to the 
increase in RELM-α expression by alveolar macrophages.  
3.2.7 Soluble YM1 and RELM-α in the lungs and BAL fluid during influenza 
infection 
Having observed decreased intra-cellular YM1 and enhanced RELM-α expression by 
macrophage subsets in the lungs and airways during influenza infection, it was of 
interest to determine if soluble levels were also altered during influenza infection. 
C57BL/6 mice were infected i.n. with 1.4 x 105 pfu influenza X31 and culled 1, 3, 6 and 
14 days post infection, BAL performed and the lungs removed. Lung homogenates and 
BAL supernatants were assessed for RELM-α and YM1 by ELISA as described in the 
Methods section.  
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Figure 3.10 RELM-α expression on lung macrophages during influenza infection. 
C57BL/6 mice were infected i.n. with 1.4x10 5 pfu influenza X31 and culled 1, 3, 6 and 
14 days after infection. Lungs were extracted, digested and single cell suspensions 
stained with anti-CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy7 fixed, 
permeabilised and stained with rabbit anti-mouse RELM-α followed by goat anti-rabbit 
IgG FITC. Representative histograms show RELM-α expression by lung CD11c+ 
macrophages (CD11chigh CD11bmedium  F4/80+) (A) and airway monocyte/macrophages 
(CD11cmedium  CD11bhigh F4/80+) (B).  The percentage of RELM-α positive lung CD11c+ 
macrophages (C) and CD11b+ monocyte/macrophages (D) was determined by flow 
cytometry. * = p<0.05, ** p<0.01, *** p<0.001 compared to day 0.  Data are 
representative of 2 independent experiments. Shaded histograms represent isotype 
control and clear histograms represent specific antibody staining. 
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Figure 3.10 RELM-alpha expression on lung macrophages during influenza infection. C57BL/6
mice were infected with 1.4x10 5 pfu influenza X31 and culled 1, 3, 6 and 14 days after infection. Lungs
were extracted, digested and single cell suspensions stained with anti-CD11c APC, anti-CD11b PerCp,
anti-F4/80 PECy7 fixed, permeabilised and stained with rabbit anti-RELM-α followed by goat anti-rabbit
IgG FITC. Representative histograms show RELM-α expression by lung CD11c+ macrophages
(CD11chigh CD11bmedium F4/80+) (A) and airway monocyte/macrophages (CD11cmedium CD11bhigh
F4/80+) (B). The percentag (red line) nd GM (blue line)of RELM-α positive lung CD11c+ macrophages
(C) and CD11b+ monocyte/macrophages (D) was determined by flow cytometry. * = p<0.05, ** p<0.01,
*** p<0.001 compared to day 0 for alveolar macrophages and day 1 for monocyte/macrophages.
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Soluble YM1 increased in lung homogenates during influenza infection, with levels 
increasing 2 fold from day 0 to day 1, over 5 fold at day 3 and up to 10 fold at 6 (Fig. 
3.11A). Levels were still 5 fold higher at day 14 compared to day 0 but this difference 
was not statistically significant (Fig. 3.11A). Soluble YM1 levels dramatically increased 
in the BAL fluid during influenza infection, increasing two fold from day 0 to day 1, four 
fold up to day 3 and up to ten fold at day 6 and day 14 (Fig. 3.11B). This similar 
increase in levels of soluble YM1 in BAL fluid and lung homogenates was in contrast to 
the trend seen for intra-cellular levels of YM1 on airway and lung macrophage 
populations, which decreased during influenza infection. This decrease in intra-cellular 
YM1 was therefore presumably due to increased secretion of YM1 during influenza 
infection, which is reflected in higher levels of YM1 observed in BAL fluid and lung 
homogenates. However, it is possible that other cell types apart from macrophages can 
secrete YM1, including neutrophils 74 which could partly be responsible for the increase 
in soluble YM1 observed. It is interesting to note that soluble YM1 had not returned to 
pre-infection levels at day 14 despite the virus being eliminated by days 7 to 10 (Fig. 
3.5E). 
Soluble RELM-α in lung homogenates increased around a hundred fold from day 0 to 
days 1, 3, 6 and 14 of influenza infection (Fig. 3.11C). Similarly, soluble RELM-α in 
BAL fluid increased significantly up to days 3, 6 and 14 of influenza infection (Fig. 
3.11D). The increase in soluble RELM-α in BAL fluid and lung homogenates during 
influenza infection correlates with an increase in the level of intra-cellular RELM-α 
expression by lung and airway macrophages. It is possible that macrophages are only 
partially responsible for the soluble RELM-α observed, as it is known that epithelial 
cells can also produce it 65. However it would be interesting to determine what factors 
induced during influenza up-regulate the production of RELM-α, a protein usually 
associated with chronic Th2-associated inflammation. 
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Figure 3.11 Soluble levels of YM1 and RELM-α in the lungs and airways during 
influenza infection. C57BL/6 mice were infected i.n. with 1.4 x 105 pfu influenza X31 
and culled 1, 3, 6 and 14 days post infection. BAL was performed and the lungs 
removed. ELISA was used to measure soluble YM1 in lung homogenate (A) and BAL 
fluid (B) and RELM-α in lung homogenates (C) and BAL fluid (D). n=5 +/- SEM * = 
p<0.05, ** = p<0.01 using one way ANOVA. Data are representative of 2 independent 
experiments. 
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Figure 3.11 Soluble levels of YM1 and RELM-α in the lungs and airways during influenza infection.
C57BL/6 mice were infected in with 1.4 x 105 pfu influenza X31 and culled 1, 3, 6 and 14 days post
infection.BAL was performed and the lungs removed. ELISA was used to measure soluble YM1 in lung
homogenate (A) and BAL fluid (B) and RELM-α in lung homogenates (C) and BAL fluid (D). (E) snap
frozen lung lobes were homogenised and viral plaque assay performed as described in the Methods
Section. n=5 +/- SEM * = p<0.05, ** = p<0.01 compared to day 0 using one way ANOVA.
A B
C D
Day 1 Day 3 Day 6 Day 14
In
fl
u
e
n
z
a
 p
fu
/m
l
E
ND
*
*
*
S
o
lu
b
le
 R
E
L
M
-α
(n
g
/m
l)
Chapter 3: The Phenotype Of Alveolar Macrophages 
104 
 
3.2.8 MR expression throughout influenza infection 
The expression of MR by alveolar macrophages was next examined during influenza 
infection. In contrast to expression of YM1 and RELM-α, MR expression was only 
analysed at day 0, 7 and day 21 in this experiment. This represents the un-inflamed 
airway, the peak of inflammation and the resolved airway.  
The majority of alveolar macrophages were MR positive at day 0, but the percentage 
positive was decreased at day 7, with only 51+/- 6.2% remaining positive for MR (Fig. 
3.12A and B). By day 21, when influenza infection is resolved and the virus is cleared, 
the percentage of MR positive alveolar macrophages had not returned to naïve levels, 
with only 68 +/- 7% MR positive cells (Fig. 3.12A and B). The reduction in the 
percentage of MR positive alveolar macrophages is not surprising in light of the fact 
that it is known that IFN-γ negatively regulates its production 389. However, even at day 
14 when levels of IFN-γ are reduced 436, the percentage of MR positive alveolar 
macrophages had not returned to naïve levels (Fig. 3.12A and B). This indicates that 
influenza infection could permanently alter the expression of MR on alveolar 
macrophages. It would be of interest to investigate a later time point after influenza 
infection.  
Like alveolar macrophages, the majority of lung CD11c+ macrophages expressed MR, 
and the percentage positive decreased at day 7 of influenza infection (Fig. 3.12C and 
D). Again IFN-γ produced during influenza infection is likely to be responsible for the 
down-regulation of MR, but levels of IFN-γ decrease by day 10 of influenza infection 
and it is interesting that levels of MR are not back to naïve levels at day 21.  
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Figure 3.12 MR expression on lung and airway macrophages during influenza 
infection. C57BL/6 mice were infected i.n. with 1.4x105 pfu influenza X31 on day 0 and 
culled at day 0, 7 or 21 days after infection. Lungs were extracted, digested and single 
cell suspensions stained with anti-CD11c APC, anti-CD11b PerCp and anti-F4/80 
PECy7, fixed permeabilised and stained with anti-MR FITC.The percentage of MR-
expressing alveolar macrophages (A and B), lung CD11c+ macrophages (C and D) and 
lung monocyte/macrophages (E and F) was determined by flow cytometry. n=5 +/- 
SEM. Data are representative 2 independent experiments. Shaded histograms 
represent isotype control and clear histograms represent specific antibody staining. 
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Figure 3.12 Mannose receptor expression on lung and airway macrophages during influenza
infection. C57BL/6 mice were infected with 1.4x10 5 pfu influenza X31 on day 0 and culled at day 0, 7 or
21 days after infection. Lungs were extracted, digested and single cell suspensions stained with anti-
CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy7, fixed permeabilised and stained with anti-MR FITC.
The percentage of MR-expr ssing alveolar macrophages (A and B), lung CD11c+ macrophages (C and
D) and lung monocyte/macrophages (E and F) was determined by flow cytometry. n=5 +/- SEM.
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Next lung CD11b+ monocyte/macrophages were analysed for MR expression. At day 0 
very few lung CD11b+ monocyte/macrophages expressed MR and contrary to what we 
observed for alveolar and lung CD11c+ macrophages, the percentage positive actually 
increased up to day 7 and 21 of influenza infection (Fig. 3.12D and E). This is 
interesting and indicates that MR might be differentially regulated on lung CD11b+ 
monocyte/macrophages during influenza infection. If alveolar macrophages and lung 
CD11c+ macrophages are in fact the same population that resides in the airways then it 
is possible that the cytokine milieu might differ between the interstitial lung CD11b+ 
macrophages and the airway-resident alveolar macrophages during influenza infection, 
and this might account for the different expression of MR observed during influenza 
infection on these two populations. 
Airway CD11b+ monocyte/macrophages were not shown as they are not present in the 
airways at day 0 or day 21, only at day 7. Therefore a comparison could not be made 
with other time points.  
A summary of MR expression by airway and lung macrophages during influenza 
infection is shown on Table 3.1 and 3.2 respectively, including RELM-α and YM1 
expression. 
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 ALVEOLAR MACROPHAGES  AIRWAY 
MONOCYTE/MACROPHAGES  
Influenza 
time 
point  
Day 0  Day 6  Day 14  Day 0  Day 6  Day 14  
RELM-α  0  48 +/- 5  14 +/- 7  ND  63 +/- 7  22 +/- 5  
YM1  97 +/- 1  32 +/- 2  91 +/- 2  ND  89 +/- 2  24 +/- 3  
MR  99 +/- 
0.3  
51+/- 7 
(day 7)  
68 +/- 7 
(day 21)  
ND  16 +/- 3 
(day 7)  
ND 
(day 21)  
 
Table 3.1 Expression of RELM-α, YM1 and MR by airway macrophage 
populations during influenza infection. The percentage of alveolar and airway 
monocyte/macrophages expressing the different markers at day 0, day 6 and day 14. 
Percentages for MR expression are from day 0, day 7 and day 21. Values are 
percentage +/- SD. ND = not detected as monocyte/macrophages are not present in 
the airways at day 0. Data are representative of 2 independent experiments. 
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 LUNG CD11c+ MACROPHAGES  LUNG CD11b
+ 
MONOCYTE/MACROPHAGES  
Influenza 
time 
point  
Day 0  Day 6  Day 14  Day 0  Day 6  Day 14  
RELM-α  6 +/- 1  17+/- 3  16 +/- 5  62 +/- 6  29 +/- 5  18 +/- 5  
YM1  97 +/- 1  62 +/- 2  89 +/- 3  87 +/- 4  25 +/- 6  21 +/- 4  
MR  67 +/- 12  38 +/- 9 
(Day 7)  
80 +/- 2 
(Day 21)  
6 +/- 2  44 +/- 10  
(Day 7)  
32 +/- 14 
(Day 21)  
 
Table 3.2 Expression of RELM-α, YM1 and MR by airway macrophage 
populations during influenza infection. The percentage of alveolar and airway 
monocyte/macrophages expressing the different markers at day 0, day 6 and day 14. 
Percentages for MR expression are from day 0, day 7 and day 21. Values are 
percentages +/- SD. Data are representative of 2 independent experiments.  
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3.2.9 Influenza-induced factors up-regulate RELM-α expression by alveolar 
macrophages 
After observing an increase in the percentage of RELM-α and a decrease in the 
percentage of YM1 positive alveolar and lung CD11c+ macrophages, it was of interest 
to determine if we could recreate this effect in vitro using factors that are present in the 
influenza-infected lung and airway. IFN-γ is highly induced during influenza infection 
and is known to negatively regulate MR expression 389. It also reportedly negatively 
regulates YM1 up-regulation by IL-4 60, 406. Polyinocinic:polycytidylic acid (PolyI:C) is a 
TLR3 agonist and mimics double stranded RNA, which is associated with viral 
infections 437. It was of interest to stimulate TLR3 in vitro to determine if this induced 
changes in YM1 and RELM-α expression by alveolar macrophages.  
Alveolar macrophages were isolated from C57BL/6 mice as described in the Methods 
section and incubated with media, BAL supernatant from an influenza-infected mouse, 
100ng/ml IFN-γ or 20ng/ml PolyI:C and incubated for 24 or 48 hours at 37°C and 5% 
CO2. We assume that factors present during influenza infection were responsible for 
the up-regulation of RELM-α and down-regulation of intra-cellular YM1 observed during 
influenza infection. Therefore BAL supernatants from influenza-infected mice at day 6 
were tested for effects on RELM-α and YM1 levels. 
None of the conditions used altered the percentage of YM1 positive cells; the majority 
of alveolar macrophages remained YM1 positive 24 hours (Fig. 3.13A) and 48 hours 
(Fig. 3.13B) post stimulation. However, at 48 hours there was a slight decrease in the 
percentage of YM1 positive cells compared to 24 hours for all conditions used. This 
might indicate that factors present in the naïve airway are required for the expression of 
YM1; however this could be an artefact and due to the fact that the cells had been in 
culture for 48 hours.  
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Figure 3.13 RELM-α is induced by BAL fluid from influenza-infected mice. 
C57BL/6 mice were culled, BAL performed and alveolar macrophages isolated as 
described in the Methods section and plated out at 7x104 cells per well of a 96 well 
plate. Cells were stimulated with media (clear bars), BAL supernatant from a day 6 
influenza-infected mouse (orange bars), 100ng/ml IFN-γ (red bars) or 20ng/ml Poly I:C 
(blue bars) and incubated for 24 or 48 hours at 37°C and 5% CO2. The cells were then 
harvested as described in the Methods section and stained with anti-CD11c APC, anti-
CD11b PerCp, anti-F4/80 PECy7, fixed, permeabilised and stained with rabbit anti- 
mouse RELM-α and rat anti-mouse YM1 followed by goat anti-rat IgG FITC or goat 
anti-rabbit IgG PE. The percentage of YM1 positive alveolar macrophages was 
determined at 24 (A) and 48 hours (B) post stimulation and the percentage of RELM-α 
positive alveolar macrophages was determined by flow cytometry 24 (C) and 48 (D) 
hours after stimulation.  n=3 +/- SEM. Data are representative of 2 independent 
experiments.  
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Fig. 3.13 RELM-α is induced by BAL fluid from influenza-infected mice. C57BL/6 mice were culled, 
BAL performed and alveolar macrophages isolated as described in the Methods Section and plated out at 
7x104 cells per well of a 96 well plate. Cells were stimulated with media (clear bars), BAL supernatant from 
a day 6 influenza-infected mouse (orange bars), 100ng/ml IFN-γ (red bars) or 20ng/ml Poly I:C (blue bars) 
and incubated for 24 or 48 hours at 37 C and 5% CO2 for 24 or 48 hours. The cells were then harvested as 
described in the Methods Section and stained with anti-CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy7, 
fixed, permeabilised and stained with rabbit anti- mouse RELM-α and rat anti-mouse YM1 followed by goat 
anti-rat FITC or goat anti-rabbit PE. The percentage of YM1 positive alveolar macrophages was determined 
at 24 (A) and 48 hours (B) post stimulation and the percentage of RELM-α positive alveolar macrophages 
was determined 24 (C) and 48 hours after stimulation.  n=3 +/- SEM. 
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Incubation of alveolar macrophages with BAL fluid taken from an influenza-infected 
mouse at day 6 of infection induced a consistent increase in the percentage of RELM-α 
positive cells 24 hours (Fig. 3.13C) and 48 hours (Fig. 3.13D) post stimulation. This 
difference was statistically insignificant but the trend was consistent and indicates that 
factors present in the influenza-infected airway are capable of inducing RELM-α 
expression in alveolar macrophages. A caveat of this experiment is that RELM-α is 
present in BAL fluid from influenza-infected mice and this could be the source of the 
intra-cellular RELM-α expression observed for macrophages stimulated with BAL fluid.  
Next, alveolar macrophages were extracted as before and stimulated with TLR 
agonists against TLRs 3 and 7 along with IFN-γ. This was to more efficiently mimic the 
situation in vivo during influenza infection, when TLRs are stimulated in an environment 
rich in inflammatory cytokines. However, the combination of TLR stimulation with IFN-γ 
had no effect on YM1 expression and did not induce the expression of RELM-α (data 
not shown).  
3.2.10 Characterising the expression of RELM-α by lung and airway 
macrophages in a BALB/c model of influenza infection 
Having observed that RELM-α is highly up-regulated by macrophages during influenza 
infection in our C57BL/6 model, it was of interest to confirm these results in a BALB/c 
model of the disease.  
Therefore BALB/c mice were infected i.n. as before with 1.4x 105 pfu influenza X31 on 
day 0 and 1, 3, 6 or 14 days post infection. BAL was performed and the lungs extracted 
and homogenised. Lung and airway macrophage populations were analysed for RELM-
α expression as before.  
There was a low percentage of RELM-α positive CD11c+ alveolar macrophages at day 
0, and the percentage positive increased from day 1 up to day 6 of infection, falling 
again at day 14 (Fig. 3.14A).  
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Figure 3.14 RELM-α positive alveolar macrophages express GITRL during 
influenza infection. BALB/c mice were infected i.n. with 1.4 x 104 pfu influenza X31 on 
day 0 and culled at day 0, 1, 3, 6, or 14 post infection. BAL was performed and the 
lungs extracted. BAL cells were stained with anti-CD11c APC, anti-CD11b PerCp, anti-
F4/80 PECy-7 and anti-GITRL PE. Cells were then fixed, permeabilised and stained 
with rabbit anti-mouse RELM-α followed by goat anti-rabbit IgG FITC. The percentage 
of RELM-α positive alveolar macrophages (A) and airway monocyte/macrophages (B) 
was determined by flow cytometry.  The percentage of RELM-α positive cells 
expressing GITRL was next determined for alveolar macrophages (C) and airway 
monocyte/macrophages (D). n=5 +/- SEM. * = p < 0.05 ** = p < 0.01. ND = not 
detected. Data represent one experiment.  
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Figure 3.14 RELM-α positive alveolar macrophages express GITRL during influenza infection. 
BALB/c mice were infected i.n. with 1.4 x 104 pfu influenza X31 on day 0 and cull d  at day 0, 1, 3, 6, 
and 14 post infection. BAL was performed and the lungs extracted. BAL fluid was stained with anti-
CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy-7 and anti-GITRL PE. The percentage of RELM-α
positive alveolar macrophages (A) and airway monocyte/macrophages (B) was determined by flow 
cytometry.  The percentage of RELM-α positive cells expressing GITRL was next determined for 
alveolar macrophages (C) and airway monocyte/macrophag s (D). n=5 +/- SEM. 
* = p < 0.05 ** = p < 0.01. 
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This trend was consistent with that seen for C57BL/6 mice during influenza infection 
(Fig 3.8A). Similarly, as we observed for CD11b+ airway monocyte/macrophages in 
C57BL/6 mice (Fig. 3.8B), there was a general reduction in the percentage of RELM-α 
positive cells throughout influenza infection. These cells could not be analysed at day 0 
as they are absent from the airways of naïve mice but at day 1 the majority of CD11b+ 
airway monocyte/macrophages expressed RELM-α  and the percentage positive 
decreased throughout influenza infection (Fig. 3.14B).   
It was of interest to further characterise this population of RELM-α positive 
macrophages which appeared during influenza infection. Of particular interest was their 
expression of co-stimulatory molecules. Macrophages constitutively express co-
stimulatory molecules such as CD80 and CD86, which are up-regulated on activation 
260. Other co-stimulatory molecules are absent but induced upon activation. For 
example, OX40L, whose receptor is the co-stimulatory molecule OX40 which is 
expressed by late activated T cells, is not expressed by macrophages in the naïve 
state, but is up-regulated on activation 224. We were interested in analysing the 
expression of a related molecule, GITRL on RELM-α positive macrophages in the lungs 
and airways.  
GITRL is reportedly expressed by splenic and bone marrow-derived macrophages 330 
but so far the expression of GITRL has not been determined in the naïve lung and 
airways. GITRL is up-regulated by murine peritoneal and bone marrow-derived 
macrophages upon stimulation with LPS 330 and signalling through GITRL on 
macrophages leads to the production of inflammatory factors 355, 359.  
Due to very low numbers of RELM-α positive alveolar macrophages at day 0 it was not 
possible to analyse GITRL expression on these cells. However at day 1 of influenza 
infection a small percentage of RELM-α positive alveolar macrophages was also 
GITRL positive and this increased up to day 6 of influenza infection (Fig. 3.14C). 
Chapter 3: The Phenotype Of Alveolar Macrophages 
114 
 
At day 14 it was impossible to analyse GITRL expression on RELM-α positive alveolar 
macrophages as this comprised a very small cell population. GITRL is up-regulated by 
macrophages upon stimulation with LPS 330. RELM-α positive alveolar macrophages 
also up-regulated it during influenza infection, which is consistent with its up-regulation 
as a result of TLR stimulation.  
It was not possible to analyse airway monocyte/macrophages at day 0, and at day 1 of 
influenza infection RELM-α positive airway monocyte/macrophages did not express 
GITRL (Fig. 3.14D). However at day 3 of infection there was a small percentage of 
RELM-α positive airway monocyte/macrophages expressing GITRL (6 +/- 2%) which 
increased slightly to 13 +/- 4% GITRL positive cells at day 6 of influenza infection. The 
difference in GITRL expression between alveolar macrophages and airway 
monocyte/macrophages was interesting and the expression of GITRL by these two 
populations will be further characterised in Chapter 5. 
Lung CD11c+ macrophages were next analysed for RELM-α expression in the BALB/c 
model of influenza infection. As in the C57BL/6 model (Fig. 3.10A), at day 0 there was 
a low percentage of RELM-α positive lung CD11c+ macrophages and this increased 
throughout influenza infection, peaking at day 3 of infection (Fig. 3.15A). The increase 
in RELM-α positive cells was however not as dramatic as observed for alveolar 
macrophages (Fig. 3.14). As in the C57BL/6 influenza infection model (Fig. 3.10B), we 
observed that the majority of lung CD11b+ monocyte/macrophages expressed RELM-α 
at day 0 and this percentage decreased throughout influenza infection (Fig. 3.15B). 
However, unlike the case in C57BL/6 mice (Fig. 3.10B), where the percentage of 
RELM-α positive cells was lowest at day 14, in the BALB/c model the percentage of 
RELM-α positive lung CD11b+ monocyte/macrophages was high at day 14,  as 
observed at day 0 (Fig. 3.15B).  
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Figure 3.15 RELM-α positive lung macrophages express GITRL during influenza 
infection. BALB/c mice were infected i.n. with 1.4 x 104 pfu influenza X31 on day 0 and 
culled at day 0, 1, 3, 6, and 14 post infection and the lungs extracted. Lung 
homogenates were stained with anti-CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy-
7 and anti-GITRL PE, stained fixed, permeabilised and stained with rabbit-anti mouse 
RELM-α followed by goat anti-rabbit IgG FITC. The percentage of RELM-α positive 
lung CD11c+ macrophages (A) and lung CD11b+ monocyte/macrophages (B) was 
determined by flow cytometry.  The percentage of RELM-α positive cells expressing 
GITRL was next determined for lung CD11c+ macrophages (C) and lung CD11b+ 
monocyte/macrophages (D). (E) Lung lobes were tested for influenza virus via plaque 
assay as described in the Methods section. n=5 +/- SEM. * = p < 0.05 ** = p < 0.01.   
ND = not detected. Data represent one experiment. Data for Figure 3.15E was 
obtained from Dr. Robert Snelgrove.  
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Figure 3.15 RELM-α positive lung macrophages express GITRL during influenza infection. 
BALB/c mice were infected i.n. with 1.4 x 104 pfu influenza X31 on day 0 and culled  at day 0, 1, 3, 6, 
and 14 post infection. BAL was performed and the lungs extracted. Lung homogenates were stained 
with anti-CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy-7 and anti-GITRL PE. The percentage of 
RELM-α positive lung CD11c+ macrophages (A) and lung CD11b+ monocyte/macrophages (B) was 
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At day 14, like C57BL/6 mice (Fig. 3.5D), BALB/c mice have also cleared the influenza 
virus from the lungs (Fig. 3.15E) and inflammation has resolved, therefore this 
apparent strain difference is not due to impaired viral clearance in the BALB/c mice.  
Next, it was again of interest to analyse the expression of the co-stimulatory molecule 
GITRL on RELM-α positive cells in the lungs. At day 0 and day 1 the percentage of 
RELM-α positive lung CD11c+ macrophages expressing GITRL was low, but 
significantly increased up to day 3 and 6 of influenza infection (Fig. 3.15C). By day 14 
the percentage of GITRL positive cells was again low as at day 0 (Fig. 3.15C). This 
pattern resembled that observed for GITRL positive RELM-α positive alveolar 
macrophages.  
The expression of GITRL was next analysed on RELM-α positive lung CD11b+ 
monocyte/macrophages. There was a very low percentage of GITRL-expressing 
RELM-α positive lung monocyte/macrophages at days 0 and 1 of influenza infection 
but this increased significantly up to day 3 of influenza infection, falling again at days 6 
and 14 (Fig. 3.15D).  
3.2.11 YM1 expression by macrophage populations in a BALB/c model of 
influenza infection 
The expression of YM1 during influenza infection was next analysed on airway and 
lung macrophage populations in BALB/c mice. As before BAL and lung lobes were 
isolated from influenza-infected mice on days 0, 1, 3, 6 and 14 after influenza infection 
and analysed by flow cytometry for YM1. 
YM1 was expressed by the majority of alveolar macrophages, as observed before for 
C57BL/6 mice (Fig. 3.7A), and was similarly lost at days 3 and 6 post influenza 
infection (Fig. 3.16A). By day 14 however, the majority of alveolar macrophages again 
expressed YM1 (Fig 3.16A).  
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Figure 3.16 YM1 positive airway macrophages co-express RELM-α during 
influenza infection. BALB/c mice were infected i.n. with 1.4 x 104 pfu influenza X31 on 
day 0 and culled at days 0, 1, 3, 6, or 14 post infection. BAL was performed and BAL 
cells stained with anti-CD11c APC, anti-CD11b PerCp, anti-F4/80 PECy-7. Cells were 
then fixed, permeabilised and stained with rat-anti mouse YM1 followed by goat anti-rat 
IgG FITC, and rabbit-anti-mouse RELM-α followed by donkey-anti-rabbit IgG PE. The 
percentage of YM1 positive alveolar macrophages (A) and airway CD11b+ 
monocyte/macrophages (B) was determined by flow cytometry.  The percentage of 
YM1 positive macrophages co-expressing RELM-α was determined for alveolar 
macrophages (C) and airway CD11b+ monocyte/macrophages (D). n=5 +/- SEM. ND = 
not detected. ND = not detected. * = p<0.05 compared to day 0 for alveolar 
macrophages and day 1 for airway monocyte/macrophages. Data represent one 
experiment.  
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Airway CD11b+ monocyte/macrophages could not be analysed at day 0 as they are 
only recruited into the airways during inflammation. However, at day 1 of influenza 
infection 79 +/- 7% of airway monocyte/macrophages expressed YM1 and the 
percentage of YM1 positive cells decreased during influenza infection up to day 14 
(Fig. 3.16B). This pattern was similar to that previously seen for C57BL/6 mice (Fig. 
3.17B). 
Next it was of interest to determine whether YM1 and RELM-α were co-expressed at 
any time during influenza infection. At day 0, there were no YM1+RELM-α+ double 
positive alveolar macrophages, as alveolar macrophages did not express RELM-α at 
day 0. However, from day 1 of influenza infection there was an insignificant increase in 
the percentage of YM1+RELM-α+ double positive alveolar macrophages, with a 
reduction at day 14 (Fig. 3.16C). Airway monocyte/macrophages could not be analysed 
at day 0 but the percentage of YM1+RELM-α+ double positive cells increased from day 
1 to day 3, and decreased up to day 14 (Fig. 3.16D). 
Representative flow plots showing co-expression of YM1 and RELM-α by alveolar 
macrophages (left hand side panels) and airway CD11b+ monocyte/macrophages (right 
hand side panels) is displayed in Fig. 3.17.  
Next, lung macrophage populations were analysed for expression of YM1 in BALB/c 
mice. As observed for C57BL/6 mice, the expression of YM1 by lung CD11c+ 
macrophages during influenza closely resembled the pattern seen for alveolar 
macrophages, with the majority of cells expressing it at day 0 and a reduction of YM1 
positive cells at days 3 and 6 of infection, but at day 14 the majority of cells were once 
again YM1 positive (Fig. 3.18A). In contrast to what was seen previously for C57BL/6 
mice, YM1 was expressed by few CD11b+ lung monocyte/macrophages at day 0, but 
the percentage positive increased up to days 3 and 6 of influenza infection, decreasing 
again at day 14 (Fig. 3.18B).  
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Figure 3.17 YM1 and RELM-α co-expression by airway macrophages in BALB/c 
mice during influenza infection. BALB/c mice were infected i.n. with 1.4 x 104 pfu 
influenza X31 on day 0 and culled at day 0, 1, 3, 6, and 14 post infection. BAL was 
performed and BAL cells were stained with anti-CD11c APC, anti-CD11b PerCp and 
anti-F4/80 PECy-7. Cells were then fixed, permeabilised and stained with rat-anti 
mouse YM1 followed by goat anti-rat IgG FITC, and rabbit-anti-mouse RELM-α 
followed by donkey-anti-rabbit IgG PE. Alveolar macrophages (left hand side panels) 
and airway monocyte/macrophages (right hand side panels) co-expressing RELM-α 
and YM1 were determined by flow cytometry. Data represent 5 animals. ND = not 
detected. Data represent one experiment.  
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Figure 3.18 YM1 positive lung macrophages co-express RELM-α during influenza 
infection. BALB/c mice were infected i.n. with 1.4 x 104 pfu influenza X31 on day 0 and 
culled at day 0, 1, 3, 6, and 14 post infection. BAL was performed and the lungs 
extracted and homogenised. Lung homogenates were stained with anti-CD11c APC, 
anti-CD11b PerCp, anti-F4/80 PECy-7. Cells were then fixed, permeabilised and 
stained with rat-anti mouse YM1 followed by goat anti-rat IgG FITC, and rabbit-anti-
mouse RELM-α followed by donkey-anti-rabbit IgG PE. The percentage of YM1 
positive lung CD11c+ macrophages (A) and lung CD11b+ monocyte/macrophages (B) 
was determined by flow cytometry.  The percentage of YM1 positive macrophages co-
expressing RELM-α was determined for lung CD11c macrophages (C) and lung 
CD11b+ monocyte/macrophages (D). n=5 +/- SEM. ND = not detected. * = p<0.05, ** = 
p<0.01  compared to day 0. Data represent one experiment.  
 
 
 
Day 0 Day 1 Day 3 Day 6 Day 14
%
 Y
M
1
+
Lung CD11c+
macrophages
Day 0 Day 1 Day 3 Day 6 Day 14
%
 Y
M
1
+
Lung CD11b+
monocyte/macrophages
%
 Y
M
1
+
R
E
L
M
-α
+
%
 Y
M
1
+
R
E
L
M
-α
+
Lung CD11c+
macrophages
C D
A B
Lung CD11b+
monocyte/macrophages
Day 0 Day 1 Day 3 Day 6 Day 14 Day 0 Day 1 Day 3 Day 6 Day 14
**
**
*
Chapter 3: The Phenotype Of Alveolar Macrophages 
121 
 
Next, as with alveolar macrophages, the co-expression of YM1 and RELM-α was 
determined during influenza infection. There was a very low percentage of YM1+RELM-
α double positive cell lung CD11c+ macrophages at day 0, with a slight increase at day 
1 of infection, but no significant changes at any of the time points analysed (Fig. 
3.18C). There was a consistently low percentage of YM1+RELM-α+ double positive 
CD11b+ lung monocyte/macrophages at all the time points analysed, with a slight 
increase at day 14 of influenza infection (Fig. 3.18D).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
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3.3 Discussion 
Findings from this chapter 
 At homeostasis alveolar macrophages express high levels of YM1 and MR 
 RELM-α is expressed by lung monocyte/macrophages but not alveolar 
macrophages at homeostasis 
 Intracellular YM1 decreases during influenza infection, with an increase in 
secreted YM1 
 MR expression decreases during influenza infection 
 RELM-α is highly inducible by lung and airway macrophages during influenza 
infection 
 YM1 and MR show similar expression profiles during influenza infection, while 
RELM-α appears to be differentially regulated. 
 RELM-α positive macrophages co-express GITRL at the peak of influenza 
infection 
3.3.1 Alveolar macrophages express high levels of YM1 and RELM-α at 
homeostasis 
YM1 and RELM-α are perceived as markers of alternatively activated macrophages 
and are usually associated with Th2-associated inflammation and helminth infections 45, 
46, 59. However, it is known that alveolar macrophages express MR 382, and human 
studies implicate another molecule constitutively expressed by alveolar macrophages, 
CD200R, as a marker of alternative activation 393. We set out to investigate the 
phenotype of alveolar macrophages in the un-inflamed lung. As well as high expression 
of MR, alveolar macrophages also expressed high levels of YM1, but not RELM-α. 
Interestingly, like alveolar macrophages, lung CD11c+ macrophages expressed high 
levels of MR and YM1 but not RELM-α. In contrast, lung CD11b+ 
monocyte/macrophages expressed fairly high levels of RELM-α and YM1 but very little 
MR. 
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It is interesting that i) some markers of alternative activation, which are usually 
associated with Th2 inflammation were expressed by alveolar macrophages in the un-
inflamed airway and ii) the markers of alternative activation were not always co-
expressed; we observed RELM-α and YM1 expression by lung monocyte/macrophages 
but not MR expression, and YM1 and MR but not RELM-α expression by alveolar 
macrophages and lung CD11c+ macrophages. This indicates a measure of site specific 
regulation of these proteins.  
Others show that surfactant protein A up-regulates MR expression by alveolar 
macrophages, and alveolar macrophages from surfactant protein A knockout mice 
have reduced MR expression 391. Alveolar macrophages associate closely with airway 
epithelial cells 438, and alveolar epithelial cells are known to produce surfactant proteins 
190. It is possible that airway epithelial cell-derived surfactant protein A is responsible for 
the high expression of MR on alveolar macrophages. Lung monocyte/macrophages, 
which presumably are found in the lung interstitium and do not associate closely with 
alveolar epithelial cells would not be subject to alveolar epithelium-derived surfactant 
proteins in the same manner as alveolar macrophages.  
High YM1 expression by alveolar macrophages may also be due to alveolar epithelium-
derived surfactant proteins. Additionally, others show that YM1 and MR can be 
expressed independently of IL-4. For example, IL-10 induces MR expression 427 and IL-
10 knockout mice have reduced MR expression by macrophages 308. Another study 
shows that IL-10 drives MR and YM1 expression by peritoneal macrophages in IL-4R 
knockout mice during Schistosoma mansoni infection and IL-10R blockade in IL-4 
knockout mice abolishes the expression of YM1 and MR by these cells 439. It is thought 
that IL-10 is crucial for maintaining lung homeostasis, and others show significant IL-10 
levels in the un-inflamed lung 306. It is known that IL-10 is produced by epithelial cells 
197 and alveolar and lung macrophages at homeostasis 43. It is possible that YM1 and 
MR are maintained at high levels on alveolar macrophages by locally produced IL-10. 
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Interestingly, unlike MR, YM1 is also expressed by lung monocyte/macrophages; this 
might also be due to the influence of IL-10. It is known that lung 
monocyte/macrophages themselves produce IL-10 43 which could act in an autocrine 
manner to induce YM1 expression.  
The presence of markers of alternative activation on alveolar macrophages in the un-
inflamed airway begs the question: what is their function at this site? Many studies 
show that MR is a scavenger receptor and is highly expressed by alveolar 
macrophages. The function of YM1 is less certain. There are many proposed functions 
for this chitinase-like molecule, but the one that stands out in the context of the un-
inflamed lung is the suggestion that it YM1 could be involved in the resolution of 
inflammation, by masking lectin binding sites and preventing entry of inflammatory cells 
to the inflamed tissues 67. One of the main functions of alveolar macrophages is to 
sequester antigen and prevent it from encountering DCs to induce an inflammatory 
response 381. It is possible that YM1 is also involved in maintaining immunological 
tolerance of inhaled antigen in the lung and airway. To address this hypothesis it would 
be of interest to determine if blockade of YM1 leads to the enhanced recruitment of 
immune cells into the lungs and airways in naïve mice.  
Intra-cellular production of RELM-α by lung monocyte/macrophages, but not alveolar 
macrophages, alludes to another mechanism by which these markers of alternative 
activation are differentially regulated. To date RELM-α expression has only been 
shown to be up-regulated under strongly Th2 polarised conditions or in the gut after 
chemically-induced colitis 59, 415 and in vitro after IL-4/IL-13 stimulation. IL-4 and IL-13 
are not thought to be prevalent in the lungs of naïve mice, and therefore an alternate 
mechanism of RELM-α regulation may exist. The lack of RELM-α expression by 
alveolar macrophages and its expression by lung monocyte/macrophages further 
indicates that it is negatively regulated by factors present in the alveolar space or 
alternatively, the factors required to induce its expression may be absent from the 
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airways. The presence of soluble RELM-α in BAL fluid from naïve mice is probably due 
to production by epithelial cells, which are known to produce it 65.  
3.3.2 YM1 and RELM-α are differentially regulated during influenza infection  
Once the phenotype of alveolar macrophages had been established in the un-inflamed 
lung and airway, we mapped the markers of alternative activation YM1, RELM-α and 
MR during influenza infection. Alveolar macrophage expression of intra-cellular YM1 
decreased throughout influenza infection and was least at day 6 of infection, the peak 
of infection. Lung and airway monocyte/macrophage expression of YM1 was similar, 
with a general loss of intra-cellular YM1 throughout influenza infection. Similarly, MR 
also appeared to be lost during influenza infection.  
The loss of MR and YM1 is perhaps not surprising as others show that IFN-γ 
antagonises their up-regulation by IL-4 406, 440. Treatment of alveolar macrophages in 
vitro did not alter the expression of YM1 in our system; however it is possible that other 
pro-inflammatory factors produced during influenza infection such as type 1 interferons, 
TNF-α and IL-6 might be responsible for the observed loss or release of intra-cellular 
YM1. Additionally, the loss of the epithelium during influenza infection might result in 
the loss of epithelium-derived surfactant proteins and this could also account for the 
loss of MR, and release of YM1.  
The observation that RELM-α was produced by alveolar macrophages during influenza 
infection was surprising; the accepted dogma is that RELM-α is induced by allergic 
Th2-biased inflammatory diseases and worm infections 46. Influenza infection leads to 
highly Th1-polarised inflammation and IL-4 is not present at high levels compared to 
IFN-γ and IL-12 441, 442. However, Munitz et al demonstrate the presence of RELM-α in 
acute chemically-induced colitis 415, which is characterised by high levels of TNF-α, IL-6 
and IL-17, and slightly less IFN-γ; IL-4 is not present at high levels in the serum in the 
acute colitis model, which is more biased towards Th1 inflammation 443. This indicates 
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that RELM-α can be induced under Th1 biased conditions. The fact that the expression 
patterns of RELM-α and YM1 during influenza are reciprocal alludes to the fact that 
they might be reciprocally regulated; perhaps RELM-α is induced by TNF-α or IL-6 
binding to their receptors on alveolar macrophages, which could down-regulate YM1 
production.  
We observed that in vitro IFN-γ or PolyI:C did not affect alveolar macrophage 
expression of RELM-α or YM1. Similarly, stimulation with TLR agonists and an 
inflammatory cytokine such as IFN-γ did not affect RELM-α or YM1 expression. Future 
experiments will test the involvement of TNF-α, IL-6 and type 1 interferons, all of which 
are present at high levels during influenza infection. IL-33, which is induced during 
influenza infection (E. L. Wissinger and T. Hussell; unpublished observations), is 
known to amplify the polarisation of alternatively activated macrophages and the effect 
of this cytokine on alveolar macrophage expression of RELM-α will also be tested in 
the future.  
3.3.3 RELM-α positive lung and airway macrophages express GITRL during 
influenza infection 
After establishing differential expression of RELM-α and YM1 in a C57BL/6 model of 
influenza infection, we also showed similar kinetics of expression in influenza-infected 
BALB/c mice. Additionally, RELM-α positive lung and airway macrophages expressed 
GITRL, a co-stimulatory molecule induced on macrophages upon activation.  
GITRL expression is not associated with a Th1 or Th2 bias, but merely functions to 
provide a survival and proliferation signal to T cells.  
RELM-α positive macrophages up-regulated GITRL at the peak of influenza infection, 
which was expected, as GITRL is up-regulated upon stimulation of macrophages with 
TLR agonists 330. A full characterisation of GITRL expression by lung and airway 
macrophages will be discussed in Chapter 5. 
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3.3.4 Conclusion  
This chapter shows that alveolar macrophages express markers of alternative 
activation YM1 and MR, unlike lung monocyte/macrophages, which express RELM-α 
and YM1 but not MR. Furthermore we show that during influenza infection these 
markers of alternative activation are differentially regulated with a loss of intra-cellular 
YM1 accompanied by an increase in secreted YM1. We also show an increase in the 
percentage of RELM-α positive macrophages during influenza infection, which 
challenges the dogma that this protein is only inducible by IL-4 and IL-13. We propose 
that alveolar macrophages represent an intermediate phenotype of macrophages 
which expresses some but not all markers of alternative activation. Their production of 
IL-10 43 indicates that they may be a hybrid of a regulatory and alternatively activated 
macrophage. 
It has not been previously shown that alveolar and lung macrophages represent a 
unique atypical alternatively activated macrophage population. YM1 and MR might 
perform homeostatic lung functions, such as regulating inflammation and phagocytosis 
of inhaled particulate matter, respectively. It is interesting that YM1 and RELM-α 
production in the BAL and lung homogenate is enhanced during a Th1-skewed 
infection such as influenza. Although these molecules are usually associated with Th2-
skewed inflammation, it is possible that it is not the Th2 cytokine milieu but the tissue 
damage, for example in worm infections, which induces their expression. It is possible 
that damage-associated signals induce the production of YM1 and RELM-α, or perhaps 
factors in the Th1 cytokine milieu are also capable of up-regulating these proteins.  
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4.0 The impact of IL-10R blockade on lung homeostasis  
4.1 Introduction 
4.1.1 Control of airway homeostasis 
In the previous chapter we showed that airway macrophages are phenotypically 
different from those that reside in the deeper lung tissues in the absence of 
inflammation. This may be regulated by a number of site-specific factors. TGF-β is 
present in the lungs at homeostasis, but is secreted as a latent form in a complex of 
three proteins 438. The integrin αvβ6, which is expressed at high levels on airway 
epithelial cells, catalyses the cleavage of the latent form of TGF-β into the active form 
438. Because of the proximity of alveolar macrophages to the epithelium, they are then 
subject to the anti-inflammatory effects of TGF-β. Expression of αvβ6 is up-regulated 
on the epithelium in response to inflammation, making more TGF-β available 438; this 
serves as a mechanism to control inflammation as well as maintaining lung 
homeostasis. 
The epithelium is involved in another myeloid regulatory mechanism, involving CD200 
and its receptor CD200R, which is highly expressed on alveolar macrophages 200. 
CD200 is expressed on the lumen of airway epithelial cells and binding to its receptor 
CD200R on alveolar macrophages, imparts a negative signal to the alveolar 
macrophage and results in down-regulation of inflammatory cytokines 200. The role of 
the CD200/CD200R interaction is evident in the phenotype of mice lacking either 
molecule. Influenza-infected CD200 null mice display excessive uncontrolled lung 
inflammation during influenza infection and die from the infection 200. Even un-infected 
CD200 null mice have more alveolar macrophages compared to wild type mice, 
suggesting an important role for this pathway in suppressing inflammation in general. 
Alveolar macrophages from CD200R knockout mice have a lower threshold of 
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activation than wild type controls and produce higher amounts of inflammatory 
cytokines to relatively low levels of inflammatory stimuli 200. 
IL-10 is proposed to play a central role in immune homeostasis in the lung and the 
effect of neutralising IL-10/IL-10R interactions will be the focus of this chapter. 
4.1.2 IL-10 and lung homeostasis 
IL-10 is a potent immuno-suppressive cytokine and important for the maintenance of 
immune homeostasis in mucosal areas such as the lungs, where an inappropriate 
immune response might result in lung pathology, which would be detrimental to the 
host. The importance of IL-10 in controlling the inflammatory response can be 
observed in IL-10 knockout mice, which develop spontaneous enterocolitis in response 
to normal gut flora 297, 444; IL-10R knockout mice similarly develop colitis and 
splenomegaly by 12 weeks of age 445.  
In the lungs and airways IL-10 is constitutively produced by a range of cells; epithelial 
cells, 197, Tregs, lung myeloid and plasmacytoid DCs and alveolar and lung interstitial 
macrophages 43, 297. 
IL-10 is abundant in the lungs at homeostasis and suppresses inflammatory cytokine 
production by T cells and macrophages 255 and decreases the expression of co-
stimulatory molecules 256, 257, 260, 446 and MHC class II on monocytes and macrophages, 
thereby lowering their activation status and their ability to present antigen 258. IL-10 
directly acts on Tregs, maintaining their expression of Foxp3 252. As well as negatively 
regulating inflammatory processes, IL-10 can also act in a stimulatory manner, for 
example by promoting MHC class II expression on B cells and enhancing their ability to 
produce antibodies 282-284. DCs pre-treated with IL-10 lose the ability to induce allergy in 
mouse models of OVA-induced allergic airways disease 43. IL-10 production by DCs in 
the lungs is an important mechanism for the tolerance induced by exposure to inhaled 
antigen 43. IL-10 acts directly on T cells, macrophages and DCs to limit inflammation 
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but also affects other myeloid regulators. For example, IL-10 up-regulates the 
expression of the myeloid regulator, CD200R on macrophages, which makes them 
more susceptible to suppression by CD200 ligation 200.  
Furthermore, IL-10 can affect the alternative activation of macrophages. IL-10 knockout 
mice have lower basal mRNA levels of YM1 and RELM-α in lung tissue during 
Schistosoma mansoni infection 308. Additionally, others show that IL-10 can be as 
potent at inducing MR expression by macrophages as IL-4 427. In the absence of IL-4, 
IL-10 can drive the expression of YM1 and MR on peritoneal macrophages 439. Dewals 
et al further show that MR and YM1 expression by peritoneal macrophages is 
abolished in IL-4R knockout mice by blockade of IL-10R 439. 
IL-10R is a member of the class II IFN receptor-like cytokine receptor family 286, 447 and 
signalling occurs via the JAK/STAT pathway and is highly dependent on STAT-3 448. IL-
10R is widely expressed by most mouse and human haematopoietic cells such as 
DCs, macrophages, monocytes, B cells, NK cells, mast cells and T cells, which is 
demonstrated by their responsiveness IL-10 288, 289, 299, 449, 450. TLR stimulation inhibits 
IL-10R function on DCs and macrophages in a MyD88-dependent manner and 
decreases the ability of these cells to respond to IL-10 once activated by TLRs 197, 304.  
4.1.3 Manipulation of IL-10/IL-10R interactions in disease 
Due to the immune suppression associated with this pathway, IL-10 and IL-10R have 
been manipulated in a variety of human diseases and mouse models of human 
diseases. In general, blockade of IL-10R enhances the immune response and addition 
of IL-10 dampens inflammation. For example, IL-10R blockade enhances the clearance 
of persistent pathogens in chronic infectious disease models such as LCMV 319, 
Hepatitis C 451 and Leishmania major infections 452. 
Clinical trials using IL-10 to treat psoriasis result in decreased local and peripheral 
inflammation 453. Additionally, mice lacking IL-10 do not recover from EAE 454-456, and 
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local administration of IL-10 renders mice completely resistant to EAE 457. IL-10 is also 
thought to play a major role in the regulation of asthma-associated inflammation; there 
are lower levels of IL-10 in the lungs of asthmatic patients 458 and they have fewer IL-
10-producing T cells in peripheral blood compared to healthy controls 459.  
Mice deficient in IL-10 have high immune-pathology and therefore worse disease 
outcome upon infection with certain pathogens such as Toxoplasma gondii 309, 
Pseudomonas aeruginosa 460 and Trypanosoma cruzi 311. However, IL-10 knockout 
mice are resistant to other pathogens associated with persistence such as Leishmania 
major 461, and Mycobacterium bovis Bacillus Calmette-Guérin 462, 463.  
The immuno-stimulatory properties of IL-10 towards certain immune subsets must also 
be considered in any therapy. For example, IL-10 has been implicated to have a role in 
the cause and/or exacerbation of the B cell-associated disease SLE 464. In Crohn’s 
disease IL-10 administration was only effective at reducing inflammation at 
intermediate doses, but slightly higher doses resulted in enhanced inflammation 465. 
Whether this is due to enhanced B cell proliferation or an outgrowth of commensal 
organisms is currently unknown. 
IL-10 is important for disease outcome in murine models of influenza infection and IL-
10 deficient mice are protected against a high dose influenza infection and mount a 
more efficient immune response to infection 306. Similar results are seen upon IL-10R 
blockade during a high dose influenza challenge 306. Conversely, another group shows 
that IL-10 produced by CD8 effector T cells during influenza infection is essential for 
controlling inflammation and bystander lung pathology and that blockade of IL-10R 
during influenza infection leads to increased mortality and immune-pathology 233. A 
third study shows that IL-10 deficient mice have improved viral clearance and survival 
after influenza infection, with enhanced specific anti-viral antibody response 307, 
probably due to heightened APC activity.  
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Clearly IL-10 is important for the outcome of influenza infection, but its role in the 
maintenance of lung homeostasis is not known. 
4.1.4 Hypothesis 
The altered homeostasis and response to infection observed in IL-10, CD200 and 
CD200R knockout mice indicate that a lack of these myeloid regulators alters the 
activation status of immune cells in the absence of inflammation. Additionally, IL-10 
clearly has an impact on the phenotype of macrophages, as it is involved in the 
regulation of YM1, MR and RELM-α. It is interesting to consider whether blockade of 
such regulation is sufficient to alter lung homeostasis and the immune response to a 
subsequent infection. 
This chapter will examine the effects of blocking IL-10R using an anti-IL-10R blocking 
antibody, which has previously been shown by others to block the effects of IL-10 in 
vivo 233, 306. We hypothesise that blockade of IL-10R will alter lung homeostasis and 
macrophage phenotype, and that the immune response to a subsequent infection will 
be more robust after IL-10R blockade. To address these hypotheses I will aim to 
answer the following questions: 
 Does IL-10R blockade result in enhanced inflammation at homeostasis? 
 Is alveolar and lung macrophage phenotype altered by IL-10R blockade? 
 What is the effect of prior IL-10R blockade on a subsequent influenza infection? 
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4.2 Results 
4.2.1 The effect of IL-10R blockade on cell numbers in the lungs and airways at 
homeostasis 
In order to examine the effects of IL-10 on lung homeostasis, an IL-10R blocking 
antibody was used. C57BL/6 mice were injected intra-peritoneally (i.p.) with 200μg anti-
IL-10R antibody (Ab) or rat IgG1 isotype control on days -8, -6, -4 and -2 (Fig. 4.1). At 
day 0 mice were culled, BAL performed to isolate airway cells and the lungs were 
extracted; analysis was performed as detailed in Fig. 4.1.  
As IL-10 is known to suppress inflammation and the proliferation of immune cells 286, it 
was of interest to analyse the effect of IL-10R blockade on the numbers of the different 
lung and airway cell populations. 
IL-10R blockade resulted in increased numbers of cells in the BAL fluid compared to 
IgG-treated controls (Fig. 4.2A). As alveolar macrophages are the main population in 
the naïve airway, there was also an increase in alveolar macrophage numbers in the 
anti-IL-10R Ab-treated mice compared to IgG-treated controls (Fig. 4.2B). Interestingly, 
IL-10R blockade had no effect on the total number of cells in the lungs or the number of 
lung CD11c+ macrophages or CD11b+ monocyte/macrophages (data not shown). 
Next it was of interest to investigate the effect of IL-10R blockade on DC populations in 
the lungs. Sub mucosal DCs were defined as CD11c+CD11b+CD103- 92 and intra-
epithelial DCs were identified by CD11c and lack of CD11b expression as well as 
expression of the integrin CD103 92. However, IL-10R blockade did not alter the 
number of sub mucosal (Fig. 4.2C) or intra-epithelial DCs in the lungs (4.2D). 
There are very few T cells in the naïve airway 426 but the effect of IL-10R blockade on 
the number of T cells in the lungs was examined. IL-10R blockade had no effect on the 
number of CD4+ or CD8+ T cells in the lungs (data not shown), nor was there any effect 
on the number of Tregs (Fig. 4.2E).  
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Figure 4.1 Experimental set up. C57BL/6 mice were injected intra-peritoneally (i.p.) 
with 200 μg anti-IL-10R Ab or rat IgG1 every other day for 8 days, after which broncho-
alveolar lavage (BAL) was performed and the lungs extracted; BAL fluid and lung 
homogenates were analysed as shown above.  
  
Day -8 -6 -4 -2 0
200 μg anti-IL-10R or 
rat IgG1 i.p.
Sacrifice
Lung
o Flow cytometry
o ELISA 
Bronchoalveolar lavage fluid
o Flow cytometry
o ELISA 
Figure 4.1 Experimental set up. C57BL/6 mice were injected intra-peritoneally (i.p.) with 200 μg anti-
IL-10R Ab or rat IgG1 every other day for 8 days, after which broncho-alveolar lavage (BAL) was 
performed and the lungs extracted; BAL fluid and lung homogenates were analysed as shown above.
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Figure 4.2 The effect of IL-10R blockade on cell populations in the lungs and 
airways. C57BL/6 mice were injected i.p. with 200μg anti-IL-10R Ab (squares) or rat 
IgG1 every other day for 8 days, after which the mice were sacrificed, BAL performed 
and the lungs extracted. Numbers of airway cells in BAL fluid (A) were determined by 
Trypan blue exclusion and the cells stained with anti-CD11c APC, anti-CD11b PerCp 
and anti-F4/80 PE-Cy7 to identify alveolar macrophages (B). Lungs were digested and 
single cell homogenates stained for intra-epithelial DCs (C; CD11c+ CD11b+ F4/80-),  
sub mucosal DCs (D; CD11c+ CD11b- CD103+) and Tregs (E; CD4+ CD25+ FoxP3+). 
Numbers of each cell type were determined by multiplying the percentage positive x 
number of cells in the myeloid/lymphocyte gate x viable airway or lung cell count.  (A 
and B) n=15 +/- SEM and represents data from 3 experiments. n=5 per group (C-E), +/- 
SEM.   * = p<0.05   
Figure 4.2 The effect of IL-10R blockade on cell populations in the lungs and airways. C57BL/6 mice
were injected i.p. with 200μg anti-IL-10R Ab (squares) or rat IgG1 every other day for 8 days, after which the
mice were sacrificed, BAL performed and the lungs extracted. Numbers of airway cells in BAL fluid (A) were
determined by trypan blue exclusion and the cells stained with anti-CD11c APC, anti-CD11b PerCp and
anti-F4/80 PE-Cy7 to identify alveolar macrophages (B). Lungs were digested and single cell homogenates
stained fo submucosal DCs (C; CD11c+ CD11b+), nterstitial DCs (D; CD11c+ CD11b+ CD103+) and Tregs
(E; CD4+ CD25+ FoxP3+). Numbers of each cell type were determined by multiplying the percentage
positive x number of cells in the myeloid/lymphocyte gate x viable airway or lung cell count. n=5 per group
and represents data from 2 experiments or n=15 (A and B) +/- SEM. * = p<0.05
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4.2.2 Effect of IL-10R blockade on macrophage phenotype 
The absence of myeloid regulators at homeostasis can lead to altered macrophage 
phenotype. For example, alveolar macrophages lacking the myeloid regulator PPAR-γ 
switch to a Th1 phenotype and the mice develop pulmonary Th1 inflammation in the 
absence of any external antigenic stimulation 466. IL-10 knockout mice have lower basal 
expression of YM1 and RELM-α in lung tissue 308. Alveolar macrophages from mice 
lacking the myeloid regulator CD200R also have a heightened state of activation and 
produce higher levels of inflammatory cytokines in response to TLR stimulation 200. 
In the absence of IL-4, IL-10 can drive the expression of YM1 and MR by macrophages 
439, and therefore it was of interest to determine if alveolar macrophage phenotype was 
altered after IL-10R blockade. Geometric mean (GM) was used as a crude measure of 
the intensity of expression of MR and YM1. IL-10R blockade did not significantly alter 
the percentage or GM of MR positive alveolar macrophages (Fig. 4.3A), nor was the 
percentage or GM of YM1 positive alveolar macrophages altered (Fig. 4.3B). There 
appeared to be an increase in the GM of both YM1 and MR but this difference was 
statistically insignificant. At homeostasis alveolar macrophages did not express RELM-
α, and this was not altered by IL-10R blockade (data not shown).  
Neither YM1 nor RELM-α expression at the intra-cellular level was affected by IL-10R 
blockade; however both proteins are secreted and therefore it was of interest to assess 
the amount of secreted protein. BAL fluid was therefore analysed by ELISA for soluble 
YM1 and RELM-α. There appeared to be slightly higher levels of soluble YM1 in BAL 
fluid of IL-10R Ab-treated mice but this did not reach statistical significance and there 
was similarly no significant difference in RELM-α levels (Fig. 4.3C).  
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Figure 4.3 Alveolar macrophage phenotype is unaffected by IL-10R blockade. 
C57BL/6 mice were injected i.p. with 200μg anti-IL-10R Ab (squares or clear bars) or 
rat IgG1 (circles or filled bars) every other day for 8 days, after which the mice were 
culled and BAL was performed; BAL cells were stained with anti-CD11c APC, anti-
CD11b PerCp and anti-F4/80 PE-Cy7. The cells were then fixed, permeabilised and 
stained with rat anti-mouse YM1 followed by goat anti-rat IgG FITC or anti-MR FITC. 
The percentage (closed symbols) and geometric mean (open symbols) of MR (A) and 
YM1 (B) positive alveolar macrophages (CD11chigh CD11blow F4/80+) were determined 
by flow cytometry. Levels of soluble YM1 (C) and RELM-α (D) in the BAL fluid were 
determined by ELISA. Data shown are representative of 3 experiments; n=5 +/- SEM.  
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Figure 4.3 Alveolar macrophage phenotype is unaffected by IL-10R blockade. C57BL/6 mice were
injected i.p. with 200μg anti-IL-10R Ab (squares) or rat IgG1 (circles) every other day for 8 days, after
which the mice were called and BAL was performed; BAL fluid was stained with anti-CD11c APC, anti-
CD11b PerCp and anti-F4/80 PE-Cy7. The cells were th n fixed, permeabilised and stained with anti-
YM1 FITC or anti-mannose receptor FITC. The percentage (closed symbols) and geometric mean (open
symbols) of mannose receptor (A) and YM1 (B) positive alveolar macrophages (CD11chigh CD11blow
F4/80+) were determined by flow cytometry. Levels of soluble YM1 (C) and RELM-α (D) in the BAL fluid
were determined by ELISA. Data shown are representative of 3 experiments; n=5 +/- SEM.
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Lung macrophage populations were next examined for the expression of YM1, RELM-α 
and MR. The percentage and GM of MR (Fig. 4.4A) and YM1 (Fig. 4.4B) positive lung 
CD11c+ macrophages was unchanged by IL-10R blockade. The percentage of RELM-α 
positive lung CD11c+ macrophages was negligible and this was not altered by IL-10R 
blockade (data not shown). Neither the percentage nor GM of MR or YM1 positive lung 
CD11b+ monocyte/macrophages was altered by IL-10R blockade (Fig. 4.5A and B 
respectively). Although the GM of YM1 on the lung monocyte/macrophages from the 
anti-IL-10R Ab-treated mice appeared to be lower than that of the controls, this 
difference was not statistically significant. However, the percentage and GM of RELM-α 
positive lung monocyte/macrophages was significantly higher after IL-10R blockade 
(Fig. 4.5C). This would indicate that these monocyte/macrophages were more 
alternatively activated, but this was not consistent with the fact that there was no 
significant difference in the expression of YM1 or MR. Therefore this could be an 
indication that YM1 and RELM-α are differentially regulated at homeostasis. 
Again, it was of interest to measure the amounts of secreted protein in the lungs by 
measuring levels of soluble YM1 and RELM-α in lung homogenates. Snap-frozen lung 
lobes were homogenised and the supernatants tested for YM1 and RELM-α by ELISA. 
IL-10R blockade did not alter the amount of secreted YM1 or RELM-α (Fig. 4.6A and B 
respectively). 
Next, the activation status of alveolar and lung macrophages was examined; CD200R 
and MHC class II were used as activation markers. CD200R is highly expressed by 
alveolar macrophages 200 and expression is diminished upon activation, while MHC 
class II expression is enhanced on macrophages upon activation 389. However, IL-10R 
blockade did not alter the expression of CD200R or MHC class II by alveolar or lung 
macrophages (data not shown).  
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Figure 4.4 Lung CD11c+ macrophage phenotype is unaffected by IL-10R 
blockade. C57BL/6 mice were injected i.p. with 200μg anti-IL-10R Ab (squares) or rat 
IgG1 (circles) every other day for 8 days, after which the mice were culled and the 
lungs extracted, digested and lung homogenates stained with anti-CD11c APC, anti-
CD11b PerCp, and anti-F4/80 PE-Cy7; the cells were then fixed, permeabilised and 
stained with rat anti-mouse YM1 followed by goat anti-rat IgG FITC or anti-MR FITC. 
The percentage (closed symbols) and geometric mean (open symbols) of MR (A) and 
YM1 (B) positive cells were determined by flow cytometry. Data shown are 
representative of 3 experiments; n=5 +/- SEM.  
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Figure 4.4 Lung CD11c+ macrophage phenotype is unaffected by IL-10R blockade. C57BL/6 mice 
were injected i.p. with 200μg anti-IL-10R Ab (squares) or rat IgG1 (circles) every other day for 8 days
after which the mice were called and the lungs extracted, digest d and lu g homogenates st ined with 
anti-CD11c APC, anti-CD11b PerCp, and anti-F4/80 PE-Cy7; the cells were then fixed, permeabilised 
and stained with anti-YM1 FITC or anti-mannose receptor FITC. The percentage (closed symbols) and 
geometric mean (open symbols) of mannose receptor (A) and YM1 (B) positive cells were determined by 
flow cytometry. Data shown are representative of 3 experiments; n=5 +/- SEM. 
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Figure 4.5 IL-10R blockade differentially affects the expression of markers of 
alternate activation on lung CD11b+ macrophages.  C57BL/6 mice were injected i.p. 
with 200 μg anti-IL-10R Ab (squares) or rat IgG1 (circles) every other day for 8 days, 
after which mice were culled and the lungs were extracted, digested and lung 
homogenates stained with anti-CD11c APC, anti-CD11b PerCp and anti-F4/80 PE-
Cy7; the cells were then fixed, permeabilised and stained with rat anti-mouse YM1 
followed by goat anti-rat IgG FITC, or anti-MR FITC or rabbit anti-mouse RELM-α 
followed by donkey anti-rabbit IgG PE. The percentage (closed symbols) and 
geometric mean (open symbols) of MR (A), YM1 (B) and RELM-α (C) positive lung 
CD11b+ monocyte/macrophages were determined by flow cytometry. Data shown are 
representative of 3 experiments; n=5 +/- SEM. * = p<0.05 
 
  
IgG Anti-IL-10R IgG Anti-IL-10R
%
 p
o
s
it
iv
e
G
e
o
 M
e
a
n
Mannose Receptor
IgG Anti-IL-10R IgG Anti-IL-10R
YM1
%
 p
o
s
it
iv
e
G
e
o
 M
e
a
n
IgG Anti-IL-10R IgG Anti-IL-10R
RELM-α
%
 p
o
s
it
iv
e
G
e
o
 M
e
a
n
Figure 4.5 IL-10R blo ade differ ntially affects the expr ssion of markers of lternate
activation on lung CD11b+ macrophages. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R
Ab (squares) or rat IgG1 (circles) every other day for 8 days, after which the lungs were extracted,
digested and lung homogenates stained with anti-CD11c APC, anti-CD11b PerCp and anti-F4/80 PE-
Cy7; the cells were then fixed, permeabilised and stained with anti-YM1 FITC, anti-mannose receptor
FITC or anti-RELM-alpha FITC. The percentage (closed symbols) and geometric mean (open
symbols) of mannose r ceptor (A), YM1 (B) and RELM-α positiv cells were determined by flow
cytometry. Data shown are representative of 3 experiments; n=5 +/- SEM.
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Figure 4.6 Blockade of IL-10R does not impact on the production of soluble YM1 
or RELM-α in the lungs. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab 
(open bars) or rat IgG1 (grey bars) every other day for 8 days, after which the mice 
were culled and the lungs extracted and snap-frozen. Snap-frozen lungs were 
homogenised and supernatants assayed for soluble YM1 (A) and RELM-α (B) by 
ELISA as described in the Methods section. Data represent 2 experiments, n=5 +/- 
SEM.  
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Figure 4.6 Blockade of IL-10R does not impact on the production of soluble YM1 or RELM-α in the 
lungs. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (open bars) or rat IgG1 (grey bars) 
every other day for 8 days, after which the lungs were extracted and snap-frozen. Snap-frozen lungs were 
homogenised and single cell suspensions assayed for soluble YM1 (A) and RELM-alpha (B) by ELISA as 
described in the Methods s ction. n=5 +/- SEM.
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4.2.3 Prior IL-10R blockade does not alter the expression of CCR2 
Alveolar macrophages renew their numbers by self-proliferation, but during 
inflammation monocytes are recruited into the airways from the bone marrow via a 
series of chemokine gradients; MCP-1 and MIP-1α are highly induced during lung 
inflammatory disease 467, 468. IL-10 inhibits the production of mouse, rat and human 
MCP-1 and MIP-1α 263, 469. We hypothesised that a lack of the suppressive effects of IL-
10 might release the inhibition of MCP-1 or MIP-1α and could result in the increased 
number of alveolar macrophages observed on IL-10R blockade.  
Alveolar and lung macrophages were examined for the expression of CCR2, which is 
the ligand for the monocyte chemo-attractant MCP-1. Despite the difference seen in 
alveolar macrophage numbers upon IL-10R blockade, there was no significant 
difference in the percentage or GM of CCR2 positive alveolar macrophages (Fig. 4.7A 
and B respectively).  
4.2.4 Prior IL-10R blockade does not affect weight loss or viral load during a 
subsequent influenza infection 
Although the lung micro-environment did not appear to have been dramatically altered 
by IL-10R blockade, it was important to investigate whether the temporary absence of 
IL-10 would alter the immune response to a subsequent influenza infection. 
As before, C57BL/6 mice were injected i.p. with 200μg anti-IL-10R Ab or rat IgG1 
isotype control on days -8, -6, -4 and -2; on day 0 the mice were then intra-nasally 
infected with 1.4x105 pfu influenza strain X31 and culled at various time points after 
infection (Fig. 4.8). Mice were weighed daily, as influenza-induced weight loss is a key 
indication of disease severity 223. As expected, the mice lost up to 20% of their original 
body weight and the peak weight loss occurred at day 6 of infection; however, there 
was no difference in weight loss between the anti-IL-10R Ab-treated mice compared to 
control mice (Fig. 4.9A).  
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Figure 4.7 IL-10R blockade does not alter CCR2 expression by alveolar 
macrophages. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (squares) 
or rat IgG1 (circles) every other day for 8 days. BAL was performed and BAL cells 
stained with anti-CD11c APC, anti-CD11b PerCP, anti-F4/80 PE-Cy7 and purified anti-
CCR2 followed by goat anti-rabbit PE.  The percentage and geometric mean of CCR2 
positive alveolar macrophages was determined by flow cytometry. n=5 +/- SEM. Data 
are representative of 2 experiments. 
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Figure 4.7 IL-10R blockade does not alter CCR2 expression by alveolar macrophages. C57BL/6
mice were injected i.p. with 200 μg anti-IL-10R Ab (squares) or rat IgG1 (circles) every other day for 8
days. BAL was performed and BAL fluid stained with anti-CD11c APC, anti-CD11b PerCP, anti-F4/80
PE-Cy7 and purified anti-CCR2 followed by goat anti-rabbit PE. . The percentage and geometric mean
of CCR2 positive alveolar macrophages was determined by flow cytometry. n=5 +/- SEM.
A
B
Chapter 4: The impact of IL-10R blockade on lung homeostasis  
 
144 
 
 
 
Figure 4.8 Experimental set up. C57BL/6 mice were injected i.p. with 200 μg anti-IL-
10R Ab or rat IgG1 every other day for 8 days, after which the mice were infected intra-
nasally (i.n.) with 1.4x105 pfu influenza strain X31. At the time points indicated BAL was 
performed and the lungs extracted and analysed as displayed above.  
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Figure 4.8 Experimental set up. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab or rat IgG1
every other day for 8 days, after which the mice were infected intra-nasally (i.n.) with 1.4x105 pfu influenza
strain X31. At the time points indicated BAL was performed and the lungs extracted and analysed as
displayed above.
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Figure 4.9 Prior IL-10R does not impact on weight loss during subsequent 
influenza infection. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (blue 
line, A; clear bars, B) or rat IgG1 (red line, A; grey bars, B) every other day for 8 days, 
after which the mice were infected i.n. with 1.4x105 pfu influenza strain X31. Mice were 
weighed daily and weight loss was expressed as a percentage of original weight (A). 
Mice were culled and lungs extracted at the time points shown; viral load was 
determined by plaque assay as described in the Methods section (B). Data shown 
represent results from 2 experiments; n=5+/- SEM  
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Figure 4.9 Prior IL-10R does not i pact on weight loss during subsequent influenza infection.
C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (blue line – A; clear bars – B) or rat IgG1 (red
line –A,;grey bars – B) every other day for 8 days, after which the mice were infected i.n. with 1.4x105 pfu
influenza strain X31. Mice were weighed daily and weight loss was expressed as a percentage of original
weight (A). Mice were culled and lungs extracted at the time points shown; viral load was determined by
plaque assay as d scribed in the Methods section (B). Data shown represent results from 2 experiments;
n=5+/- SEM
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Mice were culled 1, 3, 6 and 14 days after influenza infection, and lung lobes extracted. 
Lung lobes were tested for viral load by influenza plaque assay, as described in the 
Methods section. However, prior IL-10R blockade did not alter the ability of mice to 
clear influenza virus, as viral load was comparable between the two groups at the time 
points tested (Fig. 4.9B). Virus particles were not detectable at day 14 of influenza 
infection in either group. 
4.2.5 Prior IL-10R blockade impacts on total cellular infiltrate into the airways 
during influenza infection 
Cellular infiltrate into the lungs and airways during influenza infection correlates closely 
with weight loss in mouse models of influenza and the peak cellular infiltrate coincides 
with the peak of weight loss at day 6 of infection 223. Mice were culled 1, 3, 6 and 14 
days after influenza infection, airway cells washed out by BAL and the lungs extracted. 
As expected during influenza infection there was a steady increase in cell numbers in 
the airways which peaked at day 6 of infection; at day 3 of infection, however, there 
were significantly more cells in the airways of mice previously treated with anti-IL-10R 
Ab (Fig. 4.10A). At day 6 there again appeared to be increased numbers of cells in the 
airways of the anti-IL-10R Ab-treated mice, but this difference did not gain statistical 
significance.  
The numbers of cells in the lungs increased steadily throughout influenza infection, 
again peaking at day 6 of infection (Fig. 4.10B). At all the time points analysed there 
were comparable numbers of cells in the lungs of anti-IL-10R Ab-treated mice 
compared to control mice (Fig. 4.10B). 
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Figure 4.10 Prior IL-10R blockade increases total cell numbers in the airways at 
day 3 of a subsequent influenza infection but lung numbers are unaffected. 
C57BL/6 mice were injected i.p. with 200μg anti-IL-10R Ab (clear bars) or rat IgG1 
(grey bars) every other day for 8 days, after which the mice were infected i.n. with 
1.4x105 pfu influenza strain X31. Mice were culled at the time points shown, BAL 
performed to isolate airway cells and lungs extracted. Lungs were digested and made 
into single cell homogenate and total cell numbers in BAL fluid (A) and lungs (B) were 
determined by Trypan blue exclusion. Data are representative of 2 experiments; n=5 
+/- SEM. *=p<0.05  
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Figure 4.10 Prior IL-10R blockade increases total cell numbers in the airways at day 3 of a
subsequent influenza infection but lung numbers are unaffected. C57BL/6 mice were injected i.p.
with 200μg anti-IL-10R Ab (clear bars) or rat IgG1 (grey bars) every other day for 8 days, after which
the mice were infected i.n. with 1.4x105 pfu influenza strain X31. Mice were culled at the time points
shown, BAL performed to isolate airway cells and lungs extracted. Lun s were digest d an made into
single cell homogenate a d tot l cell numbers i the airways (A) and lungs (B) were determined by
trypan blue exclusion. Data are representative of 2 experiments; n=5 +/- SEM. *=p<0.05
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4.2.6 Prior IL-10R blockade increases T cell infiltrate into the lungs and airways 
during a subsequent influenza infection 
T cell infiltrate into the lungs and airways is a key feature of influenza infections and the 
peak in T cell infiltrate directly correlates with disease severity in mouse models of 
influenza infection 470. Therefore, it was of interest to examine the T cell infiltrate into 
the influenza-infected lungs and airways in mice previously treated with anti-IL-10R Ab. 
Mice were pre-treated with 200μg anti-IL-10R Ab as before on days -8, -6, -4 and -2, 
and on day 0 they were infected i.n. with 1.4x105 pfu influenza X31 and culled 1, 3, 6 
and 14 days afterwards; BAL was then performed, the lungs extracted and numbers of 
T cells determined by flow cytometry analysis.  
As expected, the numbers of both CD4+ and CD8+ T cells in the lungs peaked at day 6 
of influenza infection (Fig. 4.11A and B) and this coincided with the peak of weight loss 
at day 6. There were comparable numbers of CD4+ T cells in lungs of the IL-10R Ab-
treated mice and IgG-treated controls, except at day 14, when there were significantly 
more CD4+ T cells in the lungs of the IL-10R Ab-treated mice (Fig. 4.11A). Similarly, 
there was no difference in lung CD8+ T cell numbers between the anti-IL-10R Ab-
treated mice and control mice, except at day 14, when there appeared to be more 
CD8+ T cells in the lungs of the anti-iL-10R Ab-treated mice (Fig. 4.11B). However, this 
difference stopped short of reaching statistical significance (p=0.056). 
T cells in the airways were not analysed at early time points, as there are few T cells in 
the airways of naïve mice and the peak of T cell infiltrate into the airways is day 6 of 
influenza infection 223. T cells were therefore analysed at day 6 of infection and at day 
14, the resolution phase of infection. At day 6 there were significantly more CD4+ T 
cells in the airways of the IL-10R Ab-treated mice compared to IgG1-treated control 
mice (Fig. 4.11C).  
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Figure 4.11 T cell numbers in the lungs and airways during influenza infection 
following IL-10R blockade. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R 
Ab (clear bars) or rat IgG1 (grey bars) every other day for 8 days, after which the mice 
were infected i.n. with 1.4x105 pfu influenza strain X31. Mice were culled at the time 
points shown, BAL performed and the lungs extracted. BAL cells and single cell 
suspensions of lung homogenate were stained with anti-CD4 APC and anti-CD8 
PerCp. The number of CD4+ (A) and CD8+ (B) T cells in the lungs was calculated by 
multiplying the percentage CD4 or CD8 positive cells x the percentage of cells in the 
lymphocyte gate x viable cell count. Airway cells were only analysed for CD4+ (C) and 
CD8+ (D) T cells at day 6; numbers of T cells were calculated as previously specified 
for the lungs. Data represent 2 experiments; n=5 +/- SEM. *=p<0.05, ** = p<0.01.  
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Figure 4.11 T cell numbers in the lungs and airways during influenza infection following IL-10R
blockade. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (clear bars) or rat IgG1 (grey
bars) every other day for 8 days, after which the mice were infected i.n. with 1.4x105 pfu influenza strain
X31. Mice were culled at the time points shown, BAL performed and the lungs extracted. BAL fluid and
single cell suspensions of lung homogenate were stained with anti-CD4 APC and anti-CD8 PerCp. The
number of CD4+ (A) and CD8+ (B) T cells in the lungs was calculated by multiplying the percentage
D4 or CD8 positive cells x the number of cells in the lymphocyte gate x viable cell count. Airway cells
were only analysed for CD4+ (C) and CD8+ (D) T cells at day 6; numbers of T cells were calculated as
previously specified for the lungs. Data represent 2 experiments; n=5 +/- SEM. *=p<0.05, ** = p<0.01.
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However, numbers of CD8+ T cells were comparable between the two groups (Fig. 
4.11D). There was no difference in T cell numbers in the airways of either anti-IL-10R 
Ab- or IgG1-treated mice at day 14 of influenza infection (data not shown). 
4.2.7 Prior IL-10R blockade augments numbers of macrophages in the airways 
during a subsequent influenza infection  
During influenza infection, there is a vast infiltrate of macrophages into the lungs and 
airways, recruited as a result of the secretion of chemokines by resident immune cells 
94. Total cell numbers in the airways were increased at day 3 of influenza infection after 
IL-10R blockade (Fig. 4.12A), and this time point is the peak of innate immunity during 
influenza infection 221. Hence it was of interest to analyse macrophage populations in 
the airways at day 3. 
Anti-IL-10R Ab-treated mice had significantly higher numbers of 
monocyte/macrophages in the airways compared to IgG1-treated controls (Fig. 4.12B)  
and slightly higher numbers of alveolar macrophages at day 3 but this difference did 
not reach statistical significance (Fig. 4.12C). The increase in numbers of macrophages 
in the airways correlated with the increase in total number of cells in the airways 
observed at day 3 of influenza infection.  
Numbers of monocyte/macrophages and CD11c+ macrophages were also analysed in 
the lungs, however there were comparable numbers of the two macrophage 
populations between the anti-IL-10R Ab-treated mice and IgG1-treated controls (data 
not shown). 
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Figure 4.12 Prior IL-10R blockade increases total cells and macrophages in the 
airways at day 3 of a subsequent influenza infection. C57BL/6 mice were injected 
i.p. with 200 μg anti-IL-10R Ab (squares) or rat IgG1 (circles) every other day for 8 
days, after which the mice were infected i.n. with 1.4x105 pfu influenza strain X31. Mice 
were culled at day 3 and BAL performed. BAL cells were stained with anti-CD11c APC, 
anti-CD11b PerCp and anti-F4/80 PE-Cy7. The total number of cells in the airways was 
determined by trypan blue exclusion (A) and the number of monocyte/macrophages (B) 
and alveolar macrophages (C) was calculated by multiplying the percentage positive x 
percentage of cells in the myeloid gate x viable cell count in the airways. * = p<0.05,   
** = p<0.01 n=10+/- SEM. Data represent 3 experiments.  
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Figure 4.12 Prior IL-10R blockade increases total cells and macrophages in the airways at day 3 of
a subsequent influenza infection. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (squares)
or rat IgG1 (circles) every other day for 8 days, after which the mice were infected i.n. with 1.4x105 pfu
influenza strain X31. Mice were culled at day 3 and BAL performed. BAL fl id w s stained with anti-
CD11c APC, anti-CD11b PerCp and anti-F4/80 PE-Cy7. The total number of cells in the airways was
determined by trypan blue exclusion (A) and the number of monocyte/macrophages (B) and alveolar
macrophages (C) was calculated by multiplying the percentage positive x percentage of cells in the
myeloid gate x viable cell count in the airways. * = p<0.05, ** = p<0.01 n=10+/- SEM
* **
N
u
m
b
e
r 
o
f 
c
e
lls
 x
 1
0
4
C
IgG Anti-IL-10R IgG Anti-IL-10R
IgG Anti-IL-10R
Total cell numbers Recruited monocyte/macrophages
Alveolar macrophages
Chapter 4: The impact of IL-10R blockade on lung homeostasis  
 
152 
 
4.2.8 Prior IL-10R blockade results in airway macrophages with a more 
alternatively activated phenotype during a subsequent influenza infection 
A lack of myeloid regulators in the airways can lead to altered homeostasis and change 
the phenotype of macrophages; for example, alveolar macrophages lacking PPAR-γ 
become spontaneously activated with a Th1 bias 466. Although only lung 
monocyte/macrophage expression of RELM-α was altered in naïve mice after IL-10R 
blockade, it was important to investigate if there was a change in macrophage 
phenotype during influenza-induced inflammation.  
We had previously seen, surprisingly, that YM1 and RELM-α were differentially 
regulated during influenza infection (see Chapter 3). The expression of YM1 and 
RELM-α was therefore compared between the anti-IL-10R Ab-treated mice and IgG1-
treated controls. At day 6 of influenza infection, prior IL-10R blockade resulted in a 
significantly higher percentage of YM1 positive alveolar macrophages compared to 
IgG1-treated controls, however there was no difference in the GM of YM1 between the 
two groups (Fig. 4.13A). The increase in intra-cellular YM1 expression by macrophages 
during influenza infection subsequent to IL-10R blockade might imply decreased 
secretion and/or increased intra-cellular production. 
Similarly, after IL-10R blockade, there was a higher percentage of RELM-α positive 
alveolar macrophages at day 6 of a subsequent influenza infection, but again, no 
increase in GM of RELM-α (Fig. 4.13B). Prior IL-10R blockade did not alter YM1 or 
RELM-α expression at any other time points during influenza infection.  
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Figure 4.13 Prior IL-10R blockade augments the proportion of YM1 and RELM-α 
positive airway macrophages at day 6 of a subsequent influenza infection. 
C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (squares) or rat IgG1 
(circles) every other day for 8 days, after which mice were infected i.n. with 1.4x105 pfu 
influenza strain X31. Mice were sacrificed at day 6, BAL performed and BAL fluid 
stained with anti-CD11c APC, anti-CD11b PerCp and anti-F4/80 PE-Cy7; the cells 
were then fixed, permeabilised and stained with rat anti-mouse YM1 followed by goat 
anti-rat IgG FITC or rabbit anti-mouse RELM-α followed by goat anti-rabbit IgG FITC. 
The percentage (closed symbols) and geometric mean (open symbols) of YM1 (A) and 
RELM-α  (B) positive alveolar macrophages and YM1 (C) and RELM-α (D) positive 
airway monocyte/macrophages were determined by flow cytometry. Data shown are 
representative of 2 experiments; n=5 +/- SEM. * = <0.05  
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Figure 4.13 Prior IL-10R blockade augments the proportion of YM1 and RELM-α positive airway
macrophages at day 6 of a subsequent influenza infection. C57BL/6 mice were injected i.p. with
200 μg anti-IL-10R Ab (squares) or rat IgG1 (circles) every other day for 8 days, after hich mice were
infected i.n. with 1.4x105 pfu influenza strain X31. Mice were sacrificed at day 6, BAL was performed
and BAL fluid stained with anti-CD11c APC, anti-CD11b PerCp and anti-F4/80 PE-Cy7; the cells were
then fixed, permeabilised and stained with anti-YM1 or anti-RELM-α FITC. The percentage (closed
symbols) and geometric mean (open symbols) of YM1 (A) and RELM-α (B) positive alveolar
macrophages and YM1 (C) and RELM-α (D) positive airway monocyte/macrophages were determined
by flow cytometry. Data shown are representative of 2 experiments; n=5 +/- SEM. * = <0.05
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Next, airway recruited monocyte/macrophages were analysed for expression of YM1 
and RELM-α. In a similar trend to that displayed by alveolar macrophages, there was a 
higher percentage of YM1 positive monocyte/macrophages at day 6 of a subsequent 
influenza infection (Fig. 4.13C). There was also a slight increase in the GM of YM1 
positive cells but this difference did not reach statistical significance (Fig. 4.13C).  
Surprisingly, there was no difference in the percentage or GM of RELM-α positive 
monocyte/macrophages between the anti-IL-10R Ab-treated group and IgG1-treated 
controls (Fig. 4.13D). There was no difference in the percentage of YM1 or RELM-α 
positive airway monocyte/macrophages between the two groups at any other time point 
analysed (data not shown). 
4.2.9 Prior IL-10R blockade enhances the alternative activation of lung 
macrophages during subsequent influenza infection 
The expression of YM1 and RELM-α was next analysed on lung macrophage 
populations during influenza infection following IL-10R blockade. In a similar result to 
that seen in the airways, the percentage of YM1 positive lung CD11c+ macrophages 
was higher at day 6 of  influenza infection after IL-10R blockade, but there was no 
change in the GM of YM1 (Fig. 4.14A). Similarly, there was a higher percentage of 
RELM-α positive lung CD11c+ macrophages at day 6 in the anti-IL-10R Ab-treated 
mice, but there was no difference in the GM of RELM-α (Fig. 4.14B). As discussed in 
the previous chapter these may represent residual airway cells not removed by BAL. 
There was no difference in the percentage or GM of YM1 or RELM-α positive lung 
CD11c+ macrophages at any other time point analysed (data not shown). 
Interestingly, there was no difference in YM1 expression on lung 
monocyte/macrophages at day 6 of influenza infection, contrary to the result seen for 
the other lung and airway macrophage populations (Fig. 4.14C). However, after IL-10R 
blockade there was a higher percentage of RELM-α positive lung 
monocyte/macrophages at day 6 of a subsequent influenza infection (Fig. 4.14D).  
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Figure 4.14 Prior IL-10R blockade increases the proportion of YM1 and RELM-α 
positive lung CD11c+ macrophages at day 6 of a subsequent influenza infection. 
C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (squares) or rat IgG1 
(circles) every other day for 8 days, after which mice were infected i.n. with 1.4x105 pfu 
influenza strain X31. Mice were sacrificed at day 6, BAL performed and BAL cells 
stained with anti-CD11c APC, anti-CD11b PerCp and anti-F4/80 PE-Cy7; the cells 
were then fixed, permeabilised and stained with rat anti-mouse YM1follwed by goat 
anti-rat IgG FITC or rabbit anti-mouse RELM-α followed by goat anti-rabbit IgG FITC. 
The percentage (open symbols) and geometric mean (closed symbols) of YM1 (A) and 
RELM-α  (B) positive lung CD11c+ macrophages and YM1 (C) and RELM-α (D) positive 
lung monocyte/macrophages were determined by flow cytometry. Data shown are 
representative of 2 experiments; n=5 +/- SEM.  ** = p<0.01  
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Figure 4.14 Prior IL-10R blockade increased the proportion of YM1 and RELM-alpha positive
lung CD11c+ macrophages at day 6 of a subsequent influenza infection. C57BL/6 mice were
injected i.p. with 200 μg anti-IL-10R Ab (squares) or rat IgG1 (circles) every other day for 8 days, after
which mice were infected i.n. with 1.4x105 pfu influenza strain X31. Mice were sacrificed at day 6, BAL
performed and BAL fluid stained with anti-CD11c APC, anti-CD11b PerCp and anti-F4/80 PE-Cy7; the
cells were then fixed, permeabilised and stained with anti-YM1 or anti-RELM-alpha FITC. The
percentage (open symbols) and geometric mean (closed symbols) of YM1 (A) and RELM-alpha (B)
positive lung CD11c+ macrophages and YM1 (C) and RELM-α positive lung monocyte/macrophages
were determined by flow cytometry. Data shown are representative of 2 experiments; n=5 +/- SEM. **
= p<0.01
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There was no difference in YM1 or RELM-α expression at any other time points 
analysed. 
4.2.10 The effect of prior IL-10R blockade on levels of soluble YM1 and RELM-α 
during subsequent influenza infection 
As there was increased intra-cellular expression of YM1 and RELM-α by macrophages, 
it was of interest to also analyse the levels of soluble protein. Therefore BAL fluid and 
lung homogenates were analysed for soluble YM1 and RELM-α by ELISA. Consistent 
with a higher proportion of RELM-α positive airway macrophages in the anti-IL-10R Ab-
treated animals at day 6 of influenza infection (Fig.4.13), levels of soluble RELM-α in 
the BAL fluid were also higher in anti-IL-10R Ab-treated mice compared to IgG-treated 
controls at this time point (Fig. 4.15A). Conversely, although there was a higher 
proportion of YM1 positive alveolar macrophages and airway monocyte/macrophages 
in the BAL fluid of anti-IL-10R Ab-treated mice at day 6 of influenza infection (Fig. 
4.13), this did not correlate with a difference in the levels of soluble YM1 in the BAL 
fluid at this time point (Fig. 4.15B). However, there were significantly higher levels of 
YM1 in the BAL fluid of anti-IL-10R Ab-treated mice at day 3 of influenza infection (Fig. 
4.15B).  
Next, lung homogenates were tested for levels of YM1 and RELM-α. Intra-cellular 
levels of YM1 and RELM-α were higher at day 6 of influenza infection in lung CD11c+ of 
mice which had been previously treated with anti-IL-10R Ab (Fig. 4.14), therefore we 
hypothesised that secreted levels of both proteins might also be different. However, 
there was no significant difference in the levels of RELM-α (Fig. 4.15C) or YM1 (Fig. 
4.15D) in lung homogenates at any of the time points analysed during influenza 
infection. 
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Figure 4.15 The effect of prior IL-10R blockade on levels of soluble YM1 and 
RELM-α during influenza infection. C57BL/6 mice were injected i.p. with 200μg anti-
IL-10R Ab (clear bars) or rat IgG1 (grey bars) every other day for 8 days, after which 
mice were infected i.n. with 1.4x105 pfu. Mice were sacrificed at day 6, BAL performed 
and the lungs extracted. BAL fluid was then assessed for soluble RELM-α (A) and YM1 
(B) and snap-frozen lung lobes were homogenised and similarly analysed by ELISA for 
soluble RELM-α (C) and YM1 (D). Data are representative of 2 experiments. 
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Figure 4.15 Prior IL-10R blockade does not significantly change the secretion of YM1 or RELM-α
C57BL/6 mice were injected i.p. with 200μg anti-IL-10R Ab (clear bars) or rat IgG1 (grey bars) every
other day for 8 days, after which after which mice were infected i.n. with 1.4x105 pfu. Mice were
sacrificed at day 6, BAL performed and the lungs extracted. BAL fluid was then assessed for soluble
RELM-α (A) and YM1 (B) and snap-frozen lung lobes were homogenised and similarly analysed by
ELISA for soluble RELM-α (C) and YM1 (D).
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4.2.11 Prior IL-10R blockade enhances production of inflammatory cytokines by 
T cells in the airway during a subsequent influenza infection 
During influenza infection, activated T cells infiltrate the lungs and airways and secrete 
vast amounts of inflammatory cytokines which, whilst importance for viral clearance 
also cause a significant amount of bystander damage to the lungs and can impact on 
weight loss 470. It was therefore important to establish whether prior IL-10R blockade 
had affected the ability of T cells to secrete inflammatory cytokines during subsequent 
influenza infection.  
T cell production of inflammatory cytokines TNF-α and IFN-γ was assessed by intra-
cellular cytokine staining of lung homogenate and BAL fluid. Prior IL-10R blockade 
resulted in a higher number of IFN-γ- and TNF-α-producing CD4+ (Fig. 4.16A) and 
CD8+ (Fig, 4.16B) T cells at day 6 of influenza infection compared to IgG1 treatment. 
However, this enhancement of TNF-α- and IFN-γ-producing T cells was not seen in the 
lungs (data not shown). 
Previous studies show that IL-10R blockade or a lack of IL-10 during a high dose 
influenza infection results in enhanced numbers of Th17 cells in the lungs and airways 
306. Although by comparison infection with 1.4x105 pfu of influenza virus is not a high 
dose, it was important to establish if the formation of Th17 cells had been altered by 
prior blockade of IL-10R. IL-17 production by T cells was therefore determined by intra-
cellular cytokine staining. At day 6 of influenza infection after IL-10R blockade, there 
was a higher number of IL-17+ CD4+ T cells in the airways compared to IgG1-treated 
controls (Fig. 4.16C).  There was no difference in the number of IL-17 positive CD8+ T 
cells between the anti-IL-10R Ab-treated groups and IgG1-treated controls (Fig. 
4.16D). 
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Figure 4.16 Prior IL-10R blockade increases the number of IFN-γ-,TNF-α-, and IL-
17- producing T cells at day 6 of a subsequent influenza infection. C57BL/6 mice 
were injected i.p. with 200 μg anti-IL-10R Ab (clear bars) or rat IgG1 (grey bars) every 
other day for 8 days, after which mice were infected i.n. with 1.4x105 pfu. Mice were 
sacrificed at day 6, BAL performed and airway cells were stained with anti-CD4 PerCp 
and anti-CD8 FITC after which the cells were fixed and permeabilised and stained with 
anti-TNF-α PE, anti-IFN-γ PE-Cy7 and anti-IL-17 APC. The number of IFN-γ and TNF-
α positive CD4+ (A) and CD8+ T cells (B) and the number of IL-17 positive CD4+ (C) 
and CD8+ (D) T cells  was calculated by multiplying the percentage positive x 
percentage of CD4+ or CD8+ T cells x the percentage of cells in the lymphoid gate x 
viable cell count. Data are representative of 2 experiments; n=5 +/- SEM. *= p<0.05, ** 
= p<0.01.  
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Figure 4.16 Prior IL-10R blockade increases the numb r of IFN-γ-,TNF-α-, and IL-17- producing T
cells at day 6 of a subsequent influenza infection. C57BL/6 mice were injected i.p. with 200 μg anti-
IL-10R Ab (clear bars) or rat IgG1 (grey bars) every other day for 8 days, after which after which mice
were infected i.n. with 1.4x105 pfu. Mice were sacrificed at day 6, BAL performed and airway cells were
stained with anti-CD4 PerCp and anti-CD8 FITC after which the cells were fixed and permeabilised and
stained with anti- NF-α PE, anti-IFN-γ PE-Cy7 or anti-IL-17 APC, or. The number of IFN-γ and TNF-α
positive CD4+ (A) and CD8+ T cells (B) and the number of IL-17 positive CD4+ (C) and CD8+ (D) T cells
was calculated by multiplying the percentage positive x the number of cells in the lymphoid gate x
viable cell count. Data are representative of 2 experiments; n=5 +/- SEM. *= p<0.05, ** = p<0.01.
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The differentiation of Th17 cells is driven by TGF-β, IL-6 and IL-21 and IL-23 is 
required for the maintenance of this population 471. As mice previously treated with anti-
IL-10R Ab had higher numbers of Th17 cells during influenza infection (Fig. 4.16), it 
was of interest to analyse the production of these factors. Lung homogenate from 
IgG1- and anti-IL-10R Ab-treated mice was then analysed for IL-6 and IL-23 levels.  
At day 0 and day 3 of influenza infection there were significantly higher levels of IL-6 in 
the lung homogenates of mice previously treated with anti-IL-10R (Fig. 4.17A). This 
was consistent with the hypothesis that blockade of IL-10R might result in lung 
inflammation in the un-infected state and might enhance inflammation during influenza 
infection. On the other hand, there was no significant difference in the levels of IL-23 in 
the lungs of either group of mice during influenza infection (Fig. 4.17B).  
 
Figure 4.17 IL-6 but not IL-23 levels are enhanced during influenza infection in 
the lungs of mice previously treated with anti-IL-10R Ab. C57BL/6 mice were 
injected i.p. with 200 μg anti-IL-10R Ab (clear bars) or rat IgG1 (grey bars) every other 
day for 8 days, after which mice were infected i.n. with 1.4x105 pfu influenza X31 on 
day 0. Mice were sacrificed at the time points shown and the lungs extracted. Lung 
lobes were homogenised and supernatants assessed for IL-6 (A) and IL-23 (B) by 
ELISA.  n=5 +/- SEM * = p<0.05, ** = p<0.01. Data are representative of 2 
experiments. 
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Figure 4.17 IL-6 but not IL-23 levels are enhanced during influenza infection in the lungs of mice
previously treated with anti-IL-10R Ab. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab
(clear bars) or rat IgG1 (grey bars) every other day for 8 days, after which after which mice were
infected i.n. with 1.4x105 pfu on day 0. Mice were sacrificed at the time points shown and the lungs
extracted. Lung lobes were homogenised and supernatants assessed for IL-6 (A) and IL-23 (B) by
ELISA. n=5 +/- SEM * = p<0.05, ** = p<0.01.
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4.2.12 Prior IL-10R blockade does not significantly alter chemokine production 
during influenza infection 
Due to the increased numbers of monocyte/macrophages seen in the airway during 
influenza infection following IL-10R blockade (Fig.4.12B) it was of interest to analyse 
the production of macrophage chemoattractants in the lungs and airways. Macrophage 
chemoattractants MCP-1 and MIP-1α were of particular interest as they are highly 
induced during influenza infection 41, 94. 
C57BL/6 mice were pre-treated on days -8, -6, -4 and -2 with 200μg anti-IL-10R Ab or 
rat IgG, after which they were infected i.n. at day 0 with 1.4x105 pfu influenza X31. Mice 
were culled 1, 3, 6 or 14 days post infection and the lungs extracted. Lung 
homogenates were then analysed for the production of MCP-1 and MIP-1α. Levels of 
MCP-1 (Fig. 4.18A) and MIP-1α (Fig. 4.18B) were comparable between anti-IL-10R Ab-
treated mice and rat IgG1-treated mice at all time points analysed except day 6, when 
levels of both chemokines were lower in the lungs of mice which had been previously 
treated with anti-IL-10R Ab. This is interesting as numbers of macrophages in the lungs 
of anti-IL-10R Ab-treated mice were comparable with control mice at day 6 of influenza 
infection.  
4.2.13 The effect of IL-10R blockade on macrophage responses to TLR stimulus 
During Pneumocystis carinii infection, IL-10 knockout mice display heightened 
clearance of bacteria, and have increased levels of IFN-γ in BAL fluid 472. The authors 
suggest that alveolar macrophages from these mice have a lower threshold of 
activation than wild type mice. Additionally, IL-10-treated Mycobacterium bovis-infected 
macrophages have defective IFN-γ-mediated killing, which suggests that IL-10 can 
alter macrophage function 473. 
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Figure 4.18 Prior IL-10R blockade reduces chemokine levels in the lungs at day 6 
of subsequent influenza infection. C57BL/6 mice were injected i.p. with 200 μg anti-
IL-10R Ab (clear bars) or rat IgG1 (grey bars) every other day for 8 days after which 
mice were infected i.n. with 1.4x105 pfu on day 0. Mice were sacrificed at the time 
points shown and the lungs extracted. Lung lobes were homogenised and 
supernatants assessed for MCP-1 (A) and MIP-1α (B). n=5 +/- SEM. * = p<0.05. Data 
are representative of 2 experiments. 
 
In order to assess if IL-10R blockade had altered the ability of alveolar macrophages to 
respond to microbial stimulus, it was of interest to stimulate alveolar macrophages ex 
vivo with TLR agonists. C57BL/6 mice were injected i.p. with 200μg anti-IL-10R ab or 
rat IgG1 isotype control every other day for 8 days, after which the mice were sacrificed 
and BAL performed. Alveolar macrophages were then isolated from BAL fluid as 
described in the Methods section, and stimulated with an agonist to TLR-7, Imiquimod, 
at concentrations of 5μg/ml, 4μg/ml, 3μg/ml, 2μg/ml and 1μg/ml. Cell supernatants 
were collected 6 hours and 24 hours post stimulation. Imiquimod mimics the effects of 
viral TLR-7 agonists and induces the activation of NFkB 474. IL-6 and TNF-α production 
were used a read-out of responsiveness to TLR stimulation. 
Contrary to expectations, alveolar macrophages from mice which had been previously 
treated with anti-IL-10R ab had markedly reduced levels of IL-6 and TNF-α at 6 hours 
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Figure 4.18 Prior IL-10R blockade does not affect chemokine production in the lungs during
subsequent influenza infection. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (clear
bars) or rat IgG1 (grey bars) every other day for 8 days, after which after which mice were infected i.n.
with 1.4x105 pfu on day 0. Mice were sacrificed at the time points shown and the lungs extracted. Lung
lobes were homogenised and supernatants assessed for MCP-1 (A) and MIP-1α (B) n=5 +/- SEM. * =
p<0.05
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post stimulation compared to rat IgG1-treated controls (Fig 4.19A and B respectively). 
At 24 hours production of IL-6 and TNF-α was similar between the anti-IL-10R Ab-
treated alveolar macrophages and IgG-treated controls (Fig.4.19C and D respectively). 
 
 
Figure 4.19 Prior IL-10R blockade impairs TLR responsiveness at early time 
points. C57BL/6 mice were injected i.p. with 200 μg anti-IL-10R Ab (clear bars) or rat 
IgG1 (grey bars) every other day for 8 days, after which the mice were culled and BAL 
performed. Alveolar macrophages were isolated as described in the Methods and 
stimulated with concentrations of Imiquimod (R387) as displayed above. Supernatants 
were harvested and IL-6 and TNF-α levels at 6 hours (A and B respectively) and 24 
hours (C and D respectively) by ELISA. n=3 +/- SEM. Data represent one experiment. 
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4.3 Discussion 
4.3.1. IL-10R blockade does not dramatically alter lung and airway homeostasis 
It was hypothesised that a lack of regulation by IL-10 in the lung at homeostasis would 
alter the lung micro-environment and result in low grade pulmonary inflammation, 
which would have been evident in increased lung and airway cellularity, as well as 
enhanced macrophage activation. However, the differences observed were fairly 
subtle. The main difference observed on IL-10R blockade was enhanced numbers of 
airway cells and alveolar macrophages. This result is consistent with reports that a lack 
of the myeloid inhibitory receptor CD200R leads to enhanced numbers of alveolar 
macrophages 200; similar results were observed by our group upon TGF-β blockade (J. 
Goulding and T. Hussell; unpublished observations). The increase in alveolar 
macrophage number indicates a dysregulation of immune homeostasis in the airways 
and could be due to enhanced proliferation; this will be tested in future. Cell numbers in 
the lung were unaffected by IL-10R blockade, with T cell, DC and macrophage 
numbers unaffected by IL-10R blockade.  
It is not altogether surprising that IL-10R blockade did not lead to more striking airway 
inflammation, as several mechanisms exist in the lungs and airways to regulate 
inflammation. For example, TGF-β is present and is constantly being activated from its 
latent form by the integrin αvβ6 on the epithelium 438. TGF-β is a potent anti-
inflammatory cytokine and has a major role in the maintenance of lung homeostasis 438. 
In the liver IL-10 and TGF-β redundantly protect against liver injury and mortality during 
acute schistosomiasis 312. It is possible that a similar compensatory mechanism exists 
in the lungs and airways, which would explain the partial effect on alveolar macrophage 
numbers and no other evidence of altered homeostasis. Additionally, although IL-10 
enhances the expression of the regulatory molecule CD200R on macrophages 200, 
blockade of IL-10R did not alter CD200R expression (data not shown) and it is possible 
that other factors present in the airways such as TGF-β, GMCSF or surfactant proteins 
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have roles in keeping the expression of CD200R at normal levels, and therefore 
allowing macrophages to be regulated. 
Interestingly, neither TGF-β nor CD200R knockout mice display overt lung 
inflammation until a much later age and only have dsyregulated responses to infection 
200. Although IL-10 is clearly vital for maintaining homeostasis in the gut (as IL-10 
knockout mice develop spontaneous colitis) 297, it is possible that several compensatory 
mechanisms exist in the lungs and airways. It would be interesting to investigate the 
combined effect of IL-10R and TFG-β blockade, or the effects of blocking IL-10R in a 
CD200R knockout mouse. If there is redundancy between these regulatory pathways 
then it would be expected that blockade of another regulatory pathway in addition to 
the IL-10/R pathway would have an additive and therefore more pronounced effect on 
the dysregulation of homeostasis.  
4.3.2 Prior IL-10R blockade enhances the alternative activation of macrophages 
during subsequent influenza infection 
A lack of the myeloid regulator PPAR-γ in alveolar macrophages results in 
spontaneous pulmonary Th1 inflammation 466, and IL-10R blockade in IL-4R knockout 
mice decreases YM1 and MR expression. Therefore it was of interest to determine if 
IL-10R blockade affects macrophage phenotype at homeostasis. Interestingly, IL-10R 
blockade did not alter alveolar macrophage expression of markers of alternative 
activation such as MR, YM1 or RELM-α in the absence of inflammation; consistently, 
there was no change in the amount of soluble YM1 or RELM-α in the BAL fluid. Lung 
CD11c+ macrophage expression of MR, YM1 and RELM-α was similarly unchanged 
after IL-10R blockade, which is consistent with the idea that they may be residual 
alveolar macrophages not washed out by lavage. Interestingly, although lung 
monocyte/macrophage expression of MR and YM1 was unchanged, expression of 
RELM-α was enhanced upon IL-10R blockade.  
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Recent reports indicate that IL-10 and IL-4 redundantly drive the expression of YM1 
and MR 308, 439 and this might account for the lack of a change in YM1 and MR 
expression upon IL-10R blockade. The increase in the percentage of RELM-α positive 
lung monocyte/macrophages is interesting and suggests that RELM-α is regulated by 
additional factors distinct from those that regulate YM1 and MR.  
Interestingly, at day 6 of influenza infection, mice which had been previously treated 
with anti-IL-10R Ab had a significantly higher percentage of RELM-α positive alveolar, 
lung CD11c+ and lung monocyte/macrophages, and a higher percentage of YM1 
positive alveolar macrophages, airway monocyte/macrophages and lung CD11c+ 
macrophages. Soluble RELM-α was also increased in BAL fluid at day 6, and soluble 
YM1 was increased at day 3 during influenza infection subsequent to IL-10R blockade. 
Alternatively activated macrophages are conventionally induced by IL-4/IL-13 
stimulation 45, 475, and have been shown to be vital for the resolution of RSV infection in 
mice 431. However during influenza infection, the increase in the proportion of RELM-α 
and YM1 positive macrophages in the anti-IL-10R-treated group was not associated 
with faster resolution of weight loss, nor was inflammatory infiltrate lessened in these 
mice. It is unclear what role alternatively activated macrophages play in influenza 
infection and indeed what factors up-regulate their expression (this is discussed more 
in the previous chapter) as there is not a significant amount of IL-4 produced during 
influenza infection; studies report as little as 10pg/ml in lung homogenate at day 7 of 
influenza infection 442 and fewer than 1% of lung and airway T cells producing IL-4 at 
day 7 of influenza infection 441. 
It is known that IL-33 amplifies the polarisation of alternative activation of alveolar 
macrophages 149 and studies in the laboratory have shown that IL-33 is present in the 
lungs and airways at homeostasis and during influenza infection (E.L Wissinger and T. 
Hussell; manuscript in preparation). We hypothesised that IL-10R blockade may have 
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enhanced the production of IL-33, which drives the polarisation of alternatively 
activated macrophages in the lung 149. However, IL-10R blockade had no effect on IL-
33 production (data not shown). This indicates that other factors may be driving the 
increased expression of markers of alternative activation by lung and airway 
macrophages seen upon IL-10R blockade.  
The half-life of the anti-IL-10R antibody is not known, however, treatment regimens in 
other studies have ranged from daily administration to every four days 233, 306, 307. 
Therefore it is possible that the effects of the antibody might last into the influenza 
infection, although treatment was stopped two days prior to infection. It is also possible 
that, as the antibody was administered intra-peritoneally, it has systemic effects on 
sites other than the lung, and might impact on the phenotype of cells in other organs, 
such as the gut. 
4.3.3 IL-10R blockade leads to increased cellular infiltrate into the lungs and 
airways during a subsequent influenza infection 
At day 3 of influenza infection, mice which had been treated with anti-IL-10R Ab had 
increased total cell numbers and numbers of monocyte/macrophages in the airways; 
there was also a non-significant trend towards higher numbers of alveolar 
macrophages at this time point. MCP-1 and MIP-1α are chemoattractants for 
macrophage recruitment into the lungs and airways during inflammation 94; we 
hypothesised that prior IL-10R blockade led to production of more of these chemokines 
during influenza infection, and therefore increased recruitment of macrophages. It is 
also possible that the partial increase in macrophage numbers seen at homeostasis 
was an indication that the recruitment of macrophages had been altered. Although 
there was no effect on CCR2 expression by alveolar macrophages at homeostasis it is 
possible that other receptors for macrophage chemoattractants and their ligands were 
up-regulated. Additionally, MCP-1 and MIP-1α levels were not altered during influenza 
infection except at day 6, when they were actually reduced in IL-10R Ab-treated mice.  
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It is possible that the increase in monocyte/macrophage numbers seen at day 3 of 
influenza infection in the anti-IL-10R-treated animals is due to proliferation of cells in 
situ or a lack of cell death. This will be tested in future by inclusion of markers for 
proliferation such as BRDU, Ki67 or markers of apoptosis such as Annexin V.  
4.3.4 Prior IL-10R blockade augments T cell numbers in the airways during 
subsequent influenza infection 
T cells are primed by DCs in the lymph node and migrate to sites of infection via 
homing signals, where they then proliferate under the influence of cytokines like IL-2 
and co-stimulatory molecules. The increase in T cell numbers in the airways at day 6, 
which is the peak of T cell infiltrate during influenza infection, might result from the 
increased monocyte/macrophage numbers earlier in the infection. 
Monocyte/macrophages secrete myriad cytokines and chemokines such as TNF-α and 
IFN-γ which activate T cells and the endothelium. Activated monocyte/macrophages 
also express co-stimulatory molecules such as GITR ligand and OX40 ligand, which 
when bound to their receptors on T cells result in T cell proliferation and survival 123, 342. 
Higher monocyte/macrophage expression of these co-stimulatory molecules would 
result in prolonged T cell survival and T cell proliferation.  
The increase in total T cell number in the airways of the IL-10R Ab-treated mice 
correlates with a higher number of TNF-α-, IFN-γ- and IL-17-producing T cells, which 
contribute to a highly inflammatory environment. Higher influenza virus load could lead 
to increased T cell infiltrate into the lungs and airways, but as viral load was 
comparable between anti-IL-10R Ab-treated and IgG1-treated mice, this was not the 
reason for the enhanced T cell numbers. Interestingly, the increase in T cell number 
and consequently IFN-γ and TNF-α did not result in faster clearance of the virus, nor 
did it result in increased weight loss.  
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4.3.5 Prior IL-10R blockade alters macrophage responses to TLR stimulus 
There is evidence that IL-10 can alter the function of macrophages; for example IL-10 
inhibits IFN-γ-mediated killing of Mycobacterium bovis 473 and Paracoccidioides 
brasiliensis 476. Additionally, IL-10 knockout mice have enhanced IFN-γ production at 
early time points during Bordotella pertussis infection, indicating that they are 
intrinsically more activated 477. Furthermore, IL-10 decreases the production of TNF-α 
and IL-6 by macrophages 257, 258. 
It was therefore hypothesised that a lack of the suppressive effects of IL-10 at 
homeostasis would enhance the response of alveolar macrophages to antigenic 
stimuli. However when alveolar macrophages were treated with various dilutions of the 
TLR7 agonist Imiquimod, the alveolar macrophages from mice pre-treated with anti-IL-
10R Ab produced less IL-6 and TNF-α at early time points than those from mice treated 
with rat IgG1 (Fig. 4.18), indicating that perhaps they are actually less activated. 
Therefore, the absence of the regulatory effects of IL-10, instead of making alveolar 
macrophages inherently more responsive to antigenic stimuli, might just change the 
nature of the response. It would be informative to analyse the expression of co-
stimulatory molecules on these macrophages; it is possible that instead of producing 
vast amounts of cytokines, these macrophages act in a more “professional” manner, 
up-regulating the expression of co-stimulatory molecules such as GITR ligand or OX40 
ligand.  
4.4 Conclusion 
It is known that IL-10 and IL-10R knockout mice have altered immune homeostasis and 
depending on the dose of influenza used, better or worse outcome upon influenza 
infection. The aim of this study was to determine if a transient blockade of IL-10R 
would significantly alter lung homeostasis and/or alter the subsequent immune 
response to influenza infection. While there were no major alterations in lung 
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homeostasis, prior IL-10R blockade resulted in increased cellularity at key time points 
during influenza infection, as well as altering the expression profile of the markers of 
alternative activation YM1 and RELM-α. This indicates that although there is 
redundancy in myeloid regulators such that the transient blockade of IL-10R did not 
result in an overtly altered homeostasis, transient blockade of this one regulatory 
pathway was enough to alter the immune response to a subsequent influenza infection. 
Therefore, although the different myeloid regulators may be redundant in maintaining 
lung homeostasis, once an infection is added then the true magnitude of an individual 
component can be seen, such as in the case of pulmonary infections in CD200, 
CD200R, IL-10 and IL-10R knockout mice. 
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5.0 The role of GITR and GITRL in influenza-induced inflammation  
5.1 Introduction 
The last chapter revealed that blockade of IL-10R in the un-inflamed lung did not have 
a major impact on lung homeostasis; however, during a subsequent influenza infection 
mice had greater airway inflammatory infiltrate and higher production of inflammatory 
cytokines by T cells. This indicates that a transient blockade of the regulatory effect of 
the IL-10/IL-10R interaction in the un-inflamed lung is sufficient to alter the immune 
response to a subsequent influenza infection. While this is useful for understanding the 
relative contribution of the IL-10/IL-10R axis in maintaining lung and airway 
homeostasis, physiologically it is more relevant to explore a pathway that could be 
manipulated therapeutically to improve disease outcome during influenza infection. 
5.1.1 Ameliorating influenza-associated immune pathology 
Influenza-associated lung pathology directly correlates with the pathogenicity of the 
viral strain and in turn the inflammatory infiltrate into the lungs and airways 223 369, 478. 
Infected epithelial cells produce RANTES, MCP-1 and IL-8, which recruit T cells, 
monocytes and neutrophils into the lungs and airways 49. Infected alveolar 
macrophages and monocyte/macrophages secrete pro-inflammatory cytokines such as 
MIP-1α, MCP-1, TNF-α, IL-1β, IL-6 and IFN-α and IFN-β 467. This in turn leads to 
induction of other cytokines and chemokines such as MCP-1, MCP-3 and IP-10, which 
recruit more inflammatory cells into the lungs and airways 49. T cells are also recruited, 
and produce IFN-γ and TNF-α, which, while important for viral clearance, in excess are 
highly pro-inflammatory and contribute to lung pathology 223, 479, 480. The mere presence 
of the vast number of inflammatory cells recruited into the airways during influenza 
infection causes acute respiratory distress syndrome in humans and mice and 
occludes gaseous exchange in the airways 481, 482. Therefore, recent studies in mouse 
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models have focused on reducing the influx of cells into the airways in an effort to 
reduce bystander damage to the lungs. 
Therapeutic neutralisation of pro-inflammatory cytokines during influenza infection is 
beneficial for disease outcome. For example neutralisation of TNF-α reduces weight 
loss and lung pathology during influenza infection 223 and mice lacking MIP-1α also 
have reduced lung immune pathology during influenza but suffer from delayed viral 
clearance 468. Conversely CCR2 null mice have better disease outcome during 
influenza infection, and the same result is seen with blockade of CCR2 41, 94. 
Neutralisation of IFN-γ during influenza infection decreases lung cellular infiltrate 483, 
and depletion of T cells enhances survival to lethal influenza infection 470. 
Previous efforts in the laboratory have sought to reduce the influenza-associated lung 
pathology and improve disease outcome by targeting co-stimulatory molecules during 
infection. One such co-stimulatory molecule is OX40, which is expressed on late 
activated T cells and when bound by its ligand, OX40L, promotes T cell survival and 
cytokine production 123, 484. OX40 and OX40L are highly up-regulated in the lungs 
during influenza infection 224. Blockade of OX40 ameliorates influenza-induced weight 
loss and lung and airway inflammatory infiltrate leading to significantly reduced immune 
pathology without affecting viral clearance 224. This reduction in immune pathology is 
attributed to diminished proliferation and increased apoptosis of T cells 224.   
All of these studies suggest that neutralisation of one component of immunity, 
especially therapeutically, may benefit immune pathology during lung viral infection. 
This chapter will explore the role of another co-stimulatory pair which, like OX40 
belongs to the TNF receptor super family: glucocorticoid-induced TNF receptor-related 
protein (GITR) and its ligand, GITRL.  
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5.1.2 GITR and GITRL in inflammatory lung disease 
GITR expression is enhanced on lung and pleural macrophages during carrageenan-
induced pleurisy and GITR-/- mice display significantly reduced cell numbers in the 
pleural cavity compared to wild type mice, which is associated with a reduction in the 
number of neutrophils and macrophages 380.  Additionally GITR-/- mice display lower 
levels of pro-inflammatory factors such as COX-2, PGE2 and iNOS in lung 
homogenates 380. Treatment of wild type mice with GITR:Fc fusion protein, which binds 
GITRL and blocks signalling to GITR, equally leads to improved disease outcome 
during carrageenan-induced pleurisy 380. The authors attribute this diminished 
inflammation to a reduction in NFkB signalling and decreased expression of cell 
adhesion molecules on endothelium in the absence of GITR. Indeed, other groups 
show that GITR signalling leads to NFkB activation 351 and that signalling through GITR 
on macrophages leads to the production of inflammatory mediators such as COX-2 and 
cell adhesion molecules such as ICAM-1 355, 356. 
A lack of GITR is also beneficial for bleomycin-induced chronic lung inflammation; 
GITR-/- mice and wild type mice treated with GITR:Fc have reduced immune pathology 
and inflammation in the lungs and airways 379. Again, the authors attribute this 
improvement in disease outcome to an absence of GITR 379. However, GITR/GITRL 
signalling is bi-directional, and therefore a GITR-/- mouse will lack the effects of both 
GITR and GITRL signalling whereas GITR:Fc binds GITRL and prevents signalling 
through GITR but signalling through GITRL may remain intact.  Because the phenotype 
of the GITR-/- mice and the GITR:Fc-treated mice was similar, the authors suggest that 
perhaps GITR signalling is more important for the activation of macrophages 379.  
The above studies propose a role for GITR in the activation of macrophages and NFkB 
signalling, and further studies suggest that interactions between GITR on leukocytes 
and GITRL on the endothelium could aid extravasation 355, 356, thereby implicating this 
co-stimulatory pair in the progression of inflammation. 
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While many show that GITRL signalling is inflammatory 359, 485 it appears that its effects 
may be cell-specific. For example, signalling through GITRL on plasmacytoid (p) DCs 
leads to induction of IDO and is therefore anti-inflammatory 363. Furthermore, 
Grohmann et al show that dexamethasone up-regulates GITRL on pDCs and 
dexamethasone-dependent induction of IDO occurs via the interaction between GITR 
and GITRL 363. They subsequently show that improved outcome of allergic 
bronchopulmonary aspergillosis after treatment with dexamethasone is via a GITRL-
dependent up-regulation of IDO production 363. 
While blockade of GITR signalling is clearly beneficial for disease outcome in chronic 
lung inflammation, potentiating the signal is detrimental. For example in mouse models 
of asthma, treating mice with a GITR agonist exacerbates disease severity, with 
enhanced T cell activity and concomitant production of Th2 cytokines and airway 
hyper-responsiveness 365.  
GITR and GITRL are clearly important for the development of pulmonary inflammation 
but their role in acute, viral-induced pulmonary inflammation has not yet been 
determined. 
5.1.3 Hypothesis 
This chapter will explore the hypothesis that GITR and GITR ligand play a role in 
influenza-induced inflammation and will answer the following questions: 
o Are GITR and GITRL expressed in the lungs and airways during 
influenza infection? 
o What is the effect of blocking the interaction between this co-stimulatory 
pair? 
o What factors up-regulate GITR and GITRL expression? 
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5.2 Results 
5.2.1 GITR and GITR ligand expression on lung and airway cells  
The expression of GITR and GITRL on immune cell subsets in the lungs and airways 
has not been definitively characterised, therefore it was of interest to ascertain 
expression of this co-stimulatory pair on lung and airway immune cell subsets. Single 
cell suspensions of lung homogenates and BAL cells from un-infected BALB/c mice 
were stained with specific antibodies against GITR and GITRL. 
As previously published 325, 326 GITR is constitutively expressed by T cells, and CD4+ 
and CD8+  T cells in the lungs were also GITR positive (Fig. 5.1A and C). B cells were 
next examined in the lung, and appeared to have modest expression of GITR (43+/- 
4% were GITR positive) compared to CD4+ and CD8+ T cells (Fig. 5.1A and 5.1C).  T 
cells and B cells were also analysed for expression of GITRL. The percentage of 
GITRL positive CD4+ and CD8+ T cells was very low (Fig. 5.1B and D). On the other 
hand, approximately 21 +/-2.9% of B cells were positive for GITRL (Fig. 5.1B and D). 
At present it is unclear why only a proportion of B cells express GITR and GITRL. It 
would be interesting to sub-divide these B cells into those expressing specific antibody 
isotypes to determine if GITR or GITRL expression correlates with a switch from IgM 
positive to B cells double positive for IgD, IgG, or IgA. IgA would be particularly 
interesting in this mucosal site. The same is true for the proportions of CD4+ and CD8+ 
T cells expressing GITRL. It is possible that low level antigen stimulation occurs in 
small numbers of T cells in mucosal tissues. A comparison with cells in the spleen 
should also be performed in the future. It was not possible to analyse lymphoid cells in 
the air spaces due to their very low numbers in healthy mice.   
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Figure 5.1 GITR and GITR ligand expression on lymphocytes in un-infected lungs 
and airways. BALB/c mice were culled and the lungs extracted, homogenised into 
single cell suspension and stained with anti-CD4 PerCp and anti-CD8 APC or anti-
B220 PerCp and anti-CD3 APC, and anti-GITR or anti-GITRL PE. The proportion of 
CD4+ (circles) and CD8+ (squares) T cells and B cells (triangles) expressing GITR (A) 
and GITRL (B) was determined by flow cytometry. Representative histograms are 
shown of GITR (C) and GITR ligand (D) expression on CD4+ and CD8+ T cells and B 
cells. Data are representative of 3 independent experiments, n=4/5 +/- SEM. Shaded 
histograms represent isotype control staining, and clear histograms represent specific 
antibody staining. 
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Figure 5.1 GITR and GITR ligand expression on lymphocytes in un-infected lungs and airways.
BALB/c mice were culled and the lungs extracted, homogenised into single cell suspension and stained
with anti-CD4 PerCp and anti-CD8 APC or anti-B220 PerCp and anti-CD3 APC, and anti-GITR or anti-
GITRL PE. The proportion of CD4+ (circles) and CD8+ (squares) T cells and B cells (triangles)
expressing GITR (A) and GITRL (B) was determined by flow cytometry. C and D show representative
histograms of GITR and GITR ligand expression on CD4+ and CD8+ T cells and B cells. Data are
representative of 3 independent experiments, n=4/5 +/- SEM.
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Next, macrophage populations were examined for GITR and GITRL expression. 
Neither alveolar macrophages nor lung CD11c+ macrophages expressed significant 
levels of GITR (Fig. 2A and C).  We believe that the CD11c+ macrophages found in 
lung homogenates may be residual alveolar macrophages that are not washed out of 
the airways during lavage and the similar lack of GITR expression observed on these 
two macrophage populations further supports this idea. The percentage of GITR 
positive lung monocyte/macrophages was low, with just approximately 8.8 +/-1% GITR 
positive cells (Fig. 2A and C).  
Like GITR, GITRL was not expressed by alveolar and lung CD11c+ macrophages (Fig. 
2B and D). However, GITRL was expressed on approximately 18 +/- 4.9% of lung 
monocyte/macrophages (Fig. 2B and D). The low expression of GITRL on 
monocyte/macrophages and the absence of GITRL on alveolar macrophages is in 
contrast with reports that GITRL mRNA and protein is expressed by splenic, peritoneal 
and bone marrow-derived macrophages 330 and may suggest site-specific regulation of 
GITRL. Low expression of GITR and GITRL is also reported in ocular tissues 367 and 
may represent regulation of this co-stimulatory pair at sites where expression of this 
inflammatory pair would be highly deleterious.  
5.2.2 GITR and GITRL are differentially up-regulated on lymphocytes in the lungs 
and airways during influenza infection 
GITR and GITRL were differentially expressed in the un-inflamed lung, but in order to 
analyse the role this co-stimulatory pair play during influenza infection, it was of interest 
to follow their expression during influenza infection. Therefore a time course 
experiment was performed, and BALB/c mice were infected i.n. with 1.4x105 pfu 
influenza X31 at day 0. Mice were culled 4, 7 or 10 days after influenza infection, BAL 
performed and the lungs removed and homogenised.   
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Figure 5.2 GITR and GITR ligand expression on myeloid cells in un-infected 
lungs and airways. BALB/c mice were culled, BAL performed, and the lungs removed. 
BAL fluid and lung homogenates were stained with anti-CD11c APC, anti-CD11b 
PerCp, anti-F4/80 PECy-7 and anti-GITR or anti-GITRL PE. The percentage of alveolar 
macrophages (circles), lung monocyte/macrophages (squares) and lung CD11c+ 
macrophages (triangles) expressing GITR (A) and GITRL (B) were determined by flow 
cytometry. (C) and (D) display representative histograms of GITR and GITRL 
expression respectively on the above cell populations. Data are representative of 3 
independent experiments, n=4/5 +/-SEM. Shaded histograms represent isotype control 
staining, and clear histograms represent specific antibody staining. 
  
Figure 5.2 ITR and GITR ligand expression on myeloid cells in un-infected lungs and airways.
BALB/c mice were culled, BAL performed, and the lungs removed. BAL fluid and lung homogenates
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T cells in the airways were only analysed at day 7 and 10 due to limiting cell numbers 
in BAL at early time points during influenza infection. As observed in the un-inflamed 
lung, the majority of CD4+ and CD8+ T cells in the airways expressed GITR at day 7 
and this remained unchanged at day 10 (Fig. 5.3A). The GM was used as a crude 
method to determine up-regulation of GITR on T cells. Like the percentage positive, the 
GM of GITR on T cells in the airways did not significantly change from day 7 to 10 of 
influenza infection (Fig. 5.3B). 
 
Figure 5.3 GITR expression is unchanged on T cells in the airways during 
influenza infection. BALB/c mice were infected with 1.4x105 pfu influenza X31 on day 
0 and the mice culled at the time points indicated. BAL was then performed and the 
lungs extracted. BAL cells were stained with anti-CD4 PerCp, anti-CD8 FITC, and anti-
GITR or anti-GITRL PE. The percentage (A) and GM (B) of airway CD4+ (clear bars) 
and CD8+ (grey bars) T cells expressing GITR were determined by flow cytometry. n=5 
+/- SEM; data represent 2 independent experiments  
 
CD4+ and CD8+ T cells in the un-inflamed lung were almost all positive for GITR and 
this did not change at any of the time points examined during influenza infection (Fig. 
5.4A). However, the percentage of GITR positive B cells in the lungs increased during 
influenza infection from approximately 43 +/- 4% at day 0, to 66 +/- 2% positive at day 
7 (Fig. 5.4A). Like the expression of GITR on a subset of B cells in the un-inflamed 
lung, the increase in the percentage positive during influenza infection might reflect 
cells that have undergone an isotype switch. This will be analysed in the future. 
%
 G
IT
R
 p
o
s
it
iv
e
7 10 7 10
Time (days) after influenza infection
CD4+ T cells CD8+ T cells
A
Figure 5.3 GITR expression is unchanged on T cells in the airways during influenza infection.
BALB/c mice were infected with 1.4x105 pfu influenza X31 on day 0 and the mice culled at the time
points indicated. BA was then perform d and the lungs extracted. BAL fluid s stained with anti-CD4
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Figure 5.4 The intensity of GITR and GITRL on lymphocytes is differentially 
regulated during influenza infection. BALB/c mice were infected with 1.4x105 pfu 
influenza X31 on day 0 and the mice culled at the time points indicated. BAL was then 
performed and the lungs extracted. Lung homogenates and BAL cells were stained 
with anti-CD4 PerCp, anti-CD8 FITC, anti B220 PerCp and anti-GITR or anti-GITRL 
PE. The percentage (A) and GM (B) of GITR on CD4+ (clear bars) and CD8+ (grey 
bars) T cells and B cells (striped bars)  in the lungs; and the percentage (C) and GM 
(D) of GITRL on CD4+ (clear bars) and CD8+ (grey bars) T cells and B cells (striped 
bars)  in the lungs were determined by flow cytometry. * = p<0.05, ** = p<0.01, *** = 
p<0.001 compared to day 0. n=5 +/- SEM; data represent 2 independent experiments. 
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Figure 5.4 The intensity of GITR and GITRL on lymphocytes is differentially regulated during
influenza infection. BALB/c mice were infected with 1.4x105 pfu influenza X31 on day 0 and the mice
culled at the time points indicated. BAL was then performed and the lungs extracted. Lung homogenates
and BAL fluid were stained with anti-CD4 PerCp, anti-CD8 FITC, anti B220 PerCp and anti-GITR or anti-
GITRL PE. The percentage (A) and GM (B) of GITR on CD4+ (clear bars) and CD8+ (grey bars) T cells
and B cells (striped bars) in the lungs; and the percenta (C) and GM (D) of GITRL on CD4+ (clear
bars) and CD8+ (grey b rs) T cells and B cells (striped bars) in the lungs were determined by flow
cytometry. * = p<0.05, ** = p<0.01, *** = p<0.001 compared to day 0. n=5 +/- SEM; data represent 2
independent experiments
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Previous studies report that GITR is up-regulated by T cells upon activation 324. 
Therefore, although the percentage of GITR positive T cells in the lung did not 
significantly change during influenza infection, it was of interest to examine the intensity 
of GITR on these cells, by analysing the GM. As expected, the GM of GITR on CD4+ 
and CD8+ T cells increased during influenza infection, peaking at day 7 of infection, a 
time point when T cell numbers are maximal and levels of inflammatory cytokines in the 
lungs are high and therefore T cells are activated 224 (Fig. 5.4B). At day 10 of influenza 
infection the GM of GITR on T cells remained high (Fig. 5.4B). Therefore, GITR 
expression was increased on a per cell basis during influenza infection. Although the 
percentage of GITR positive B cells increased during influenza infection, the intensity of 
GITR on these cells did not change, as indicated an absence of change in GM values 
(Fig. 5.4B).  
Some studies report that GITRL is up-regulated on T cells upon TCR stimulation 326, 354, 
while others report no up-regulation of GITRL 330. As activated T cells infiltrate the 
lungs during influenza infection it was important to assess whether T cells in the highly 
inflammatory environment of the influenza-infected lung expressed GITRL. There was 
very low expression of GITRL on T cells in the un-inflamed lung and for CD4+ T cells 
there was no significant change in the percentage positive at the time points examined 
during influenza infection (Fig. 5.4C). However, the percentage of GITRL positive CD8+ 
T cells increased significantly up to day 7 of infection (Fig. 5.4C). Unlike GITR 
expression on B cells, there was no significant change in the percentage of GITRL 
positive B cells in the lungs at any of the time points investigated (Fig. 5.4C). Once 
again, the question arises: why do only a subset of CD8+ T cells express GITRL and 
why do only a subset up-regulate it? The up-regulation is by approximately 10%. 
Perhaps this proportion are specific for influenza MHC class I epitopes, a hypothesis 
that could be tested by staining with MHC class I pentamers loaded with immune 
dominant peptides specific for BALB/c mice. 
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In accordance with flow cytometry data showing a low percentage of GITRL positive 
CD4+ T cells and no significant change during influenza infection, there was no change 
in the GM of GITRL on these cells (Fig. 5.4D). There was also no change in the GM of 
GITRL on CD8+ T cells and a small but significant increase in GM of GITRL on B cells 
at day 10 of influenza infection compared to day 0 (Fig. 5.4D). 
5.2.3 GITR and GITRL are up-regulated on myeloid cells in the lungs and airways 
during influenza infection 
Myeloid cells in the lungs were next examined for GITR and GITRL expression during a 
time course experiment of influenza infection. Mice were infected as before on day 0 
with 1.4x104 pfu influenza strain X31 and culled 4, 7 or 10 days afterwards.  
 The up-regulation of GITR and GITRL on macrophage populations was the most 
dramatic effect of any cell population during influenza infection. From a low starting 
percentage, GITR positive CD11c+ alveolar macrophages  increased significantly 
during influenza infection, peaking at day 7 (Fig. 5.5A). Interestingly, at day 10 the 
percentage of GITR positive cells was still high compared to day 0 (Fig. 5.5A). It would 
be of interest to determine whether GITR ever returned to base line by examining later 
time points. Airway monocyte/macrophages expressing CD11b but low levels of CD11c  
infiltrate the airways during influenza infection and these were examined at days 4, 7 
and 10 post infection but are not present at day 0 so could not be analysed at that time 
point. There was a slight but insignificant increase in the percentage of GITR positive 
monocyte/macrophages in the airways throughout influenza infection (Fig. 5.5A). 
However, this was not as dramatic as the increase in GITR expression by CD11c+ 
alveolar macrophages. 
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Figure 5.5 GITR and GITRL expression on airway macrophages during influenza 
infection. BALB/c mice were infected with 1.4x105 pfu influenza X31 on day 0, the 
mice culled and BAL performed at the time points indicated. BAL cells were stained 
with anti-CD11c APC, anti-CD11b PerCp, anti F4/80 PECy-7 and anti-GITR or anti-
GITRL PE. The percentage and GM of of alveolar macrophages (clear bars) and 
airway moncoyte/macrophages (grey bars) expressing GITR (A and B, respectively) 
and GITRL (C and D respectively) were determined by flow cytometry. * = p<0.05, ** = 
p<0.01, *** = p<0.001 compared to day 0. n=5 +/- SEM; data represent 2 independent 
experiments.  
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Figure 5.5 GITR and GITRL expression on airway macrophages during influenza infection. BALB/c
mice were infected with 1.4x105 pfu influenza X31 on day 0, the mice culled and BAL performed at the
time points indicated. BAL fluid was stained with anti-CD11c APC, anti-CD11b PerCp, anti F4/80 PECy-
7 and anti-GITR or anti-GITRL PE. The percentage and GM of of alveolar macrophages (clear bars) and
airway moncoyte/macrophages (grey bars) expressing GITR (A and B, res ectiv ly) and GITRL (B and
C respectively) w re determined by flow cytomet y. * = p<0.05, ** = p<0.01, *** = p<0.001 com ared to
day 0. n=5 +/- SEM; data represent 2 independent experiments
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The intensity of GITR expression on macrophage populations in the airways was next 
measured by analysing GM. The GM of GITR on CD11c+ alveolar macrophages 
increased significantly from day 0 to day 4 of influenza infection, but there was no 
significant increase in GM at any other time points compared to day 0 (Fig. 5.5B). On 
the other hand, the intensity of GITR on infiltrating CD11b+ airway 
monocyte/macrophages decreased from day 4 to day 7 and 10, contrary to the trend 
seen for the percentage of positive cells (Fig. 5.5B). 
Like GITR, there was a low percentage of GITRL positive alveolar macrophages at day 
0, but the percentage positive increased significantly during influenza infection up to 
days 7 and 10 of infection (Fig. 5.5C). GITRL expression on infiltrating 
monocyte/macrophages could not be examined at day 0 but there was no change in 
the percentage positive between days 4, 7 and 10 post influenza infection (Fig. 5.5C). 
GITRL intensity on alveolar macrophages followed a similar pattern to the percentage 
positive, with a significant increase up to day 7; however, there was no change in 
GITRL intensity on airway monocyte/macrophages at any of the time points analysed 
(Fig. 5.5D). In the airways the up-regulation of GITR and GITRL therefore seems to 
occur predominantly on CD11c+ alveolar macrophages. 
GITR and GITRL expression was next examined on myeloid cells in the lungs. Lung 
CD11c+ macrophages, which we believe may be residual alveolar macrophages not 
washed out by lavage, had little expression of GITR at day 0 but this increased 
significantly from day 4 of the infection, peaking at day 7; at day 10 the percentage of 
GITR positive CD11c+ macrophages decreased but was still slightly higher than that 
observed at day 0 (Fig. 5.6A).  
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Figure 5.6 The regulation of GITR and GITRL expression on myeloid cells in the 
lungs during influenza infection. BALB/c mice were infected with 1.4x105 pfu 
influenza X31 on day 0, mice culled and the lungs extracted at the time points 
indicated. Lung homogenates were stained with anti-CD11c APC, anti-CD11b PerCp, 
anti F4/80 PECy-7 and anti-GITR or anti-GITRL PE. The percentage and GM of lung 
CD11c+ macrophages (clear bars) and lung moncoyte/macrophages (grey bars) 
expressing GITR (A and B, respectively) and GITRL (C and D respectively) were 
determined by flow cytometry. * = p<0.05, ** = p<0.01, *** = p<0.001 compared to day 
0. n=5 +/- SEM; data represent 2 independent experiments. 
  
0 4 7 10 0 4 7 10
Time (days) after influenza infection
G
M
 G
IT
R
Lung CD11c+
macrophages
Lung 
monocyte/
macrophages
C
0 4 7 10 0 4 7 10
Time (days) after influenza infection
G
M
 G
IT
R
 l
ig
a
n
d
Lung CD11c+
macrophages
Lung monocyte/
macrophages
D
Figure 5.6 The regulation of GITR and GITRL expression on myeloid cells in the lungs during
influenza infection. BALB/c mice were infected with 1.4x105 pfu influenza X31 on day 0, mice culled
the lungs extracted at the time points indicated. Lung homogenates were stained with anti-CD11c APC,
anti-CD11b PerCp, anti F4/80 PECy-7 and anti-GITR or anti-GITRL PE. The percentage and GM f lung
CD11c+ m rophages (clear bars) and lung monocyte/macrophages (grey bars) expressing GITR (A and
B, respectively) and GITRL (B and C respectively) were determined by flow cytometry. * = p<0.05, ** =
p<0.01, *** = p<0.001 compared to day 0. n=5 +/- SEM; data represent 2 independent experiments
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Lung monocyte/macrophages similarly up-regulated expression of GITR, with the peak 
of percentage positive cells at day 7; there was still a significantly higher percentage of 
GITR positive monocyte/macrophages at day 10, compared to day 0 (Fig. 5.6A). The 
intensity of GITR on lung CD11c+ macrophages peaked at day 4 of influenza infection, 
unlike the percentage positive, which was highest at day 7, while the intensity of GITR 
on lung monocyte/macrophages was highest at day 4 and day 7 (Fig. 5.6B). 
The percentage of GITRL positive lung CD11c+ macrophages and lung 
monocyte/macrophages increased during influenza infection, peaking at day 7 of 
infection in a similar trend to GITR expression on these cell types (Fig. 5.6C). GITRL 
intensity similarly increased on lung monocyte/macrophages during influenza infection, 
peaking at day 7 for both lung CD11c+ macrophages and lung monocyte/macrophages 
(Fig. 5.6D). 
The expression of GITR and GITRL on macrophage and lymphocyte populations 
during influenza infection is summarised in Table 5.1. The percentage of GITR and 
GITR ligand positive alveolar and lung CD11c+ macrophages significantly increased 
during influenza infection, however the percentage of GITR and GITRL positive airway 
monocyte/macrophages did not significantly change during influenza infection. On the 
other hand, influenza infection led to an increase in the percentage of GITR and GITRL 
positive lung CD11b+ monocyte/macrophages. 
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Table 5.1 Summary of GITR and GITRL expression on lymphocyte and 
macrophage populations during influenza infection. The percentage of GITR and 
GITRL positive cells is shown at day 0 (naïve mice) and at day 7, the peak of influenza 
infection. Values shown are averages +/- SD. GITR expression is high on naïve T cells 
and remains high during influenza infection while GITRL is only significantly up-
regulated by CD8+ T cells. Roughly half of B cells in the lungs express GITR at 
homeostasis and this percentage significantly increases during influenza infection. All 
macrophage populations analysed up-regulated GITR and GITR ligand during 
influenza infection. ND= not detected. Data represent 2 independent experiments. 
  
Cell type GITR positive
Day 0                  Day 7
GITRL positive
Day 0                    Day 7
Lung CD4+ T 
cells
99  (+/- 0.13) 99  (+/- 0.2) 3.6 (+/- 0.3) 12 (+/- 9)
Lung CD8+ T 
cells                  
93 (+/- 0.7) 98 (+/- 0.3) 8 (+/- 3) 21(+/- 1)
Lung B cells 43 (+/- 4) 66 (+/- 2) 21 (+/- 3) 13 (+/- 3)
CD11c+ alveolar
macrophages
0 51 (+/- 22) 0 31(+/- 7)
Infiltrating 
airway CD11b+
monocyte/
macrophages
ND 24 (+/-29) ND 10 (+/- 12)
CD11c+ lung 
macrophages
0 41 (+/- 7) 0 64 (+/- 8) 
CD11b+ lung 
macrophages
8.8 (+/- 1) 75 (+/- 3) 18 (+/- 4.9) 62 (+/- 8)
Table 5.1 Summary of GITR and GITRL expression on lymphocyte and macrophage populations 
during influenza infection. Percentage of GITR and GITRL positive cells is shown at day 0 (naïve 
mice) and at day 7, the peak of influenza infection. Values shown are averages +/- SD. GITR expression 
is hig  on naïve T cells and remains high during influenza infection whil  GITRL is only significantly up-
regulated by CD8+ T cell . Roughly half of B cells in the lungs express GITR at homeostasis and this 
percentage significantly increases during influenza infection. All macrophage populations analysed up-
regulated GITR and GITR ligand during influenza infection. 
                           Chapter 5: The role of GITR and GITRL in influenza-induced inflammation 
188 
 
5.2.4 Blockade of GITRL during influenza infection leads to increased weight loss 
and lung cellular infiltrate at early time points during influenza infection 
As GITR and GITRL were up-regulated on immune cell subsets in the lungs and 
airways during influenza infection, it was of interest to determine the importance of the 
interaction between the two during infection. Signalling through GITRL on 
macrophages leads to the production of pro-inflammatory cytokines 359 and signalling 
through GITR on T cells leads to survival and proliferation of T cells 325. Additionally, 
signalling through GITR on macrophages is also pro-inflammatory, leading to the 
production of TNF-α and IL-8 355.  Therefore we hypothesised that blockade of GITRL 
might lead to a reduction in inflammation in the lungs during influenza infection and 
therefore decreased immune pathology. 
BALB/c mice were infected i.n. with 1.4x105 pfu influenza virus, strain X31 on day 0 
and injected with 200μg anti-GITRL Ab or rat IgG1 i.p. on days 0, 2, 4 and 6. Mice were 
culled 4 or 7 days after infection and tissues were harvested as shown in Fig. 5.7A. 
Anti-GITRL binds to GITRL and blocks bi-directional signalling between GITR and 
GITRL (Fig. 5.7B). At present studies assume that the anti-GITRL antibody does not 
signal to GITRL. 
Mice were weighed daily and weight loss measured as a percentage of original body 
weight; mice were then culled and BAL performed and the lungs and mediastinal lymph 
nodes extracted. Viable cell counts in the BAL fluid, mediastinal lymph node and lung 
homogenates were enumerated by Trypan blue exclusion.  
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Figure 5.7 Experimental protocol. (A) BALB/c mice were infected i.n with 1.4x105 pfu 
influenza X31 on day 0; mice were then injected i.p. with 200μg anti-GITRL Ab or rat 
IgG1 i.p. on day 0, 2, 4 and 6. 4 mice per group were then culled at day 4 or 7 post 
influenza infection and the rest of the mice rested for four weeks, after which they were 
infected i.n. with 100 pfu influenza A/PR/8 and culled 4 days later. BAL was performed 
on sacrificed mice and the lungs and mediastinal lymph nodes extracted.  (B) Anti-
GITRL Ab binds GITRL and blocks bi-directional signalling between GITR and GITRL. 
GITR is shown on T cells and GITRL on APCs for simplicity but during influenza 
macrophages could also be GITR positive and T cells GITRL positive.  
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Mice treated with anti-GITRL Ab displayed transient enhanced weight loss at days 4 
and 5 post infection compared to IgG1-treated controls, but there was no difference at 
any other time points, indicating that anti-GITRL treatment may have accelerated 
influenza-induced weight loss during innate immune activation (Fig. 5.8A). There was a 
slight but insignificant increase in the viable cell count in the BAL fluid of anti-GITRL 
Ab-treated mice compared to IgG1-treated controls at day 4 of influenza infection, but 
no difference at day 7 (Fig. 5.8B). Anti-GITRL Ab treatment resulted in a significant 
increase in total cell numbers in the lungs at day 4 of influenza infection, but like in the 
airways, cell numbers were similar between the two groups at day 7 (Fig. 5.8C). Weight 
loss during influenza infection is associated with excess inflammatory infiltrate into the 
lungs; therefore the increase in cell numbers in the lungs was consistent with increased 
weight loss observed at day 4 in anti-GITRL Ab-treated mice. 
Total viable cell numbers in the mediastinal lymph nodes, which drain the lungs were 
unaffected by GITRL blockade (Fig. 5.8D). 
5.2.5 GITRL blockade enhances T and myeloid cell numbers in the lungs during 
influenza infection 
Influenza infection is associated with recruitment of T cells and macrophages into the 
lungs and airways, and this inflammatory infiltrate is associated with disease severity in 
influenza-infected mice 94. It is reported that signalling through GITR on T cells leads to 
T cell proliferation and signalling through GITRL on macrophages causes production of 
inflammatory factors, which could lead to recruitment of more cells into the airways 359. 
Therefore, we hypothesised that blocking the interaction between the two would lead to 
a reduction in T and myeloid cell numbers in the lungs and therefore a reduction in 
immune pathology.  
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Figure 5.8 The impact of GITRL blockade on influenza-associated weight loss 
and cellular infiltrate. BALB/c mice were infected with 1.4x105 pfu influenza X31 on 
day 0 and injected i.p. with 200 μg anti-GITRL Ab (closed symbols/grey bars) or rat 
IgG1 (open symbols/clear bars) on day 0, 2, 4 and 6; mice were then culled 4 or 7 days 
after infection, BAL performed and the lungs and mediastinal lymph nodes extracted. 
Weight was measured daily and expressed as a percentage of original weight (A). 
Total number of viable cells in the BAL fluid (B), and homogenates of lungs (C) and 
mediastinal lymph nodes (D) were determined using Trypan blue exclusion.  * = p<0.05 
n=4 +/- SEM. Data represent one experiment. 
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Figure 5.8 The impact of GITRL blockade on weight loss and cellular infiltrate. BALB/c mice were
infected with 1.4x105 pfu influenza X31 on day 0 and injected i.p. with 200 μg anti-GITRL Ab (closed
symbols/grey bars) or rat IgG1 (open symbols/clear bars) o day 0, 2, 4 and 6; mice were then culled 4 or
7 days after infection, BAL performed and the lungs and m diastinal lymph nodes extracted. Weight was
measured daily and expressed as a percentage of original weight (A). Total number of viable cells in the
BAL fluid (B), lungs (C) and mediastinal lymph nodes (D) were enumerated using Trypan blue exclusion.
* = p<0.05 n=4 +/- SEM.
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However, at day 4 of infection, there was a higher number of both CD4+ and CD8+ T 
cells in the lungs of anti-GITRL Ab-treated mice compared to IgG1-treated controls 
(Fig. 5.9A). In contrast, GITRL blockade did not alter the number of T cells in the lungs 
at day 7 (5.9B) nor was there a difference in T cell numbers in the airways at day 7 of 
infection (Fig. 5.9C). Airway T cells were not analysed at day 4 as the low number of T 
cells present at this time point make the results hard to interpret. 
There was a slight but insignificant increase in the number of lung CD11c+ 
macrophages, and a significant increase in the number of lung monocyte/macrophages 
at day 4 of influenza infection upon GITRL blockade (Fig. 5.10A). In contrast, there was 
no difference in numbers of either macrophage population in the lung at day 7 of 
influenza infection (Fig. 5.10B). Anti-GITRL Ab-treated mice had significantly higher 
numbers of CD11c+ alveolar macrophages in the airways at day 4 compared to IgG1-
treated controls; there were also slightly more CD11b+ airway monocyte/macrophages 
in anti-GITRL Ab-treated mice at day 4, but this difference did not achieve statistical 
significance (Fig. 5.10C). At day 7, in contrast to day 4, IgG-1 treated mice had higher 
numbers of alveolar macrophages in the BAL fluid compared to anti-GITRL Ab-treated 
mice (Fig. 5.10D). 
The increase in numbers of T cells and macrophages observed upon GITRL blockade 
reflected the increase in total viable cell count in the lungs observed at day 4 post 
infection. 
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Figure 5.9 GITRL blockade increases T cell numbers in the lungs at day 4 but not 
day 7 of influenza infection. BALB/c mice were infected i.n. with 1.4x105  pfu 
influenza X31 on day 0, and injected with 200 ug anti-GITRL Ab (grey bars) or rat IgG1 
(clear bars) on day 0, 2, 4 and 6. Mice were then culled 4 or 7 days after infection, BAL 
performed and the lungs removed. Lung homogenates and BAL cells were stained with 
anti-CD4 APC and anti-CD8 PerCp and the number of CD4+ and CD8+ T cells in the 
lungs at day 4 (A) and day 7 (B) and airways at day 7 (C) was determined by 
multiplying the percentage positive x number of cells in the lymphocyte gate x total 
number of viable cells. * p<0.05 n=4 +/- SEM. Data represent one experiment. 
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Figure 5.9 GITRL blockade increases T cell numbers in the lungs at day 4 but not day 7 of
influenza infection. BALB/c mice wer inf cted with 1.4x105 pfu influenza X31 on d y 0, and injected
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Figure 5.10 The effect of GITRL blockade on macrophage populations in the 
lungs and airways during influenza infection. BALB/c mice were infected i.n. with 
1.4x105 pfu influenza X31 on day 0 and injected i.p. with 200 μg anti-GITRL Ab (grey 
bars) or rat IgG1 (clear bars) on days 0, 2, 4 and 6; mice were then culled 4 or 7 days 
after influenza infection and BAL performed and lungs removed. Single cell 
suspensions of lung homogenate and BAL cells were stained with anti-CD11c APC, 
anti-CD11b PerCp and anti-F4/80 PECy-7 to identify lung CD11c macrophages and 
lung monocyte/macrophages at day 4 (A) and day 7 (B), and alveolar macrophages 
and airway monocyte/macrophages at day 4 (C) and day 7 (D). * p<0.05 n=4 +/- SEM. 
Data represent one experiment. 
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Figure 5.10 The effect of GITRL blockade on macrophage populations in the lungs and airways
during influenza infection. BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on day 0 and
injected i.p. with 200 μg anti-GITRL Ab (grey bars) or rat IgG1 (clear bars) on days 0, 2, 4 and 6; mice
were then culled 4 or 7 days after influenza infection and BAL performed and lungs removed. Single cell
suspensions of lung hom gen te and BA fluid were stained with anti-CD11c APC, anti-CD11b PerCp
and anti-F4/80 PECy-7 to identify lung CD11c macrophages and lung monocyte/macrophages at day 4
(A) and day 7 (B), and alveolar macrophages and airway monocyte/macrophages at day 4 (C) and day 7
(7). * p<0.05 n=4 +/- SEM.
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5.2.6 The impact of GITRL blockade on intra-cellular cytokine production by T 
cells 
During influenza infection, T cells are recruited into the lungs and airways and produce 
high amounts of IFN-γ and TNF-α, which, while important for their anti-viral effects and 
activation of macrophages, also contribute to immune pathology 223, 479, 480. Production 
of the above two intra-cellular cytokines are an indicator of the activation state of T 
cells, and therefore it was important to assess the effect of anti-GITRL treatment on 
intracellular expression of these cytokines by T cells. 
Anti-GITRL treatment did not alter the proportion of IFN-γ positive CD4+ T cells in the 
lungs at day 4 post influenza infection; but there was a slight but insignificant increase 
in the percentage of IFN-γ positive CD8+ T cells (Fig. 5.11A). When taking total 
recruited cells into account, anti-GITRL Ab-treated mice had significantly higher 
numbers of IFN-γ positive CD4+ and CD8+ T cells in the lungs compared to IgG-treated 
controls at day 4 (Fig. 5.11B). At day 7 of influenza infection anti-GITRL treatment 
induced an increase in the percentage of IFN-γ positive CD8+ T cells but had no effect 
on the percentage of IFN-γ positive CD4+ T cells (Fig. 5.11C); there was, however a 
slight but insignificant increase in the total number of IFN-γ positive CD4+ and CD8+ T 
cells (Fig. 5.11D). 
Intra-cellular production of TNF-α by T cells was also assessed. Like IFN-γ, TNF-α is 
associated with influenza-induced immune pathology 223. Unlike IFN-γ, anti-GITRL Ab 
treatment did not alter the percentage of TNF-α-producing CD4+ or CD8+ T cells in the 
lungs at day 4 (Fig. 5.12A), however, the total number of TNF-α positive CD4+ and 
CD8+ T cells was enhanced (Fig. 5.12B). In contrast, anti-GITRL Ab treatment had no 
effect on the percentage or total numbers of CD4+ or CD8+ T cells producing TNF-α at 
day 7 (Fig. 5.12C and D respectively). 
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Figure 5.11 The effect of GITRL blockade on intracellular IFN-γ production by T 
cells in the lungs. BALB/c mice  were infected i.n. with 1.4x105 pfu influenza X31 on 
day 0 and injected i.p. with 200 μg anti-GITRL Ab (circles) or rat IgG1 (squares) on 
days 0, 2, 4 and 6. Mice were culled 4 or 7 days after influenza infection and the lungs 
removed. Single cell suspensions of lung homogenate were stained with anti-CD4 APC 
and anti-CD8 PerCp, fixed, permeablised and stained with anti-IFN-γ FITC. The 
percentage of CD4+ (closed symbols) and CD8+ (open symbols) IFN-γ-producing T 
cells at day 4 (A) and day 7 (C) was determined by flow cytometry; the number of IFN-γ 
positive CD4+ (closed symbols) and CD8+ (open symbols) at day 4 (B) and day 7 (D) 
was determined by multiplying the percentage positive x percentage of CD4/CD8 T 
cells x percent of lymphocytes x total viable lung cell count. n=4 +/- SEM * =  p<0.05. 
Data represent one experiment. 
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Figure 5. 1 Th ffect of GITRL blockade on intracellular IFN-γ production by T cells i the
lungs. BALB/c mice were infected i.n. ith 1.4x105 pfu influenza X31 on day 0 and injected i.p. with
200 μg anti-GITRL Ab (circles) or rat IgG1 (squares) on day 0, 2, 4 and 6. Mice were culled 4 or 7 days
after influenza infection and the lungs removed. Single cell suspensions of lung homogenate were
stained with anti-CD4 APC, anti-CD8 PerCp, fixed, permeablised and stained with anti-IFN-γ FITC. The
percentage of CD4+ (closed symbols) and CD8+ (open symbols) TNF-α positive T cells at day 4 (A) and
day 7 (C) was determined by flow cyto etry; the number of IFN-γ positive CD4+ (closed symbols) and
CD8+ (open symbols) at day 4 (B) and day 7 (D) were determined by multiplying the percentage
positive x number of CD4/CD8 T cells x number of lymphocytes x total viable lung cell count. n=4 +/-
SEM * = p<0.05
Day 7
Day 4
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Figure 5.12 The effect of GITRL blockade on intracellular TNF-α production by T 
cells in the lungs. BALB/c mice  were infected i.n. with 1.4x105 pfu influenza X31 on 
day 0 and injected i.p. with 200 μg anti-GITRL Ab (circles) or rat IgG1 (squares) on day 
0, 2, 4 and 6. Mice were culled 4 or 7 days after influenza infection and the lungs 
removed. Single cell suspensions of lung homogenate were stained with anti-CD4 
APC, anti-CD8 PerCp, fixed, permeablised and stained with anti-TNF-α PE. The 
percentage of CD4+ (closed symbols) and CD8+ (open symbols) TNF-α positive T cells 
at day 4 (A) and day 7 (C) was determined by flow cytometry; the number of TNF-α  
positve CD4+ (closed symbols) and CD8+ (open symbols) at day 4 (B) and day 7 (D) 
was determined by multiplying the percentage positive x percentage of CD4/CD8 T 
cells x percentage of lymphocytes x total viable lung cell count. * p<0.05 n=4 +/- SEM. 
Data represent one experiment. 
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Figure 5.12 The effect of GITRL blockade on intracellular TNF-α production by T cells in the
lungs. BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on day 0 and injected i.p. with
200 μg anti-GITRL Ab (circles) or rat IgG1 (squares) on day 0, 2, 4 and 6. Mice were culled 4 or 7 days
after influenza infection and the lungs removed. Single cell suspensions of lung homogenate were
stained with anti-CD4 APC, anti-CD8 PerCp, fixed, permeablised and stained with anti-TNF-α FIT .
The percentage of CD4+ (closed symbols) and CD8+ (open symbols) TNF-α positive T cells at day 4 (A)
and day 7 (C) was determined by flow cytometry; the number of TNF-α positve CD4+ (closed symbols)
and CD8+ (open symbols) at day 4 (B) and day 7 (D) were determined by multiplying the percentage
positive x number of CD4/CD8 T cells x number of lymphocytes x total viable lung cell count. * p<0.05
n=4 +/- SEM.
Day 4
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Intra-cellular cytokine production by T cells in the BAL fluid was also assessed on day 
4 and day 7 of influenza infection post anti-GITRL treatment. However, GITRL 
blockade did not impact on either the proportion or number of IFN-γ- or TNF-α-
producing T cells (data not shown). 
Next, the total amount of inflammatory cytokines in the BAL fluid and lung homogenate 
was determined. IL-6 is produced predominantly by macrophages in the early phase of 
influenza infection and is highly pro-inflammatory; hence it was of interest to assess IL-
6 levels as a reflection of lung inflammation. IL-6 was present in BAL fluid at day 4 and 
7 in both anti-GITRL Ab- and IgG1-treated mice; however, at day 7 there were 
significantly higher levels of IL-6 in BAL fluid of anti-GITRL Ab-treated mice (Fig. 
5.13A). Furthermore, anti-GITRL Ab-treated mice had slightly higher levels of IL-6 in 
lung homogenates at day 4 and day 7 but this difference did not reach statistical 
significance (Fig. 5.13B). The increase in IL-6 levels further indicates that anti-GITRL 
Ab treatment enhanced influenza-associated inflammation during innate immune 
activation. 
TNF-α, though mainly produced by T cells in the later stages of infection, is also 
produced by monocytes and macrophages in the early stages of influenza infection 221. 
We therefore measured TNF-α in BAL fluid and lung homogenate. Unlike IL-6, GITRL 
blockade did not alter TNF-α levels in BAL fluid (Fig. 5.13C) or lung homogenate (Fig. 
5.13D). 
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Figure 5.13 The impact of GITRL blockade on cytokine production during 
influenza infection. BALB/c  mice were infected i.n. with 1.4x105  pfu influenza X31 on 
day 0 and injected i.p with 200μg anti-GITRL Ab (grey bars) or rat IgG1 (clear bars) on 
day 0, 2, 4 and 6. Mice were culled 4 or 7 days after influenza infection and BAL 
performed and lungs removed. IL-6 was then quantified in the BAL fluid (A) and lung 
homogenate (B), and TNF-α levels were  determined in the BAL fluid (C) and lung 
homogenate (D) at day 4 and 7 post influenza infection by ELISA, as described in the 
Methods section. n=4 +/- SEM. * p<0.05. Data represent one experiment. 
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Figure 5.13. The impact of GITRL blockade on cytokine production during influenza infection. 
BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on day 0 and injected i.p with 200μg anti-
GITRL Ab (grey bars) or rat IgG1 (clear bars) on day 0, 2, 4 and 6. Mice were culled 4 or 7 days after 
influenza infection and BAL performed and lungs removed. IL-6 was then quantified in the BAL fluid (A) 
and lung homogenate (B), and TNF-α levels were  determined in the BAL id (C) and lung homogenate 
(D) at day 4 and 7 post influenza infection by ELISA, as described in the Methods section. n=4 +/- SEM. * 
p<0.05.
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5.2.7 GITRL blockade does not affect viral clearance during influenza infection 
We hypothesised that though anti-GITRL treatment may have caused increased lung 
inflammation, this may have enhanced viral clearance, or perhaps inflammation was 
increased due to increased viral load.  
Lung lobes were therefore tested for influenza virus via an influenza plaque assay as 
described in the Methods section. Anti-GITRL Ab treatment did not affect viral 
clearance; at day 4 anti-GITRL Ab- and IgG1-treated mice had comparable viral load in 
the lungs, and by day 7 neither group had detectable levels of influenza virus (Fig. 
5.14). 
 
Figure 5.14 GITRL blockade during influenza infection does not affect viral 
clearance. BALB/c mice  were infected i.n. with 1.4x105 pfu influenza X31 on day 0 
and injected i.p. with 200 μg anti-GITRL Ab (grey bars) or rat IgG1 (clear bars) on day 
0, 2, 4 and 6. Mice were culled 4 or 7 days after influenza infection and the lungs 
removed. Snap-frozen lung lobes were homogenised and viral plaque assay performed 
to detect viral particles. n=4 +/- SEM. (ND: not detected). Data represent one 
experiment. 
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Figure 5.14 GITRL blockade during influenza infection does not affect viral clearance. BALB/c
mice were infected i.n. with 1.4x105 pfu influenza X31 on day 0 and injected i.p. with 200 μg anti-
GITRL Ab (grey bars) or rat IgG1 (clear bars) on day 0, 2, 4 and 6. Mice were culled 4 or 7 days after
influ nza i fection and the lungs removed. Snap-frozen lung lobes were homogenised and viral plaque
assay performed to detect viral particles. n=4 +/- SEM. (ND: not detected)
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5.2.8 GITRL blockade does not impact on the immune response to subsequent 
infection with a heterologous strain of influenza virus 
To test if GITRL blockade had an impact on the immune response to a re-challenge 
infection, mice previously treated with anti-GITRL Ab or rat IgG1 during a primary 
influenza X31 infection (H3N2) were infected with influenza A/PR/8 (H1N1) as 
displayed in the experimental protocol in Fig. 5.7. These viruses share the same NP 
protein, which is one of the dominant intracellular proteins against which T cells are 
raised 486. There is no antibody cross-reactivity between the two viruses, as the surface 
HA and NA proteins are different, but as the NP proteins are the same, there is T cell 
cross-reactivity 487, 488. Mice previously infected with influenza X31 mount a swift T cell 
response to infection with an influenza PR/8 virus which results in rapid clearance of 
the virus 489, 490. 
As expected, mice previously infected with influenza X31 did not lose a significant 
amount of weight after infection with influenza PR/8 (Fig. 5.15A). BAL was performed 
and the lungs and mediastinal lymph nodes extracted. Prior GITRL blockade during the 
primary influenza infection had no effect on cellular infiltrate into the airways during 
subsequent PR/8 infection (Fig. 5.15B) but induced a slight but insignificant reduction 
in cell numbers in the lungs compared to IgG1-treated controls (Fig. 5.15C), and a 
significant reduction in cell numbers in the lymph node (Fig. 5.15D). This suggests 
reduced inflammation in mice previously treated with anti-GITRL during the last 
influenza infection. 
During secondary influenza infection, there is a rapid expansion of T cells in the lungs 
and therefore numbers of T cells were assessed after secondary influenza infection. 
Anti-GITRL treatment during a primary infection led to a slight decrease in the number 
of CD4+ T cells and a significant decrease in the number of CD8+ T cells in the lungs 
during secondary influenza infection with influenza A/PR/8 (Fig. 5.16A and B 
respectively).   
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Figure 5.15 The impact of prior treatment with anti-GITRL during primary 
influenza infection on re-infection with a subsequent heterologous influenza 
virus. BALB/c mice were infected i.n. with 1.4 x105 pfu influenza X31 and injected i.p. 
with 200 μg anti-GITRL Ab (circles) or rat IgG1 (squares) on day 0, 2, 4 and 6. Four 
weeks after primary X31 infection, mice were then infected with 100 pfu influenza PR/8 
and weighed daily, with weight loss expressed as a percentage of original weight (A). 
Mice were culled 4 days after PR/8 infection, BAL performed and the lungs and 
mediastinal lymph nodes removed. Total viable cell count in BAL fluid (B) and single 
cell suspensions of lungs (C) and lymph node (D) were determined by Trypan blue 
exclusion. * = p<0.05, n=4 +/- SEM. Data represent one experiment. 
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Figure 5.15 The impact of prior treatment with anti-GITRL during primary influenza infection on re-
infection with a subsequent heterologous influenza virus. BALB/c mice were infected i.n. with 1.4 x105
pfu influenza X31 and injected i.p. with 200 μg anti-GITRL Ab (circles) or rat IgG1 (squares) on day 0, 2, 4
and 6. Four weeks after primary X31 infection, mice wer then infected with 0 pfu influenza PR/8 and
weighed daily, with weight loss expressed as a percentage of original weight (A). Mice were culled 4 days
after PR/8 infection, BAL performed and the lungs and mediastinal lymph nodes removed. Total viable cell
count in BAL fluid (A) and single cell suspensions of lungs (C) and lymph node (D) was determined by
Trypan Blue exclusion. * = p<0.05, n=4 +/- SEM.
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Figure 5.16 Prior treatment with anti-GITRL Ab during primary influenza infection 
leads to decreased cellular infiltrate into the lungs during subsequent 
heterologous influenza infection.  BALB/c mice were infected i.n. on day 0 with 1.4 
x105 pfu influenza X31 and injected i.p. with 200 μg anti-GITRL Ab (circles) or rat IgG1 
(squares) on day 0, 2, 4 and 6. Four weeks after primary X31 infection, mice were then 
infected with 100 pfu influenza PR/8. Mice were culled 4 days after PR/8 infection and 
the lungs removed. Single cell suspensions of lung homogenate were then stained with 
anti-CD4 APC and anti-CD8 PerCp or anti-CD11c APC, anti-CD11b PerCp and anti-
F4/80 PECy7. The number of CD4+ (A) and CD8+ (B) T cells and lung CD11c+ 
macrophages (C) and lung monocyte/macrophages (D) was determined by multiplying 
the percent positive for the various markers x percentage of cells in the 
lymphocyte/myeloid gate x total viable cell count in the lungs. * = p<0.05, n=4 +/- SEM. 
Data represent one experiment 
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Figure 5.16 Prior treatment with anti-GITRL Ab during primary influenza infection leads to higher
cellular infiltrate into the lungs during subsequent heterologous influenza infection. BALB/c mice
w e infected i.n. with 1.4 x105 pfu influenza X31 and injected i.p. with 200 μg anti-GITRL Ab (circles) or rat
IgG1 (squares) on day 0, 2, 4 and 6. Four weeks after primary X31 infection, mice were then infected with
100 pfu influenza PR/8. Mice were culled 4 days after PR/8 infection and the lungs removed. Single cell
suspensions of lung homogenate were then stained with anti-CD4 APC and anti-CD8 PerCp or anti-CD11c
APC, anti-CD11b PerCp and anti-F4/80 PECy7. The number of CD4+ (A) and CD8+ (B) T cells and lung
CD11c+ macrophages (C) and lung monocyte/macrophages (D) was determined by multiplying the percent
positive for the v rious markers x number of cells in the lymphocyte/myeloid gate x total viable cell count in
the lungs. * = p<0.05, n=4 +/- SEM.
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T cell production of intra-cellular IFN-γ and TNF-α was also analysed,  
but prior GITRL blockade did not have an effect on IFN-γ or TNF-α production by lung 
T cells (data not shown). T cells were not analysed in the airways due to limiting cell 
numbers. Next the number of macrophages in the lungs was examined. Anti-GITRL-
treated mice had fewer CD11c+ macrophages in the lungs (Fig. 5.16C) but numbers of 
monocyte/macrophages were unaffected (Fig. 5.16D). Likewise, there was no 
difference in macrophage populations in the airways (data not shown). 
Next, in order to assess the level of inflammation in the lungs and airways, the amount 
of TNF-α in BAL fluid and lung homogenate was measured by ELISA. Mice which had 
been treated with anti-GITRL Ab during primary influenza infection had slightly lower 
levels of TNF-α in BAL fluid (Fig. 5.17A) and lung homogenates (Fig. 5.17B) which did 
not gain statistical significance. The reduction in TNF-α levels correlated with lower 
numbers of macrophages and T cells observed in anti-GITRL Ab-treated mice. 
Neither anti-GITRL- nor IgG1-treated mice had detectable influenza virus in the lungs 
at day 4 post PR/8 infection (data not shown).  
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Figure 5.17 GITRL blockade during primary influenza infection does not impact 
on cytokine production during a secondary infection. BALB/c mice were infected 
i.n. on day 0 with 1.4x105 pfu influenza X31 on day 0 and injected i.p. with 200μg anti-
GITRL Ab or rat IgG1 on days 0, 2, 4 and 6. Mice were then rested for 3 weeks and 
infected i.n. with 100 pfu influenza PR/8 and culled 4 days after. BAL was performed 
and the lungs removed. TNF-α levels were determined in BAL fluid (A) and lung 
homogenate (B) by ELISA as described in the Methods section. n=4 +/- SEM. Data 
represent one experiment 
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Figure 5.17 GITRL blockade during primary influenza infection does not impact on cytokine 
production during a secondary infection. BALB/c mice were infected i.n. on day 0 with 1.4x105 pfu
influenza X31 on day 0 and injected i.p. with 200μg anti-GITRL Ab or rat IgG1 on day 0, 2, 4 and 6. Mice 
were then rested for 3 weeks and infected i. . with 100 pfu influenza PR/8 and culled 4 days after. BAL was 
performed and the lungs removed. TNF-α levels were determined in BAL fluid (A) and lung homogenate (B) 
by ELISA as described in the Methods section. n=4 +/- SEM. 
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5.2.9 Blockade of the GITR:GITRL interaction during influenza infection using 
GITR:Fc 
The results above suggest that blockade of the GITR:GITRL interaction actually 
enhanced influenza-induced inflammation. GITR-Fc contains the cysteine-rich region of 
mouse GITR fused to the Fc portion of human IgG1 330. Some studies report that 
GITR:Fc not only binds to GITRL and prevents GITRL engaging GITR, but that 
GITR:Fc signals through GITRL 359, 361, 362. In contrast, others show that GITR:Fc simply 
binds to GITRL and blocks GITR binding 379, 380, 491. Whatever the mode of action of 
GITR:Fc, however, all studies reports that treatment with this protein ameliorates 
inflammation in different mouse models of inflammatory disease 366, 380, 380, 492. 
Therefore, it was of interest to determine if this would also be the case in influenza-
induced inflammation. 
Mice were infected i.n. on day 0 as before with 1.4x105 pfu influenza X31 and injected 
i.p. with 1μg of GITR:Fc or control Fc daily (Fig. 5.18A and B). The dose of 
1μg/mouse/day was inferred from studies where mice were given 6.25μg GITR:Fc via 
mini-osmotic pump over 7 days, for treatment of bleomycin-induced lung inflammation, 
which was successful 379. Treatment was given i.p. so a comparison could be made 
with the previous study with anti-GITRL Ab treatment. Mice were culled at day 7 of 
influenza infection, BAL performed and the lungs and lymph nodes removed and 
homogenised. 
Unlike treatment with anti-GITRL, GITR:Fc had no effect on weight loss during 
influenza infection (Fig. 5.19A). Similarly, GITR:Fc treatment did not alter cellular 
infiltrate into the airways (Fig. 5.19B), lungs (Fig. 5.19C) or mediastinal lymph nodes 
(Fig. 5.19D) at day 7 of influenza infection. The absence of an effect of GITR:Fc on 
weight loss correlated with the lack of an impact on cellular infiltrate. 
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Figure 5.18 Experimental set up. (A) BALB/c mice were infected i.n. with 1.4x105 pfu 
influenza X31 on day 0; mice were then injected daily i.p. with 1μg GITR:Fc or control 
Fc daily. Mice were culled 7 days later and BAL performed and lungs and mediastinal 
lymph nodes removed. (B) GITR:Fc binds to GITRL and it is not known if it signals 
through GITRL or simply binds and blocks bi-directional signalling between GITR and 
GITRL. GITRL can also be expressed by T cells and GITR by APCs.  
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Figure 5.18 Experimental set up. (A) BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on
day 0; mice were then injected i.p. with 1μg GITR:Fc or control Fc daily. Mice were then culled 7 days
later and BAL performed and lungs and mediastinal lymph nodes removed. (B) GITR:Fc binds to GITRL
and it is not known if it signals through GITRL or simply binds and blocks. GITRL can also be expressed
by T cells and GITR by APCs.
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Figure 5.19 Treatment with GITR:Fc does not alter weight loss or cell recruitment 
into the airways, lungs and lymph node. BALB/c mice were infected i.n. with 1.4x105 
pfu influenza X31 on day 0 and injected daily with 1μg GITR:Fc (circles) or control Fc 
(squares). Mice were weighed daily and weight loss expressed as a percentage of 
original body weight (A). Mice were culled 7 days after infection and BAL performed 
and lungs and lymph node extracted. Total viable cell counts in BAL fluid (B), lung 
homogenate (C) and mediastinal lymph nodes (D) were enumerated by Trypan blue 
exclusion. n=5 +/- SEM. Data represent one experiment 
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Figure 5.1 reatment with GITR:Fc does not alter weight loss or cell recruitment into the airways,
lungs and lymph node. BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on day 0 and
injected daily with 1μg GITR:Fc (circles) or control Fc (squares). Weight was measured daily and weight
loss expressed as a percentage of original body weight (A). Mice were culled 7 days after infection and
BAL performed and lungs and lymph node extracted. Total viable cell counts in BAL fluid (B), lung
homogenate (C) and mediastinal lymph nodes (D) were enumerated by Trypan blue exclusion. n=5 +/-
SEM.
                           Chapter 5: The role of GITR and GITRL in influenza-induced inflammation 
209 
 
T cell numbers were next determined in the BAL fluid and lung homogenate at day 7 of 
influenza infection. Unlike GITRL blockade, GITR:Fc treatment did not affect the influx 
of CD4+ (Fig. 5.20A) or CD8+ T cells (Fig. 5.20B) into the airways. Similarly, numbers of 
CD4+ (Fig, 5.20C) and CD8+ (Fig. 5.20D) T cells in the lungs were not affected by 
GITR:Fc treatment. 
Next, macrophage numbers were analysed at day 7 of influenza infection post GITR:Fc 
treatment. GITR:Fc- and control Fc-treated mice had similar numbers of alveolar 
macrophages (Fig. 5.21A) and airway monocyte/macrophages (Fig. 5.21B) in the BAL 
fluid. GITR:Fc treatment equally did not affect numbers of lung CD11c+ macrophages 
(Fig. 5.21C) and lung monocyte/macrophages (Fig. 5.21D). 
T cell activation was then examined, and production of intra-cellular IFN-γ was used as 
a indicator of T cell activation. GITR:Fc treatment had no impact on intra-cellular IFN-γ 
production by CD4+ T cells in the airways (Fig. 5.22A) or lungs (Fig. 5.22C) or CD8+ T 
cells in the airways (Fig. 5.22B) or lungs (Fig. 5.22D).  
There was also no difference in the numbers of IFN-γ-producing CD4+ or CD8+ T cells 
in the lungs and airways (data not shown). 
In our model of influenza infection, the dose of GITR-Fc used did not result in less 
severe inflammation, as observed in chemically-induced lung inflammation models 379, 
380. It is possible that this is due to insufficient dose of the protein or the route of 
administration was sub-optimal. It was not possible to test other doses/administration 
routes due to the cost of this reagent.  
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Figure 5.20 Treatment with GITR:Fc does not alter T cell recruitment into the 
airways or lungs. BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on 
day 0 and injected daily with 1μg GITR:Fc (circles) or control Fc (squares) i.p. Mice 
were culled 7 days after infection and BAL performed and lungs extracted. Lung 
homogenates and BAL cells were stained with anti-CD4 APC and anti-CD8 PerCp. The 
number of CD4+ (A) and CD8+ (B) T cells in the airways and the number of CD4+ (C) 
and CD8+ (D) T cells in the lungs was determined by multiplying the percentage 
positive by flow cytometry x percent of cells in the lymphocyte gate x total viable cell 
count in the airways or lungs. n=5 +/- SEM. Data represent one experiment 
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Figure 5.20 Treatment with GITR:Fc does not alter T cell recruitment into the airways or lungs.
BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on day 0 and injected daily with 1μg
GITR:Fc (circles) or control Fc (squares). Mice were culled 7 days after infection and BAL performed and
lungs extracted. Lung homogenates and BAL fluid were stained with anti-CD4 APC and anti-CD8 PerCp.
The number of CD4+ ( ) and CD8+ (B) T cells in the airways and the number of CD4+ (C) and CD8+ (D) T
cells in the lungs was determined by multiplying the percentage positive by flow cytometry x percent of
cells in the lymphocyte gate x total viable cell count in the airways or lungs. n=5 +/- SEM.
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Figure 5.21 Treatment with GITR:Fc does not affect macrophage inflitrate into the 
airways or lungs. BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on 
day 0 and injected daily with 1μg GITR:Fc (circles) or control Fc (squares) i.p. Mice 
were culled 7 days after infection and BAL performed and lungs extracted. Lung 
homogenates and BAL cells were stained with anti-CD11c APC, anti-CD11b PerCp 
and anti-F4/80 PECy7 to identify alveolar macrophages (A), airway lung 
monocyte/macrophages (B), lung CD11c+ macrophages (C) and lung 
monocyte/macrophages (D). n=5 +/- SEM. Data represent one experiment 
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Figure 5.21 Treatment with GITR:Fc does not affect macrophage inflitrate into the airways or lungs.
BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on day 0 and injected daily with 1μg
GITR:Fc (circles) or control Fc (squares). Mice were culled 7 days after infection and BAL performed and
lungs extracted. Lung homogenates and BAL fluid were stained with anti-CD11c APC, anti-CD11b PerCp
and anti-F4/80 PECy7 to isolate alveolar macrophages (A), airway lung monocyte/macrophages (B), lung
CD11c+ macrophages (C) and lung monocyte/macrophages (D). n=5 +/- SEM.
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Figure 5.22 Treatment with GITR:Fc does not affect intra-cellular cytokine 
production by T cells in the lungs. BALB/c mice were infected i.n. with 1.4x105 pfu 
influenza X31 on day 0 and injected daily i.p. with 1μg GITR:Fc (circles) or control Fc 
(squares) i.p. Mice were culled 7 days after infection and BAL performed and the lungs 
extracted. BAL cells and lung homogenates were stained with anti-CD4 APC, anti-CD8 
PerCp, fixed and then permeabilised and stained with anti-IFN-γ FITC. The percentage 
of IFN-γ-producing CD4+ T cells (A;C) and CD8+ T cells (B;D) in the airways and lungs 
respectively was determined by flow cytometry. n=5 +/- SEM. Data represent one 
experiment. 
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Figure 5.22 Treatment with GITR:Fc does not affect intra-cellular cytokine production by T cells in
the lungs. BALB/c mice were infected i.n. with 1.4x105 pfu influenza X31 on day 0 and injected daily with
1μg GITR:Fc (circles) or control Fc (squares). Mice were culled 7 days after infe tion and BAL performed
and the lungs extracted. BAL fluid and lung homogenates were stained with anti-CD4 APC, anti-CD8
PerCp, fixed and then permeabilised and stained with anti-IFN-γ FITC. The percentage of IFN-γ-producing
CD4+ T cells (A;C) and CD8+ T cells (B;D) in the airways and lungs respectively was determined by flow
cytometry. n=5 +/- SEM.
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5.2.10 Regulation of GITRL on alveolar macrophages 
Previous studies show an up-regulation of GITRL mRNA transcripts on splenic B cells 
and peritoneal and bone marrow-derived macrophages in response LPS stimulation 330 
and GITR and GITRL mRNA is induced during carrageenan-induced lung inflammation 
380.  GITR and GITRL expression was up-regulated on macrophage populations in the 
lungs and airways and was sustained during influenza infection. It was therefore of 
interest to determine what factors up-regulate GITR and GITRL on alveolar 
macrophages during influenza infection.  
GITRL expression was high in the lungs and airways at day 7 of influenza infection, 
when the lung micro-environment is highly inflammatory, with pro-inflammatory 
cytokines such as IFN-γ and TNF-α present at high levels 48, 479. Therefore we 
hypothesised that IFN-γ might have a role in the up-regulation of GITRL observed 
during influenza infection. Alveolar macrophages were isolated from un-infected 
BALB/c mice as described in the Methods section and stimulated with 10ng/ml IFN-γ or 
a media only control. Other studies report that GITRL expression upon stimulation in 
vitro is transient and peaks at 4 hours 330. However, no expression of GITRL was 
observed at 4 hours (Fig. 5.23A) or 24 hours (Fig. 5.23B) post stimulation.  
LPS treatment up-regulates GITRL expression on peritoneal and bone marrow-derived 
macrophages 330, therefore alveolar macrophages were isolated as before and 
stimulated with LPS (10ng/ml). Another TLR agonist, lipotechoic acid (LTA) was also 
used, along with 20ng/ml IL-1α, which is extremely pro-inflammatory for many cell 
types including macrophages 493. Because GITRL expression on alveolar macrophages 
was maximal at day 7 of influenza infection, which is relatively late in infection, we 
hypothesised that up-regulation in vitro might also be at a later time point. Therefore, in 
the next experiment, alveolar macrophages were harvested 24 or 48 hours post 
stimulation. However, no GITRL expression was detected on alveolar macrophages 24 
hours (Fig. 5.23C) or 48 hours (Fig. 5.23D) post stimulation.  
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Figure 5.23 GITRL is not up-regulated after in vitro stimulation of alveolar 
macrophages. BALB/c mice were culled and BAL performed to isolate alveolar 
macrophages as described in the Methods section. 7 x 104 alveolar macrophages were 
stimulated with 10ng/ml IFN-γ (grey bars) or incubated with media (clear bars) and the 
cells harvested 4 (A) or 24 hours (B) later and stained with anti-CD11c APC, anti-
CD11b PerCp and anti-GITRL PE. In another experiment, alveolar macrophages were 
isolated as previously described and incubated with media (clear bars) or media 
containing 10μg/ml lipotechoic acid (LTA) (grey bars), 10ng/ml LPS (striped bars) or 
20ng/ml IL-1α (chequered bars) and harvested after 24 hours (C) or 48 hours (D). (E) 
Alveolar macrophages were next incubated overnight with media (clear bars), LPS 
(10ng/ml) (grey bars), or PolyI:C (20 ng/ml) and harvested after 24 hours. n=3 +/- SEM. 
Data represent two experiments. 
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Figure 5.23 GITRL is not up-regulated after in vitro stimulation of alveolar macrophages. BALB/c mice
were culled and BAL performed to isolate alveolar macrophages as described in the Methods section.
Alveolar macrophages were stimulated with 10ng/ml IFN-γ (grey bars) or incubated with media (clear bars)
and the cells harvested 4 (A) or 24 hours (B) later and stained with anti-CD11c APC, anti-CD11b PerCp and
anti-GITRL PE. In another experiment, alveolar macr phages wer isolated as previously described d
incubated with media (clear bars) or media containing 10μg/ml lipotechoic acid (LTA) (grey bars), 10ng/ml
LPS (striped bars) or 20ng/ml IL-1α (chequered bars) and harvested after 24 hours (C) or 48 hours (D). (E)
Alveolar macrophages were next incubated overnight with media (clear bars), LPS (10ng/ml) (grey bars), or
Poly:Ic (20 ng/ml) and harvested after 24 hours. n=3 +/- SEM.
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PolyI:C (polyinosinic-polycytidylic acid) is an agonist for TLR-3 and mimics dsRNA, 
which is associated with virus infections 494. As GITRL was up-regulated on 
macrophages during influenza infection, we hypothesised that the use of a viral TLR 
agonist might induce GITRL in vitro on macrophages, as it might better replicate the 
situation seen in vivo. Therefore alveolar macrophages were isolated as described 
previously and stimulated with 20ng/ml PolyI:C or incubated with media for 24 hours; 
cells were also stimulated with LPS (10ng/ml). As before, GITRL was not up-regulated 
by alveolar macrophages after stimulation with either LPS or PolyI:C (Fig. 5.23E).  
Lastly, it was of interest to determine the factors that up-regulate GITR expression. 
Alveolar macrophages were isolated as previously described and stimulated with 
10ng/ml IFN-γ, 10ng/ml LPS or a media control and harvested 24 hours later and 
stained for GITR expression. Like GITRL, GITR was not up-regulated by alveolar 
macrophages after stimulation in vitro (Fig. 5.24). 
 
Figure 5.24 GITR is not up-regulated on alveolar macrophages upon activation in 
vitro. BALB/c mice were culled and BAL performed and alveolar macrophages were 
isolated as described in the Methods section. 7 x 104 alveolar macrophages were then 
incubated for 24 hours with media (clear bar), LPS (10ng/ml) (grey bar), IFN-γ 
(10ng/ml) (striped bar) or LPS and IFN-γ (chequered bar). Macrophages were 
harvested as described in the Methods section and stained with anti-CD11c APC, anti-
CD11b PerCp and anti-GITR PE. Data represent 2 experiments; n=3 +/- SEM. Data 
represent two experiments. 
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Figure 5.24 GITR is not up-regulated on alveolar macrophages upon activation in vitro. BALB/c mice
were culled and BAL performed and alveolar macrophages were isolated as described in the Methods
section. Alveolar macrophages were then incubated overnight with media (clear bar), LPS (10ng/ml) (grey
bar), IFN-γ (10ng/ml) (striped bar) or LPS and IFN-γ (chequered bar). Data represent 2 experiments; n=3 +/-
SEM
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This result was interesting as GITR and GITRL were up-regulated by alveolar 
macrophages during influenza infection. However, it is possible that TLR stimulus is not 
sufficient to up-regulate GITR and GITRL, and this may require a combination of 
factors including the inflammatory cytokine milieu associated with the influenza-infected 
airway. Furthermore, previous studies only show GITRL mRNA up-regulation after 
stimulation in vitro so it is possible that the products are post-transcriptionally 
regulated, which would correspond with our data showing no expression at the protein 
level upon stimulation in vitro. 
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5.3 Discussion 
5.3.1 GITR and GITRL are differentially regulated on T cells during influenza 
infection 
GITR is reportedly constitutively expressed by mouse splenic T cells 330 and the same 
was true for T cells in the lung. GITRL was not expressed by T cells in the un-inflamed 
lung. Consistent with reports that GITR is up-regulated on activated T cells 324, 326, 367, 
we observed an increase in GM of GITR on T cells during influenza infection, peaking 
at day 7 of infection, a time point which correlates with a multitude of inflammatory 
cytokines in the lungs and airways, and when T cell activation is maximal 223. Some 
studies report GITRL up-regulation on CD4+ and CD8+ T cells after TCR stimulation in 
vitro 326, 354 while others report no up-regulation of GITRL 330. This discrepancy may be 
due to the experimental conditions used. However, during influenza infection, GITRL 
was only up-regulated by CD8+ T cells, and there was no significant increase in GITRL 
expression on CD4+ T cells. The peak of GITRL expression on CD8+ T cells was at day 
7 of infection, which coincided with the peak of GITR intensity on these cells.  
It is not currently known if GITRL is preferentially up-regulated on CD8+ T cells. 
However, GITR co-stimulation is reportedly more important for CD8+ T cells, as GITR 
null CD8+ T cells have lower NFkB activation and produce lower amounts of 
inflammatory cytokines upon co-stimulation with CD28, while co-stimulation of CD4+ T 
cells is unaffected 354.  Other TNFRSF molecules are known to have different effects on 
CD4+ versus CD8+ T cell co-stimulation; for example, 4-1BB co-stimulation enhances 
anti-CD3-induced CD8+ T cell proliferation 10 to 100 fold compared to a 2 to 3 fold 
induction of CD4+ T cell proliferation 495. The function of GITRL on T cells has not yet 
been elucidated; it is possible that as well as APC-T cell interactions between GITRL 
and GITR, T-T cell interactions might occur between GITR and GITRL.  Future studies 
to elucidate the effect of GITRL signalling on T cells would involve using TCR 
stimulation to up-regulate GITRL in the first instance, and then the cells would be 
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treated with an anti-GITRL agonistic antibody. Changes in proliferation of cells and 
production of IL-2 could be used to measure the effect of GITRL signalling.  
It was interesting that only a subset of CD8+ T cells in the lungs expressed GITRL 
during influenza infection. This may denote antigen-specific cells that should be 
examined using MHC class I pentamers loaded with influenza-specific CD8 peptides. 
Preferential up-regulation of co-stimulatory molecules on antigen-specific CD8+ T cells 
is reported for OX40 224, 496, ICOS 497, 498 and 4-1BB 499 . In this case the result of 
ligation would be enhanced survival of antigen-specific T cells.  
5.3.2 GITRL is up-regulated by lung and airway macrophages in vivo during 
influenza infection  
In the absence of inflammation GITR and GITRL were not expressed by alveolar and 
lung CD11c+ macrophages. The lack of GITR and GITRL expression on alveolar or 
lung CD11c+ macrophages compared to splenic, peritoneal and bone marrow-derived 
macrophages 330 indicates that there may be some site specific regulation involved in 
the control of GITR and GITRL expression. There was a small but consistent proportion 
of GITR and GITRL positive monocyte/macrophages in the un-inflamed lung, however, 
and the relevance of this population would be of interest to investigate. The low 
expression of GITR and GITRL seen in the lungs and airways is consistent with data 
showing similar low expression of this pair on APCs in ocular tissue, which implies that 
in areas where even low level inflammation is detrimental, this pair is tightly regulated 
367. It would also of interest to isolate alveolar macrophages from their environment or 
neutralise some of the anti-inflammatory mediators known to be expressed in the un-
inflamed lung to see if GITR/L expression appears. 
GITR and GITRL were up-regulated by alveolar and lung CD11c+ macrophages during 
influenza infection. Lung monocyte/macrophages also up-regulated GITR and GITRL; 
however, there was no significant up-regulation of GITR or GITRL airway 
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monocyte/macrophages. The up-regulation of GITR and GITRL correlates with reports 
that this pair is up-regulated on macrophages in the lungs during chemically-induced 
inflammation and in ocular tissue during HSV infection of the eyes 367, 379, 380.  
The lack of significant up-regulation of GITR and GITRL on airway 
monocyte/macrophages is interesting and warrants further investigation. It is possible 
that these cells lose GITR and GITRL upon entry into the airways or perhaps they 
represent an immature monocyte population that is yet to acquire expression.  
5.3.3 GITRL up-regulation requires complex factors  
Attempts to induce GITRL expression in vitro by stimulation of alveolar macrophages 
with LPS were unsuccessful, though other studies show GITRL mRNA up-regulation by 
splenic and bone marrow-derived macrophages in vitro, with peak expression 4 hours 
after stimulation with LPS 330. As GITRL was maximally up-regulated at day 7 of 
influenza infection, we next attempted to up-regulate GITRL on alveolar macrophages 
by stimulation with IFN-γ, which is abundant in the lungs and airways at that time point 
221. However, IFN-γ treatment did not alter GITRL expression. Stimulation of alveolar 
macrophages with the TLR agonists LTA and PolyI:C also proved unsuccessful in up-
regulating GITRL in vitro. It is possible that for alveolar macrophages GITRL up-
regulation requires several pro-inflammatory factors. Perhaps a combination of pro-
inflammatory cytokines such as TNF-α, IFN-γ and IL-6 is required to up-regulate GITRL 
on alveolar macrophages, in addition to TLR stimulation. Additionally cell-cell contact 
may be required between macrophages and T cells for GITRL up-regulation. It would 
be interesting to analyse the effect of several pro-inflammatory factors on GITRL 
expression in vitro. A positive control would be to stimulate cells with BAL fluid from 
influenza-infected mice at the peak of infection. Presumably all the factors required to 
up-regulate GITRL would be present in the supernatant. However, the BAL procedure 
causes extensive dilution of mediators. A concentration of BAL fluid may therefore be 
required.  
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The need for multiple signals to induce expression of GITR and GITRL on alveolar 
macrophages implies tight control of this pair at homeostasis, which is probably due to 
the reportedly pro-inflammatory outcome of signalling through this pair 359, 361, 362.  
5.3.4 GITRL blockade enhances influenza-associated inflammation 
Blockade of the GITR-GITRL interaction during influenza infection resulted in 
accelerated weight loss and increased T cell and macrophage numbers early in 
influenza infection, as well as increased levels of IL-6 at day 7 of influenza infection. 
The increase in cellular infiltrate into the lungs indicates that GITRL blockade may have 
induced an increase in the production of chemokines such as MCP-1, MIP-1α and cell 
adhesion molecules which facilitate extravasation of cells into the lungs. Overall, it 
appeared that GITRL blockade increased influenza-induced inflammation in the lungs. 
This result was surprising as other groups have shown that a lack of GITR:GITRL 
signalling is beneficial for mouse models of inflammatory disease 379, 380. These studies 
have employed both GITR null mice and wild type mice treated with GITR:Fc fusion 
protein, with similar results. Our studies, however, indicated that GITRL could have an 
anti-inflammatory role in influenza-induced inflammation. Others have indeed shown 
that GITRL signalling on pDCs is anti-inflammatory via production of IDO 363. 
As this thesis was written, a study was published highlighting the role of GITR on CD8+ 
T cells during influenza infection. Snell et al show impaired survival of donor GITR-/- 
antigen-specific CD8+ T cells during primary and secondary influenza infection 
compared to wild type CD8+ T cells 500. This is attributed to a lack of GITR-activated 
Bcl-xL, a pro-survival molecule induced upon GITR signalling in T cells 
500. These data 
are in contrast with the increased T cell numbers observed upon GITRL blockade in 
our model of influenza infection. It would be of interest to analyse antigen-specific T cell 
numbers. The discrepancy between the results observed by Snell et al might have 
implications for the mode of action of the anti-GITRL blocking antibody used in this 
study – see section 5.3.6. Differences in results might also be due to the fact that most 
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of the studies carried out by Snell et al were performed with GITR-/- transferred to 
influenza-infected recipient mice, and not in mice which had the GITR/GITRL 
interaction knocked out globally, as in our model.  
On re-challenge with a heterologous influenza virus, mice previously treated with anti-
GITRL Ab during primary influenza infection had reduced T cell numbers in the lungs. 
This data is consistent with reports from the above study that GITR-/- CD8+ T cells have 
impaired survival during secondary influenza infection 500. Furthermore, mice lacking 4-
1BBL, a related molecule of the TNF super family, have reduced expansion of memory 
T cells during secondary infection 498. As observed during GITRL blockade, Bertram et 
al show that 4-1BBL knockout mice did not have impaired T cell responses during 
primary influenza infection but responses to secondary infection were impaired 498. 
Similarly, Dawicki et al show that OX40 is necessary for recall responses during 
secondary infection with influenza virus 501. The authors suggest that 4-1BBL and 
OX40L are responsible for providing survival signals to T cells which ensure their entry 
into the memory pool 498, 501. It is known that signalling through GITR on T cells induces 
their expansion 344. Therefore a lack of the proliferation signals from GITR could 
account for the reduced T cell infiltrate upon secondary influenza infection. Although 
anti-GITRL Ab-treated mice had a bigger T cell infiltrate into the lungs in the primary 
infection, perhaps GITR signalling is required to ensure the survival of these cells.  
 An alternative explanation is that the enhanced T cell infiltrate upon GITRL treatment 
during the first influenza infection actually enhanced the memory T cell pool and that on 
re-challenge resolution of infection and inflammation is faster, leading to an apparent 
reduced response at day 4. Though anti-GITRL and IgG-treated groups of mice cleared 
culturable virus by day 4, the viral plaque assay is relatively insensitive and so RT PCR 
at earlier time points should be employed together with antigen-specific ELISPOT or 
MHC class I pentamer staining to rule out this possibility. 
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5.3.5 Treatment with GITR:Fc does not impact on influenza-induced inflammation 
To confirm the results using anti-GITRL blocking antibody, we treated mice with 
GITR:Fc during influenza infection in order to replicate previous results in other 
inflammatory disease models. Treatment with GITR:Fc fusion protein ameliorates 
disease severity in mouse models of chronic and acute chemically-induced lung 
inflammation 379, 380. Additionally, GITR null mice also have reduced disease severity 
379, 380. Other studies report improved outcome of spinal cord injury upon treatment with 
GITR:Fc 502 and treatment with GITR:Fc reduces inflammation and disease severity in 
mouse models of acute pancreatitis 503. 
In contrast to other studies where GITR:Fc proved beneficial for reduction of 
inflammation, GITR:Fc treatment did not alter any of the phenotypic markers of 
influenza-induced inflammation; there was no effect on weight loss, cellular infiltrate or 
cytokine production. This result is difficult to interpret because 1) the dose of GITR:Fc 
might not have been optimal and further studies testing different doses of GITR:Fc 
would indicate whether a different result might have been achieved with a  higher dose 
of GITR:Fc. 2) It is not definitively known if GITR:Fc signals through GITRL. To confirm 
the role of GITRL during influenza-induced lung inflammation, it would be of interest to 
use an agonistic anti-GITRL antibody treatment during influenza infection. 
5.3.6 Confounding factors 
It is interesting that in our system blockade of the interaction between GITR and GITRL 
is not beneficial for resolution of inflammation. It might indicate an anti-inflammatory 
role for GITRL in our model of influenza, but it might also indicate that the antibody 
used to block GITRL, although marketed as a blocking antibody, may actually have 
signalled through GITRL. This would result in a blockade of signal through GITR but 
would also result in the pro-inflammatory activation of macrophages through GITRL. 
One of the goals of up-regulating GITRL in vitro was to then ligate it with the anti-
GITRL Ab and test the effect of signalling through this antibody on alveolar 
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macrophages. This was not possible because of the lack of up-regulation of GITRL on 
alveolar macrophages in vitro.  
Without testing the effects of the GITR:Fc and the anti-GITRL antibodies on signalling 
through GITRL, it is impossible to accurately make an interpretation of the results. The 
in vivo data from the anti-GITRL antibody experiments indicate that the antibody could 
be signalling through GITRL, but without further study on the mode of action of this 
antibody it would be impossible to interpret the results. Similarly, one cannot draw any 
conclusions from the GITR:Fc experiments because i) the dose and route of 
administration of the antibody needs to be validated and ii) the mode of action of the 
action also needs to be determined.   
5.4 Conclusion 
The aim of this chapter was to determine the role of GITR and GITRL in influenza-
induced inflammation. We showed that GITR was constitutively expressed by T cells in 
the lungs and GITR and GITRL were up-regulated on T and myeloid cells in the lungs 
and airways during influenza infection. We focused on blocking GITRL because unlike 
GITR, it was not highly expressed in the un-inflamed lung and was highly inducible 
during influenza infection. The results indicate that GITRL might have a novel anti-
inflammatory role in influenza-induced inflammation. Teasing apart the relative 
contributions of this co-stimulatory pair in influenza-induced inflammation is difficult 
because both are inducible on different cell types and signalling through GITR and 
GITRL on different cells yields different effects.  
The following important questions have been raised by the work in this chapter. 
1. Does GITRL expression denote antigen-specific CD8+ T cells? 
2. Is GITRL expression on CD8+ T cells pro- or anti-inflammatory? 
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3. Can multiple pro-inflammatory cytokines and TLR agonists as well as cognate 
interactions with T cells cause an increase in GITRL expression on alveolar 
macrophages in vitro? 
4. What is the impact of anti-GITRL and GITR:Fc on GITRL function – blocking or 
stimulatory? 
5. Do GITRL null mice display enhanced lung inflammation naturally or during 
infection? 
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6.0 Concluding discussion  
This thesis has shown several important concepts that warrant further discussion 
beyond the results presented in each chapter: 
1. Alveolar macrophages express a distinct profile of markers of alternative 
activation compared to interstitial lung macrophages.  
2. Markers of alternative activation are differentially regulated during influenza 
infection.  
3. The outcome of influenza infection can be altered by manipulating immune 
modulatory molecules prior to, and during influenza infection. 
6.1 Alveolar macrophages as a unique macrophage subset 
The results in this thesis show that at homeostasis alveolar macrophages express YM1 
and MR but not RELM-α (Fig. 6.1A), while interstitial lung macrophages express YM1 
and RELM-α but not MR (Fig. 6.1B). Alveolar macrophages are distinct from interstitial 
lung macrophages in many other aspects.  For example, interstitial lung macrophages 
are reportedly better at priming a naïve T cell response, secrete higher levels of IL-6 
and IL-1 upon activation and have higher MHC class II expression compared to 
alveolar macrophages 44. On the other hand alveolar macrophages have increased Fc-
receptor-independent phagocytosis and production of reactive oxygen species 
compared to interstitial macrophages 44.  
Data from the laboratory shows much higher expression of CD200R on alveolar 
macrophages compared to interstitial lung macrophages 200. We further show that 
CD200R interaction with CD200 on the luminal aspect of respiratory epithelium is a key 
mechanism of macrophage suppression 200. Furthermore, alveolar macrophages 
uniquely express high levels of CD11c (Fig. 6.1A), a complement receptor associated 
with DCs, and low expression of CD11b compared to tissue macrophages, including 
interstitial lung macrophages, which express CD11b but not CD11c (Fig. 6.1B) 420.  
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Figure 6.1. The homeostatic airway. A) CD11c+ alveolar macrophages express YM1 
and MR at homeostasis. B) CD11b+ interstitial lung macrophages express RELM-α and 
YM1 but not MR. C) Surfactant proteins bind to TLRs and SIRP-α on alveolar 
macrophages and decrease phagocytosis and the release of inflammatory cytokines. 
D) CD200, IL-10, MUC-1 and TGF-β activated by αvβ6 negatively regulate alveolar 
macrophages. 
 
These differences are likely to be as a result of the anatomical location of alveolar 
macrophages, which are found in the alveolar space and are easily isolated by airway 
lavage, as opposed to lung interstitial macrophages, which are found in the  lung tissue 
and can only be isolated by digestion of lung tissue. Differences in phenotype of lung 
versus alveolar macrophages could therefore be as a result of: 
i) Differences in secretion of soluble factors  
Soluble factors which are high in the airways include surfactant proteins that are 
secreted by alveolar type II epithelial cells, Clara cells and sub mucosal cells 189 and 
immuno-histochemical staining shows localisation of surfactant proteins on the luminal 
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aspect of epithelium and on alveolar macrophages 189, 504, 505. Surfactant proteins have 
potent immune modulatory effects on alveolar macrophages; SPA and D bind to SIRP-
α, a negative regulator on alveolar macrophages, decreasing inflammatory cytokine 
production in response to LPS stimulation by inhibiting p38 and NFkB activation 506, 507 
(Fig. 6.1C). Additionally, SPA binds to TLRs 2 and 4 on alveolar macrophages and 
interferes with their binding to peptidoglycan, and therefore decreases peptidoglycan-
induced TNF-α production by alveolar macrophages 508, 509.  
It is possible that interstitial lung macrophages are not subject to the effects of 
surfactant proteins, which is supported by reports that they are expressed on the 
luminal aspect of the epithelium (Fig. 6.1C). As surfactant proteins are known to 
promote MR expression, this could account for the different expression of MR observed 
between the two macrophage populations 391, 510. Interestingly, treating bone marrow-
derived macrophages with SPD results in their expression of CD11c 420. It is not 
currently known how this occurs but it would be interesting to isolate alveolar or bone 
marrow-derived macrophages, incubate them with SPA or D and examine their 
expression of YM1; like MR, expression might be induced by SPA or D.  
A key regulator of alveolar macrophage activity is TGF-β, which is activated from its 
latent form by αvβ6 produced by the epithelium 438 (Fig. 6.1D). TGF-β and IL10 up-
regulate CD200R expression by splenic macrophages that do not normally express it 
200. Similarly, differences in TGF-β and IL-10 expression between the lung tissue and 
alveolar space might account for differences observed in markers of alternative 
activation between the two compartments. Again, this could be tested as described 
above. Unpublished observations from our laboratory suggest that alveolar 
macrophages alter their phenotype once removed from the lung, which may be due to 
removal of site-specific factors that regulate their phenotype. This would be an 
interesting experiment to perform in the future to see if MR and YM1 expression 
decrease.  
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ii) Oxygen tension 
Alveolar macrophages are exposed to high oxygen partial pressures, as they are in 
direct contact with the outside environment. Presumably, interstitial lung macrophages 
in the lung tissue are not subject to such high oxygen partial pressures. Culture of bone 
marrow-derived and peritoneal macrophages in conditions of high oxygen tension 
results in them behaving more like alveolar macrophages; they become less able to 
prime a naïve T cell response and produce lower levels of inflammatory cytokines upon 
stimulation with LPS 511. This is attributed to altered intracellular redox potential in 
macrophages cultured at high oxygen tension.  
iii) Mucous  
Alveolar epithelial cells secrete mucous that traps foreign particles and microbes which 
are wafted up out of the airways by the muco-ciliary elevator. Muc 1, a mucin-like 
glycoprotein found in the mucous layer has immune modulatory properties and 
suppresses alveolar macrophage responses to TLRs 2, 3, 4, 5, 7 and 9 by decreasing 
NFkB activation in response to TLR stimulation 512 (Fig. 6.1D). Again, unlike alveolar 
macrophages, interstitial macrophages would not be subject to the immune modulatory 
properties of mucins and this might account for some of the differences observed 
between the two populations.  
It is possible that differences in the above mentioned parameters could account for the 
unique expression pattern of YM1, RELM-α and MR by alveolar versus lung 
macrophages. Additionally their presence in the homeostatic lung implies that factors 
besides IL-4 and IL-13 could regulate the induction of these proteins. Perhaps they 
contribute to the maintenance of homeostasis in the lungs and airways. Certainly 
uptake of microbes mediated by MR would be beneficial for avoiding the induction of 
an immune response. Studies have not yet interrogated the function of YM1 or RELM-α 
at homeostasis; only during Th2-biased inflammation. It would be of interest to 
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determine what effect blockade of either of these proteins has on the lung micro-
environment.  
6.2 Influenza infection and the effect on macrophage phenotype  
During influenza infection, much of the homeostatic regulation of the airways is lost. 
Influenza virus infects and kills epithelial cells, and this leads to the loss of epithelium-
derived regulatory factors such as TGF-β and CD200. Additionally, the presence of the 
virus activates the immune response leading to production of inflammatory cytokines 
and chemokines by epithelial cells and resident alveolar macrophages. This leads to a 
highly inflammatory environment in which TNF-α and IFN-γ dominate.  
It is in this inflammatory environment that RELM-α, GITR and GITRL expression is 
observed by alveolar macrophages and airway recruited monocyte/macrophages 
(Figure 6.2). GITRL is up-regulated by bone marrow-derived macrophages upon 
stimulation with LPS, which implies it is up-regulated upon activation 330. GITR is up-
regulated by lung macrophages during bleomycin-induced inflammation 379. 
Presumably activation of viral TLRs combined with inflammatory cytokines produced by 
epithelial cells and infiltrating cells could account for the up-regulation of GITR and 
GITRL observed during influenza infection.  
The expression of RELM-α during influenza infection is less easy to account for. Other 
studies of RELM-α have focused on models of Th2 inflammation and report that it is 
highly induced in that scenario. It reportedly negatively regulates Th2 inflammation in 
Schistosoma mansoni-induced lung inflammation 72 and promotes airway remodelling 
in mouse models of allergic airway disease 65, 66. However, RELM-α is up-regulated in 
DSS-induced colitis and promotes inflammation in this model 415. 
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Figure 6.2. Influenza-induced changes in macrophage phenotype. Influenza 
infection leads to epithelial cell death and epithelium-associated regulatory factors are 
lost. The airways are highly inflammatory, with inflammatory cytokines produced by 
macrophages, epithelial cells and other leukocytes. Intra-cellular and secreted RELM-α 
increase, as does secreted YM1. Intra-cellular YM1 largely decreases. Airway and lung 
macrophages up-regulate GITR and GITRL expression.  
 
The authors show that treatment of mice suffering from colitis with RELM-α leads to 
increased eosinophils, neutrophils and lymphocytes 415. Additionally, RELM-α 
augments LPS-induced IL-6 and TNF-α production by bone marrow-derived 
macrophages 415. Blockade of RELM-α during influenza infection would shed light on its 
role in this infection model. It is possible that it might augment inflammatory cytokine 
production by activation of viral TLRs during influenza infection, and could therefore 
promote influenza-induced inflammation. 
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It must be noted that the apparent induction of RELM-α by alveolar macrophages might 
indicate that alveolar macrophages are changing their phenotype, but it is possible that 
it could represent a proportion of RELM-α positive infiltrating monocyte/macrophages 
which have up-regulated CD11c once in the airways. To rule out this possibility it would 
be necessary to label the resident airway cells prior to influenza infection in order to 
differentiate the infiltrating monocyte/macrophages from the resident alveolar 
macrophages. 
Intra-cellular YM1 is reduced during influenza infection while extra-cellular levels 
increase throughout influenza infection. This might suggest that the reason lower levels 
are observed intra-cellularly is because secretion is enhanced. YM1 expression has not 
to date been studied in a classical Th1 inflammation setting. In vitro stimulation of 
alveolar macrophages with IFN-γ did not affect YM1 expression and therefore it is 
possible that several factors are necessary for its regulation. Perhaps 
inflammation/tissue damage induces its secretion. Previous studies suggest that YM1 
might be involved in the resolution of inflammation 68. It binds oligosaccharides with a 
free amine group, found in many lectin receptors 68. Therefore, it is proposed that 
soluble YM1 may compete with inflammatory cells for binding sites to lectin receptors 
and in this way prevent the entry of inflammatory cells into the site of infection 68. This 
correlates with its release in the lungs during influenza infection. However, a blockade 
of YM1 would be necessary to dissect its role in influenza-induced inflammation. 
By days 10 to 14 of influenza infection, inflammation has largely resolved in the lungs 
and airways and influenza virus is cleared. However, RELM-α is still present in BAL 
fluid but intra-cellular expression is absent from alveolar macrophages. RELM-α 
present in BAL fluid might be produced by epithelial cells, which are known to secrete it 
66. Interestingly levels remain high in the resolved lung and airway compared to the 
naïve state. Similarly extra-cellular YM1 remains high and there remains fairly high 
expression of GITR and GITRL on alveolar macrophages compared to naïve mice. 
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Additionally, MR expression remains low. This is potentially due to residual low levels 
of IFN-γ, TNF-α or other inflammatory cytokines. Epithelium and mucous cell 
metaplasia are reported at day 21 of influenza infection, when inflammation is largely 
resolved 513 and this might also impact on the ability of alveolar macrophages to return 
to their naïve phenotype. The influenza time course should be extended to determine if 
alveolar macrophage phenotype ever returns to that observed in naïve mice. This 
altered phenotype may also contribute to the reported desensitisation of alveolar 
macrophages for prolonged periods of time following influenza infection 514 and the 
increased susceptibility to subsequent bacterial infection (J. Goulding and T Hussell; in 
press).  
6.3 Manipulation of immunity in the lungs and airways  
Previous work from the laboratory suggests the concept of the innate immune rheostat 
in the airways. This suggests that there is a threshold of antigen below which an 
inflammatory response will not be mounted. The presence of negative regulators in the 
airways such as IL-10, TGF-β, SIRP-α and CD200R keeps this threshold fairly high in 
resting alveolar macrophages to prevent them from responding inappropriately to 
innocuous antigen 515. However, this regulation is lost during influenza infection and 
alveolar macrophages become activated, with increased inflammatory cytokine 
production and oxidative burst 516. Once the infection has cleared, in an effort to once 
more raise the threshold of activation, levels of negative regulators such as CD200R 
are enhanced during resolution of infection and the airways are once more highly 
regulated 200. This highly regulated state can leave the airways susceptible to infection. 
For example, bacterial super-infection post influenza infection in mice is associated 
with high levels of IL-10, which leads to bacterial outgrowth and death 517.  
A redundancy in negative regulators in the lung is probably the reason why there was 
not a more pronounced inflammatory phenotype upon IL-10R blockade, or potentially 
the blocking antibody regimen was not long enough. However, the increased IL-6 
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production and higher alveolar macrophage numbers hints at enhanced inflammation. 
This correlates with previous data from the laboratory which shows increased alveolar 
macrophage numbers in CD200R knockouts 200 and upon blockade of TGF-β in wild 
type mice (J Goulding and T Hussell; unpublished observations).  
IL-10 promotes the expression of MR and YM1, however the lack of a change in 
expression of these proteins upon IL-10R blockade correlates with studies showing that 
surfactant proteins can also drive MR expression 391 and YM1 may similarly be 
regulated by surfactant proteins or other factors in the airway micro-environment such 
as GMCSF. 
It is interesting to note that though IL-10R blockade had minimal effects in the non-
inflamed lung, following influenza infection several parameters were affected including 
increased cellular infiltrate into the lungs and airways and higher levels of inflammatory 
cytokines. Unlike previous studies where IL-10R was blocked during influenza infection 
233, 306, 307, this was a blockade of IL-10R prior to influenza infection and caused 
increased inflammation with enhanced T cell activation. This indicates that merely a 
transient blockade of an immune modulatory pair such as IL-10 and IL-10R can alter 
the outcome of a subsequent infection. 
It is possible that although IL-10R blockade did not result in an obvious inflammatory 
phenotype at homeostasis, the threshold of activation had been altered. The increase 
in macrophage numbers in the airways and increased IL-6 levels would correlate with 
enhanced innate immunity, which ultimately could have resulted in enhanced T cell 
activation. Levels of CD200R and MHC class II on macrophages were unchanged, 
however, future experiments would test SIRP-α and TGF-β expression. 
Efforts to reduce influenza-induced immune pathology in the past have focused on 
blocking activation signals to leukocytes. For example, blockade of OX40 causes 
apoptosis of activated T cells and reduces inflammatory mediators, with accelerated 
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recovery from influenza 224. Similarly, GITRL blockade was hypothesised to reduce 
influenza-induced inflammation by blocking the pro-inflammatory signal to 
macrophages by GITRL signalling 359, and the pro-survival signal to T cells upon GITR 
triggering 344. However, this led to increased inflammation and potentially worse 
disease. This result might imply that GITRL is important for the regulation of influenza-
induced inflammation. Indeed, it is known that reverse signalling through GITRL on 
pDCs leads to IDO production, which protects against Th2 inflammation in the lungs 
363. This would imply a novel role for GITRL in the regulation of influenza-induced 
immunity and suggests that potentiating GITRL signalling on pDCs might be beneficial 
for the outcome of influenza infection. A recent study showed that GITRL expansion of 
Tregs is necessary for the prevention of corneal allografts 518. It is possible that GITRL 
blockade decreased Treg numbers during influenza infection and led to the increased 
inflammation observed. Future experiments should be performed to analyse the effect 
of GITRL blockade on Tregs during influenza infection. 
6.4 Conclusion 
This thesis shows for the first time that alveolar macrophages and lung macrophages 
have distinct expression profiles with regards to markers of alternative activation, which 
are differentially regulated during Th1-biased influenza-induced inflammation. I also 
show that prior blockade of IL-10R is sufficient to alter the immune response to a 
subsequent influenza infection, and that blocking GITRL during influenza infection is 
detrimental. These results provide further insight into the phenotype of alveolar 
macrophages and regulation of lung and airway homeostasis and influenza-induced 
inflammation. 
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